Improved chimeric receptors
By designing chimeric receptors containing mutant Fc domains and intracellular signaling domains, and combining specific antibodies to guide CAR-T cells, the problems of target detumour toxicity and treatment-related toxicity in CAR-T cell therapy are solved, and the problem of target detumour toxicity and treatment-related toxicity is achieved. Tumor-specific activation and safety improvement.
Patent Information
- Application Number
- CN202380029027.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-25
- Filing Date
- 2023-03-24
- Publication Date
- 2024-12-06
AI Technical Summary
Existing CAR-T cell therapies face limitations on target detumour toxicity and treatment-related toxicity when treating tumors, and traditional methods have limitations in improving safety and selective activation of CAR-T cells, especially in targeting nonspecificity Antigens may cause side effects.
A chimeric receptor is designed that comprises a mutated Fc domain and a transmembrane domain, and binds at least one intracellular stimulating or costimulatory signaling domain, binding to the mutated Fc domain through an antibody to guide T cells Targeting tumor cells to avoid binding to non-mutated Fc domains, thereby reducing side effects.
Selective activation and targeting in tumor cells is achieved, toxicity to healthy tissues is reduced, the safety of the therapy and tumor specificity are improved, and the occurrence of side effects is reduced.
Smart Images

Figure BDA0005051726250000821 
Figure BDA0005051726250000831 
Figure BDA0005051726250000841
Abstract
Description
Technical Field
[0001] The present invention generally relates to a chimeric receptor comprising an extracellular domain comprising a mutated Fc domain. The present invention also relates to a transduced immune cell expressing the chimeric receptor of the present invention and / or a nucleic acid molecule encoding the chimeric receptor of the present invention. The present invention further provides a kit comprising: such cells and / or nucleic acid molecules encoding the chimeric receptor; and an antibody capable of binding to the chimeric receptor. Background Art
[0002] Adoptive T cell therapy (ACT) is a powerful therapeutic approach using cancer-specific T cells (Rosenberg and Restifo, Science 348(6230) 2015: 62-68). ACT can use naturally occurring tumor-specific cells or T cells that have been genetically engineered to be tumor-specific using T cells or chimeric antigen receptors (Rosenberg and Restifo, Science 348(6230) 2015: 62-68). ACT can successfully treat and induce remission even in patients with advanced and otherwise treatment-refractory diseases, such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, or melanoma (Dudley et al., J Clin Oncol 26(32)2008:5233-5239; Grupp et al., N Engl J Med 368(16)2013:1509-1518; Kochenderfer et al., J Clin Oncol. 33(6)2015:540-549).
[0003] However, despite the impressive clinical efficacy, ACT is limited by treatment-related toxicity. The specificity of the engineered T cells used in ACT and the resulting targeting and off-target effects are mainly driven by the tumor-targeted antigen binding part implemented in the antigen binding receptor (Hinrichs et al., Nat Biotechnol.31 (11) 2013, 999-1008). Due to intolerable treatment toxicity, the non-exclusive expression of tumor antigens or the time difference of expression levels can lead to serious side effects or even the failure of ACT. In fact, except for a few lineage-specific antigens (such as CD19, CD20 or BCMA), traditional CAR-T cells progress slowly, especially in solid tumors, where epithelial tumor antigens are targeted, and these antigens are frequently expressed in normal tissues, resulting in on-target off-tumor toxicities, for example, CAR-T cells targeting HER2 have confirmed this point (Morgan et al., Mol Ther 18 (4) 1020: 843-851). Therefore, the method of making CAR-T cells more tumor-specific has great therapeutic potential.
[0004] In addition, the availability of tumor-specific T cells for effective lysis of tumor cells depends on the long-term survival and proliferation capacity of engineered T cells in vivo. On the other hand, since the persistence of uncontrolled T cell responses can cause damage to healthy tissues, the in vivo survival and proliferation of T cells may also lead to unnecessary long-term effects (Grupp et al., 2013N Engl J Med 368 (16): 1509-18, Maude et al. 2014 2014N Engl J Med 371 (16): 1507-17).
[0005] One approach to limiting severe treatment-related toxicity and improving the safety of ACT is to limit the activation and proliferation of T cells by introducing adaptor molecules that control the formation of immune synapses. Such adaptor molecules include small molecule dual-module switches, such as the recently described folate-FITC switch (Kim et al., J Am Chem Soc 2015; 137: 2832-2835). Another approach includes artificially modified antibodies that include a tag for directing and guiding T cells to specifically target tumor cells (Ma et al., PNAS 2016; 113 (4): E450-458, Cao et al. Angew Chem 2016; 128: 1-6, Rogers et al. PNAS 2016; 113 (4): E459-468, Tamada et al. Clin Cancer Res 2012; 18 (23): 6436-6445).
[0006] However, existing approaches have several limitations. Immune synapses that rely on molecular switches require the introduction of additional elements that may trigger an immune response or lead to nonspecific off-target effects. On the other hand, the introduction of tag structures into existing therapeutic monoclonal antibodies may affect the efficacy and safety of these constructs. In addition, the addition of tags requires additional modification and purification steps, making the production of such antibodies more complicated and further requiring additional safety testing.
[0007] Another limitation of existing methods is the possibility of producing on-target off-tumor effects. In most indications, clean targets are missing because the target antigen (although highly expressed on tumor cells) is also expressed on healthy tissues. In order to reduce side effects and increase the selection of drug-treatable target antigens, cancer-specific T cells with only local activity are beneficial to this. In order to improve the selectivity of CAR T cells activated only in tumors, different methods have been developed, such as oxygen-sensitive CAR (Juillerat A et al., Sci Rep. 2017; 7: 39833. Published on January 20, 2017, doi: 10.1038 / srep39833). Direct CARs with protease-sensitive connectors have also been developed to improve the safety of traditional ACT (Han X et al., Mol Ther. 2017; 25 (1): 274-284. doi: 10.1016 / j.ymthe. 2016.10.011). However, tumor-activated CARs are complex and often rely on tumor-intrinsic activation triggers, such as tumor-associated proteases. Due to the heterogeneous nature of cancer, the presence of these activation triggers can vary greatly between different tumor lesions, cancer types, and patients.
[0008] Adaptor molecules (which are otherwise biologically inert but interact specifically with engineered chimeric receptors) can allow control of T cell activation in a dose-dependent manner. Such adaptor approaches thus provide an alternative general strategy to control therapy-related side effects. However, engineered orthogonal ligand / receptor systems are often based on mutated ligand-receptor interfaces that carry the risk of immunogenicity when administered to patients. This can lead to the formation of anti-drug antibodies, which can potentially result in loss of exposure to the therapeutically active component of the cell therapy.
[0009] Therefore, improved therapies are needed to address the challenges of ACT. Summary of the invention
[0010] The present invention provides chimeric receptors with improved properties as described below.
[0011] Provided herein is a chimeric receptor comprising
[0012] (i) an extracellular domain comprising a mutated Fc domain or a fragment thereof, and
[0013] (ii) Transmembrane domain.
[0014] In one embodiment, the chimeric receptor further comprises (iii) at least one intracellular stimulatory signaling domain and / or at least one co-stimulatory signaling domain.
[0015] In one embodiment, the extracellular domain comprises a mutated CH2 domain and / or a mutated CH3 domain.
[0016] In one embodiment, the extracellular domain comprises a mutated CH2 domain and / or a mutated CH3 domain, wherein the mutated CH2 domain and / or the mutated CH3 domain comprises an amino acid substitution (numbered according to the Kabat EU index):
[0017] (a) I253A, H310A and H435A;
[0018] (b) I253A;
[0019] (c) I253A and H310A;
[0020] (d) I253A and H435A;
[0021] (e) H310A and H435A;
[0022] (f) H310A;
[0023] (g) H435A;
[0024] (h) L234A, L235A and P329G; or (i) L234A, L235A, I253A, H310A, P329G and H435A.
[0025] In one embodiment, the transmembrane domain is selected from the group consisting of CD8, CD4, CD3z, FCGR3A, NKG2D, CD27, CD28, CD137, OX40, ICOS, DAP10 or DAP12 transmembrane domains or fragments thereof.
[0026] In one embodiment, the stimulatory signaling domain is selected from the group consisting of: an intracellular domain of CD3z, an intracellular domain of FCGR3A, and an intracellular domain of NKG2D, or a fragment thereof, which retains stimulatory signaling activity.
[0027] In one embodiment, the costimulatory signaling domain is selected from the group consisting of: an intracellular domain of CD27, an intracellular domain of CD28, an intracellular domain of CD137, an intracellular domain of OX40, an intracellular domain of ICOS, an intracellular domain of DAP10, and an intracellular domain of DAP12, or a fragment thereof, which retains costimulatory signaling activity.
[0028] In one embodiment, the costimulatory signaling domain is: the CD28 intracellular domain, or a fragment thereof that retains the CD28 costimulatory activity.
[0029] In one embodiment, the chimeric receptor comprises a stimulatory signaling domain comprising: the intracellular domain of CD3z, or a fragment thereof, which retains the CD3z stimulatory signaling activity, and wherein the chimeric receptor comprises a co-stimulatory signaling domain comprising: the intracellular domain of CD137, or a fragment thereof, which retains the CD137 co-stimulatory signaling activity.
[0030] In one embodiment, the stimulatory signaling domain comprises the amino acid sequence of SEQ ID NO:13, and the co-stimulatory signaling domain comprises the amino acid sequence of SEQ ID NO:12.
[0031] In one embodiment, the chimeric receptor comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:87, SEQ ID NO:106, SEQ ID NO:125, and SEQ ID NO:127.
[0032] In one embodiment, a chimeric receptor is provided, comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:87, SEQ ID NO:106, SEQ ID NO:125 and SEQ ID NO:127.
[0033] In one embodiment, an isolated polynucleotide encoding a chimeric receptor as described above is provided.
[0034] In one embodiment, a polypeptide encoded by the isolated polynucleotide as described above is provided.
[0035] In one embodiment, a vector, in particular an expression vector, is provided, which comprises the polynucleotide as described above.
[0036] In one embodiment, a transduced T cell is provided, comprising the polynucleotide as described above or the vector as described above.
[0037] In one embodiment, a transduced T cell capable of expressing a chimeric receptor as described above is provided.
[0038] In one embodiment, a kit is provided, comprising (A) transduced T cells capable of expressing a chimeric receptor as described above, wherein the chimeric receptor comprises an extracellular domain comprising a mutated Fc domain or a fragment thereof; and (B) an antibody comprising at least one antigen binding portion capable of binding to the mutated Fc domain but not to the non-mutated parent Fc domain, wherein the antibody comprises at least one effector portion.
[0039] In one embodiment, a kit is provided, comprising (A) an isolated polynucleotide encoding a chimeric receptor as described above, wherein the chimeric receptor comprises an extracellular domain comprising a mutated Fc domain or a fragment thereof; and (B) an antibody comprising at least one antigen binding portion capable of binding to the mutated Fc domain but not to the non-mutated parent Fc domain, wherein the antibody comprises at least one effector portion. In one embodiment, the effector portion is: (i) an antigen binding portion capable of binding to a target cell antigen; or (ii) and an immune activation portion, particularly a cytokine.
[0040] In one embodiment, there is provided a kit as hereinbefore described for use as a medicament.
[0041] In one embodiment, a chimeric receptor as described above or a transduced T cell as described above is provided, which is used as a medicament, wherein the chimeric receptor comprises an extracellular domain, which comprises a mutated Fc domain or a fragment thereof, wherein the transduced T cell expressing the chimeric receptor is administered before, simultaneously with or after administration of an antibody, the antibody comprising: at least one antigen binding portion capable of binding to a target cell antigen; and at least one antigen binding portion capable of binding to the mutated Fc domain but not to the non-mutated parent Fc domain.
[0042] In one embodiment, a kit as described above is provided for use in the treatment of a disease, in particular in the treatment of cancer.
[0043] In one embodiment, a method for treating a disease in a subject is provided, the method comprising: administering to the subject transduced T cells, the transduced T cells being capable of expressing a chimeric receptor as described above, wherein the chimeric receptor comprises an extracellular domain, the extracellular domain comprising a mutated Fc domain or a fragment thereof; and administering a therapeutically effective amount of an antibody before, simultaneously with, or after administering the transduced T cells, the antibody comprising at least one antigen binding portion capable of binding to the mutated Fc domain but not to the non-mutated parent Fc domain, wherein the antibody comprises at least one effector portion. In one embodiment, the effector portion is: (i) an antigen binding portion capable of binding to a target cell antigen; or (ii) and an immune activation portion, particularly a cytokine.
[0044] In one embodiment, there is provided a use of the chimeric receptor as described above, the polynucleotide as described above, or the transduced T cell as described above for the manufacture of a medicament.
[0045] In one embodiment, the medicament is for the treatment of cancer. In one embodiment, the cancer is selected from cancers of epithelial, endothelial or mesothelial origin and hematological cancers. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Figure 1: Schematic representation of a chimeric receptor of the invention comprising a CH2 domain comprising the substitution P329G (A) or a CH2-CH3 domain comprising the substitutions I253A, H310A, P329R (CH2 domain) and H435A (CH3 domain) (B). Schematic representation of the corresponding DNA construct (C).
[0047] Figure 2: Expression of CH2 P329G construct in Jurkat TCRabKO CD4+ cells (Promega) after lentiviral transduction and pool sorting of eGFP positive cells. The construct was detected with anti-P329G VH3xVL1 (clone M-1.7.24) humanized IgG labeled with AF647. Schematic diagram of the assay (A). CH2 P329G construct surface expression (B) and corresponding eGFP expression (C). Jurkat TCRab KO CD4+ wild-type cells were used as negative control.
[0048] Figure 3 FolR1 with high (HeLa), medium (Ovcar3) and low (HT-29) target expression levels +Activation of the sorting pool of Jurkat TCRabKO CD4+ cells transduced with CH2 P329G construct (SEQ ID NO:87) after stimulation with anti-FolR1 x anti-CH2_P329G bispecific antibodies (SEQ ID No:108, SEQ ID No:109, SEQ ID No:110, SEQ ID No:111) in the presence of target cells. Activation was assessed by quantifying the intensity of CD3 downstream signaling reported by luciferase expression controlled by the NFAT promoter. Schematic diagram of the assay (A). Dose-dependent activation of Jurkat cells in the presence of HT29 (B), Ovcar-3 (C) or HeLa (D) as target cells. Cells transduced with mock were used as negative controls. Depicted are technical means from three replicates, with error bars indicating SD.
[0049] Figure 4: Binding of anti-FolR1 x anti-CH2-CH3 AAA P329R bispecific antibodies (SEQ ID No 108, SEQ ID No 112, SEQ ID No 113, SEQ ID No 114) on unsorted Jurkat NFAT cells (Promega) transduced with a lentivirus with a CH2-CH3 AAA P329R construct (SEQ ID NO: 105). Binding was assessed via a secondary R-phycoerythrin (PE) AffiniPure F(ab')2 fragment goat anti-human IgG (F(ab')2 fragment specific). Schematic diagram of the assay (A). Dose-dependent binding of the CH2-CH3 AAA P329R construct to transduced Jurkat cells (B). Jurkat NFAT wild-type cells were used as negative control.
[0050] Figure 5: Expression of CH2-CH3 AAA P329R construct (SEQ ID NO: 105) in Jurkat NFAT cells after lentiviral transduction. The construct was detected with anti-AAA x FolR1 2+1 bispecific antibody (SEQ ID No: 108, SEQ ID No: 112, SEQ ID No: 113, SEQ ID No: 114) and secondary PE AffiniPure F(ab')2 fragment goat anti-human IgG (F(ab')2 fragment specific). Schematic diagram of the assay (A). Surface expression of CH2-CH3 AAA P329R construct (B) and corresponding eGFP expression (C). Jurkat NFAT wild-type cells were used as negative control.
[0051] Figure 6: In FolR1 with high target expression level+ Target cells (HeLa) and anti-FolR1 xAAA 2+1 bispecific antibodies (SEQ ID No: 108, SEQ ID No: 112, SEQ ID No: 113, SEQ ID No: 114) in combination, the activation of unsorted Jurkat NFAT cells transduced with CH2-CH3 AAA P329R construct (SEQ ID NO: 105). Activation was assessed by quantifying the intensity of CD3 downstream signaling reported by luciferase expression controlled by the NFAT promoter. Schematic diagram of the assay (A). Dose-dependent activation of Jurkat cells in the presence of HeLa as target cells (B). Jurkat NFAT wild-type cells were used as negative controls. Depicted are technical means from three replicates, with error bars indicating SD.
[0052] Figure 7 : Schematic diagram depicting the use of a chimeric receptor of the invention in combination with an exemplary immune activating Fc binding molecule having an IL2v (cytokine) effector portion.
[0053] FIG. 8A to FIG. 8D : FIG. 8A to FIG. 8B Depicted is a schematic diagram of a chimeric receptor of the present invention comprising ( Fig. 8A ) CH2 domain containing P329G mutation or ( Figure 8B ) contains a CH2-CH3 domain with mutations I253A, H310A, P329G (CH2 domain) and H435A (CH3 domain). FIG. 8C to FIG. 8D A schematic diagram of the corresponding DNA construct is depicted.The DNA construct used in the accompanying examples also contains the eGFP encoding gene separated from the chimeric receptor via a 2A self-cleaving peptide.
[0054] FIG. 9A to FIG. 9B : Primary T cells expressing the chimeric receptors of the present invention. Human CD4 and CD8 T cells were transduced with CH2-CH3 AAA P329G CAR (SEQ ID NO: 127), CH2-CH3 AAA P329R CAR (SEQ ID NO: 125) or CH2P329G CAR (SEQ ID NO: 87), respectively. The expression of the constructs was assessed by eGFP expression and surface staining of CAR. For the latter, anti-PG VH3xVL1 huIgG-AF647 (CH2-CH3 AAA P329G CAR, CH2P329G CAR) ( Fig.9A) or anti-AAA x FolR1 2+1 TCB and secondary APC-F(ab)2 fragment anti-huIgG (JacksonImmunoResearch, #109-136-097) (CH2-CH3 AAA P329GCAR, CH2-CH3 AAA P329R CAR) ( Fig. 9B Between 86% and 89% of primary T cells expressed the chimeric receptor.
[0055] FIG. 10A to FIG. 10F : T cell-mediated killing. CH2-CH3 AAA P329G CAR (SEQ ID NO: 127, FIG. 10A to FIG. 10B ) / CH2-CH3 AAA P329R CAR (SEQ ID NO: 125, FIG. 10C to FIG. 10D ) or CH2 P329G CART cells (SEQ ID NO: 87, FIG. 10E to FIG. 10F ) were incubated with HeLa NLR (NucLight Red) cells. Anti-AAA x FolRI 2+1 / anti-AAA x FolRI 1+1 or anti-PG x FolRI 2+1 / anti-PG x FolRI 1+1 antibodies were used as adaptor molecules. The system tracked red blood cell counts over 6 days. Wells without adaptor molecules were used as negative controls, and 10 nM anti-FolR1 TCB was used as positive controls. Dose-dependent reductions in red blood cell counts (cancer cell killing) or cancer cell growth were observed. Depicted are technical means from replicates, with error bars indicating SD.
[0056] FIG. 11A to FIG. 11C : T cell-mediated killing. CH2-CH3 AAA P329G CAR (SEQ ID NO: 127, Fig.11A ) / CH2-CH3 AAA P329R CAR (SEQ ID NO: 125, Fig. 11B ) or CH2 P329G CAR T cells (SEQ ID NO: 87, Fig. 11C ) were incubated with MKN45 NLR (NucLight Red) cells. Anti-AAA x CEA 2+1 or anti-PGx CEA 2+1 antibodies were used as adapter molecules. Wells without adapter molecules were used as negative controls, and 10 nM anti-CEA TCB was used as positive controls. Dose-dependent reductions in red blood cell counts (cancer cell killing) or cancer cell growth were observed. Depicted are technical means from replicates, with error bars indicating SD.
[0057] FIG. 12A to FIG. 12B: CH2-CH3 AAA P329G CAR (SEQ ID NO: 127) / CH2-CH3 AAA P329RCAR (SEQ ID NO: 125) or CH2 P329G CAR (SEQ ID NO: 87) T cells were stained with anti-PG and anti-AAA antibodies to assess whether AAA and P329G mutations can be combined at the same time ( Fig. 12A ). Fig. 12B Double positive (BV421+, AF647+) CAR-T cells are shown, showing that AAA and P329G mutations can be combined at the same time. As expected, CH2-CH3 AAA P329R CAR or CH2 P329GCAR T cells only show corresponding single staining.
[0058] FIG. 13A to FIG. 13D : STAT5 phosphorylation (pSTAT5) of primary T cells transduced with CH2-CH3 AAA P329G CAR (SEQ ID NO: 127) / CH2-CH3 AAA P329R CAR (SEQ ID NO: 125) or CH2 P329G CAR (SEQ ID NO: 87) after stimulation with anti-P329G-IL2v. The median fluorescence intensity of pSTAT5 after gating eGFP+ (CAR+) or eGFP- (CAR-) cells is shown. Anti-P329G-IL2v is targeted to CAR T cells via the P329G mutation, which results in the presence of approximately 50 times (CH2 PG CAR, Fig.13A ) or 225 times (CH2 CH3AAA PG CAR, Fig. 13B ). As expected, this effect was not observed for CH2 CH3 AAA PR CAR T cells ( Fig. 13C The pSTAT5 MFI of cells incubated with Proleukin was comparable between cell products and between eGFP+ and eGFP- ( Fig.13D ). Depicted are technical means from replicates, error bars indicate SD. EC50 values were calculated using GraphPadPrism 8.4.2 (log(agonist) vs. response variable slope (four parameters)). DETAILED DESCRIPTION
[0059] definition
[0060] Unless otherwise defined below, the terms used herein are generally as used in the art.
[0061] "Acceptor human framework" for the purposes of this paper is such a framework, which comprises the amino acid sequence of the light chain variable domain (VL) framework or the heavy chain variable domain (VH) framework derived from the human immunoglobulin framework or people's shared framework as defined below. The acceptor human framework "derived from" the human immunoglobulin framework or people's shared framework may comprise the amino acid sequence identical to the human immunoglobulin framework or people's shared framework, or it may comprise amino acid sequence changes. In some aspects, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less or 2 or less. In some aspects, the VL acceptor human framework is identical to the VL human immunoglobulin framework sequence or people's shared framework sequence in sequence.
[0062] An "activating Fc receptor" is an Fc receptor that, upon engagement by the Fc domain of an antibody, initiates a signaling event that stimulates cells bearing the receptor to perform effector functions. Human activating Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32), and FcαRI (CD89).
[0063] Antibody-dependent cell-mediated cytotoxicity (ADCC) is an immune mechanism that causes immune effector cells to lyse antibody-coated target cells. Target cells are cells that specifically bind to antibodies or derivatives thereof comprising Fc regions, and the specific binding is usually through the protein portion of the N-terminus of the Fc region. As used herein, the term "reduced ADCC" is defined as a reduction in the number of target cells lysed by the ADCC mechanism defined above at a given antibody concentration in the culture medium surrounding the target cells within a given time, and / or an increase in the antibody concentration necessary to achieve lysis of a given number of target cells by the ADCC mechanism in the culture medium surrounding the target cells within a given time. ADCC reduction is relative to ADCC mediated by the same antibody produced by the same type of host cells but not yet engineered using the same standard production, purification, formulation and storage methods (such methods are known to those skilled in the art). For example, the reduction of ADCC mediated by an antibody comprising an amino acid substitution that reduces ADCC in the Fc domain is relative to ADCC mediated by the same antibody without the amino acid substitution in the Fc domain. Suitable assays for measuring ADCC are well known in the art (see, e.g., PCT Publication No. WO 2006 / 082515 or PCT Publication No. WO 2012 / 130831).
[0064] An "effective amount" of a pharmaceutical agent (eg, a pharmaceutical composition) refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
[0065] "Affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can generally be expressed by the dissociation constant (K D ) represents. Affinity can be measured by conventional methods known in the art, including those described herein. Specific illustrative and exemplary methods for measuring binding affinity are described below.
[0066] The term "amino acid" refers to naturally occurring amino acids and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are amino acids encoded by the genetic code, as well as amino acids that are later modified, such as hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds having the same basic chemical structure as naturally occurring amino acids, i.e., an α carbon bound to a hydrogen atom, a carboxyl group, an amino group, and an R group, such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. Amino acid mimetics refer to compounds that have a structure different from the general chemical structure of amino acids but function in a manner similar to naturally occurring amino acids. In this article, amino acids may be represented by their well-known three-letter symbols or the single-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Committee.
[0067] As used herein, the term "amino acid mutation" means that amino acid substitution, deletion, insertion and modification are covered. Any combination of substitution, deletion, insertion and modification can be performed to obtain the final construct, provided that the final construct has the desired characteristics, such as reduced binding to Fc receptors, or increased association with another peptide. Amino acid sequence deletions and insertions include amino terminal and / or carboxyl terminal deletions and insertions of amino acids. Specific amino acid mutations are amino acid substitutions. For the purpose of changing the binding characteristics of, for example, Fc regions, non-conservative amino acid substitutions, i.e., replacing one amino acid with another amino acid having different structures and / or chemical properties, are particularly preferred. Amino acid substitutions include replacement with non-naturally occurring amino acids or with naturally occurring amino acid derivatives of twenty standard amino acids (e.g., 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid mutations can be produced using genetic or chemical methods well known in the art. Genetic methods can include site-directed mutagenesis, PCR, gene synthesis, etc. It is also useful to envision methods for changing amino acid side chain groups by methods other than genetic engineering (such as chemical modification). Various names can be used herein to indicate the same amino acid mutation. For example, substitution of proline at position 329 of the Fc domain with glycine can be represented as 329G, G329, G 329 , P329G or Pro329Gly.
[0068] The term "antibody" herein is used in the broadest sense and includes various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity.
[0069] "Antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody and binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv and scFab); single domain antibodies (dAb); and multispecific antibodies formed from antibody fragments. For a review of certain antibody fragments, see Holliger and Hudson, Nature Biotechnology 23:1126-1136 (2005).
[0070] The term "antigen binding domain" refers to a portion of an antibody that includes a region that specifically binds to and is complementary to part or all of an antigen. The antigen binding domain can be provided, for example, by one or more antibody variable domains (also referred to as antibody variable regions). In particular, the antigen binding domain includes an antibody light chain variable domain (VL) and an antibody heavy chain variable domain (VH).
[0071] As used herein, the term "antigen binding molecule" in its broadest sense refers to a molecule that specifically binds to an antigenic determinant. Examples of antigen binding molecules are immunoglobulins and their derivatives, such as fragments thereof, and antigen binding receptors and their derivatives.
[0072] As used herein, the term "antigen binding portion" refers to a polypeptide molecule that specifically binds to an antigenic determinant. In one embodiment, the antigen binding portion is capable of directing the entity to which it is attached to a target site, for example, to a specific type of tumor cell or tumor stroma with an antigenic determinant. Antigen binding portions include antibodies and fragments thereof as further defined herein. Specific antigen binding portions include the antigen binding domain of an antibody, which includes an antibody heavy chain variable region and an antibody light chain variable region (e.g., scFv fragment). In certain embodiments, the antigen binding portion may include an antibody constant region as further defined herein and known in the art. Available heavy chain constant regions include any of the following five isotypes: α, δ, ε, γ or μ. Available light chain constant regions include any of the following two isotypes: κ and λ.
[0073] In the context of the present invention, the term "chimeric receptor" relates to an engineered receptor comprising: an extracellular domain comprising a mutated Fc domain, in particular a mutated CH2 and / or CH3 domain; a transmembrane domain; and at least one intracellular stimulatory signaling domain; and / or at least one co-stimulatory signaling domain. A chimeric receptor can be made from polypeptide parts of different origins. Therefore, it can also be understood as a "fusion protein" and / or a "chimeric protein". In general, a fusion protein is a protein produced by the combination of two or more genes (or preferably cDNAs) that originally encoded separate proteins. Translation of the fusion gene (or fusion cDNA) produces a single polypeptide, preferably with functional properties derived from each original protein. Recombinant fusion proteins are artificially produced by recombinant DNA technology for biological research or treatment. Further details of the chimeric receptors of the present invention are described below.
[0074] "Antigen binding site" refers to the site of an antigen binding molecule that provides interaction with an antigen, i.e., one or more amino acid residues. For example, the antigen binding site of an antibody comprises amino acid residues from the complementarity determining region (CDR). Natural immunoglobulin molecules typically have two antigen binding sites, and Fab molecules typically have a single antigen binding site.
[0075] The term "antigen binding domain" refers to a portion of an antibody or antigen binding receptor that contains a region that specifically binds to and is complementary to part or all of an antigen. The antigen binding domain can be provided, for example, by one or more immunoglobulin variable domains (also referred to as variable regions). Specifically, the antigen binding domain comprises an immunoglobulin light chain variable domain (VL) and an immunoglobulin heavy chain variable domain (VH).
[0076] As used herein, the term "antigenic determinant" is synonymous with "antigen" and "epitope", and refers to a site on a polypeptide macromolecule (e.g., a conformational configuration consisting of a continuous stretch of amino acids or different regions of non-continuous amino acids), to which an antigen-binding portion binds, thereby forming an antigen-binding portion-antigen complex. Useful antigenic determinants can be found, for example, on the surface of tumor cells, on the surface of virus-infected cells, on the surface of other diseased cells, on the surface of immune cells, in free matter in serum and / or in the extracellular matrix (ECM). Unless otherwise indicated, the protein referred to herein as an antigen can be any natural form of protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). In a specific embodiment, the antigen is a human protein. When referring to a specific protein herein, the term encompasses "full length", unprocessed protein, and any form of protein produced by intracellular processing. The term also encompasses naturally occurring protein variants, such as splice variants or allelic variants.
[0077] According to the present invention, "antibodies", i.e. therapeutic antibodies, may have one, two, three or more binding domains and may be monospecific, bispecific or multispecific. Antibodies may be full-length antibodies from a single species or may be chimeric or humanized. For antibodies having more than two antigen binding domains, some of the binding domains may be identical and / or have the same specificity.
[0078] As used herein, the term "transmembrane domain" or the abbreviation "TD" defines a polypeptide segment that is capable of integrating into the cell membrane (or plasma membrane) of a cell. A transmembrane domain can be fused to an extracellular and / or intracellular polypeptide domain, wherein these extracellular and / or intracellular polypeptide domains are constrained in the cell membrane. In the context of the chimeric receptors of the present invention, the transmembrane domain confers membrane attachment and constraint to the chimeric receptors of the present invention. The chimeric receptors of the present invention comprise at least one transmembrane domain and an extracellular domain comprising a CH2 domain. In addition, the transmembrane domain can be fused to an intracellular signaling domain.
[0079] The ability of an antigen binding portion to bind to a specific antigenic determinant can be measured by enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to those skilled in the art, such as surface plasmon resonance (SPR) technology (analyzed on a BIAcore instrument) (Liljeblad et al., Glyco J 17, 323-329 (2000)) and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). In one embodiment, the extent of binding of an antigen binding portion to an unrelated protein is less than about 10% of the extent of binding of the antigen binding portion to the antigen, as measured, for example, by SPR. In certain embodiments, the dissociation constant (K) of an antigen binding portion or an antigen binding molecule comprising the antigen binding portion binding to an antigen is D ) is ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM or ≤0.001 nM (e.g., 10 -8 M or lower, e.g. 10 -8 M to 10 -13 M, for example 10 -9 M to 10 -13 M).
[0080] As used herein, the term "CDR" refers to the "complementarity determining region" well known in the art. CDR is the part of an immunoglobulin, or antigen binding receptor, that determines the specificity of the molecule and contacts the specific ligand. CDR is the most variable part of the molecule and contributes to the antigen binding diversity of these molecules. There are three CDR regions CDR1, CDR2 and CDR3 in each V domain. CDR-H describes the CDR region of the variable heavy chain, while CDR-L relates to the CDR region of the variable light chain. VH means variable heavy chain and VL means variable light chain. CDR regions derived from Ig regions can be determined as described in: "Kabat" (Sequences of Proteins of Immunological Interest, 5th Edition NIH Publication no. 91-3242 U.S. Department of Health and Human Services (1991); Chothia J. Mol. Biol. 196 (1987), 901-917) or "Chothia" (Nature 342 (1989), 877-883).
[0081] The term "CD3z" refers to the T-cell surface glycoprotein CD3 zeta chain, also known as the "T-cell receptor T3 zeta chain" and "CD247".
[0082] The term "chimeric antigen receptor" or "CAR" refers to an antigen binding receptor consisting of an extracellular portion of an antigen binding portion (e.g., a single-chain antibody domain) fused to an intracellular signaling domain / co-signaling domain (such as, for example, CD3z and CD28) via a spacer sequence. Compared to CAR, the chimeric receptor according to the present invention comprises a different extracellular domain, that is, the extracellular domain of the chimeric receptor according to the present invention does not comprise a target antigen binding portion (e.g., the chimeric receptor of the present invention does not comprise scFv). However, the transmembrane domain and intracellular signaling domain contained in the chimeric receptor according to the present invention are similar or identical to the transmembrane domain and intracellular signaling domain that can be used in CAR.
[0083] The "class" of an antibody refers to the type of constant domain or constant region possessed by the heavy chain of the antibody. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and some of these antibodies can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. In some aspects, the antibody is an IgG1 isotype. In some aspects, the antibody is an IgG1 isotype with P329G, L234A, and L235A substitutions to reduce the effector function of the Fc region. In other aspects, the antibody is an IgG2 isotype. In some aspects, the antibody is an IgG4 isotype with S228P substitutions in the hinge region to improve the stability of the IgG4 antibody. The heavy chain constant domains corresponding to different classes of immunoglobulins are referred to as α, δ, ε, γ, and μ, respectively. The light chain of an antibody can be classified into one of two types based on the amino acid sequence of its constant domain, which are called kappa (κ) and lambda (λ).
[0084] As used in the present application, the term "human-derived constant region" or "human constant region" refers to the constant heavy chain region and / or constant light chain kappa or lambda region of a human antibody of subclass IgG1, IgG2, IgG3 or IgG4. Such constant regions can be used in human antibodies or humanized antibodies and are well known in the art and described, for example, by Kabat, EA, et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991) (see also, e.g., Johnson, G. and Wu, TT, Nucleic Acids Res. 28 (2000) 214-218; Kabat, EA, et al., Proc. Natl. Acad. Sci. USA 72 (1975) 2785-2788). Unless otherwise specified herein, the numbering of amino acid residues in the constant region is according to the EU numbering system (also known as Kabat's EU index) as described in Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th Edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991), NIH Publication 91-3242.
[0085] The so-called "crossover" Fab molecule (also referred to as "Crossfab") refers to the following Fab molecule: wherein the variable domains of the Fab heavy chain and light chain are exchanged (i.e., replaced with each other), i.e., the crossover Fab molecule comprises a peptide chain (VL-CH1, in the N-terminal to C-terminal direction) consisting of the light chain variable domain VL and the heavy chain constant domain 1CH1, and a peptide chain (VH-CL, in the N-terminal to C-terminal direction) consisting of the heavy chain variable domain VH and the light chain constant domain CL. For clarity, in the crossover Fab molecule in which the variable domains of the Fab light chain and the variable domains of the Fab heavy chain are exchanged, the peptide chain comprising the heavy chain constant domain 1CH1 is referred to herein as the "heavy chain" of the crossover Fab molecule.
[0086] As used herein, the term "CSD" refers to a costimulatory signaling domain. An example of a costimulatory signaling domain is the intracellular domain of CD137, or a fragment thereof.
[0087] "Effector functions" refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptor); and B cell activation.
[0088] As used herein, the terms "engineering, engineered, engineered" are considered to include any manipulation of the peptide backbone, or post-translational modification of a naturally occurring or recombinant polypeptide or fragment thereof. Engineering includes modifications to the amino acid sequence, glycosylation pattern, or side chain groups of individual amino acids, as well as combinations of these methods.
[0089] The term "expression cassette" refers to a recombinant or synthetically produced polynucleotide, and a series of specified nucleic acid elements that allow a specific nucleic acid to be transcribed in a target cell. The recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus or nucleic acid fragment. Typically, the recombinant expression cassette portion of the expression vector includes, in addition to other sequences, a nucleic acid sequence to be transcribed and a promoter. In certain embodiments, the expression cassette of the present invention comprises a polynucleotide sequence encoding a bispecific antigen binding molecule of the present invention or a fragment thereof.
[0090] "Fab molecule" refers to a protein composed of the VH and CH1 domains of the heavy chain ("Fab heavy chain") and the VL and CL domains of the light chain ("Fab light chain") of an immunoglobulin.
[0091] The term "Fc domain" or "Fc region" herein is used to define the C-terminal region of an immunoglobulin heavy chain, which contains at least a portion of a constant region. The term includes a native sequence Fc region and a variant Fc region. Although the boundaries of the IgG heavy chain Fc region may be slightly different, the human IgG heavy chain Fc region is generally defined as extending from Cys226 or from Pro230 to the carboxyl terminus of the heavy chain. However, the antibody produced by the host cell can undergo post-translational cleavage of one or more (particularly one or two) amino acids from the C-terminus of the heavy chain. Therefore, the antibody produced by the host cell by expressing a specific nucleic acid molecule encoding a full-length heavy chain can include a full-length heavy chain, or the antibody can include a cleavage variant (also referred to herein as "a cleaved variant heavy chain") of the full-length heavy chain. This may be a situation where the last two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, according to the Kabat EU index numbering). Therefore, the C-terminal lysine (Lys447) or C-terminal glycine (Gly446) and lysine (K447) in the Fc region may or may not exist. If not otherwise specified, the amino acid sequence of the heavy chain comprising the Fc domain (or the subunit of the Fc domain as defined herein) is represented herein as having no C-terminal glycine-lysine dipeptide. In one embodiment of the invention, the heavy chain of the subunit including the Fc domain as specified herein includes other C-terminal glycine-lysine dipeptide (G446 and K447, according to the EU index numbering of Kabat). In one embodiment of the invention, the heavy chain of the subunit including the Fc domain as specified herein includes other C-terminal glycine residues (G446, according to the EU index numbering of Kabat). The composition of the present invention, such as a pharmaceutical composition as described herein, comprises a population of antigen binding molecules of the present invention. The population of antigen binding molecules may include a molecule with a full-length heavy chain and a molecule with a cleaved variant heavy chain. The antigen binding molecule population can be composed of a mixture of molecules with full-length heavy chains and molecules with cut variant heavy chains, wherein at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the antigen binding molecules have cut variant heavy chains. In one embodiment of the invention, the composition comprising the antigen binding molecule population of the present invention comprises antigen binding molecules, and the antigen binding molecules comprise heavy chains, and the heavy chains comprise subunits of Fc domains as specified herein and other C-terminal glycine-lysine dipeptides (G446 and K447, according to the EU index numbering of Kabat). In one embodiment of the invention, the composition comprising the antigen binding molecule population of the present invention comprises immunoactivation Fc domain binding molecules, and the immunoactivation Fc domain binding molecules comprise heavy chains, and the heavy chains comprise subunits of Fc domains as specified herein and other C-terminal glycine residues (G446, according to the EU index numbering of Kabat).In one embodiment of the invention, such compositions comprise a population of antigen-binding molecules, which are composed of the following molecules: molecules comprising heavy chains comprising subunits of Fc domains as specified herein; molecules comprising heavy chains comprising subunits of Fc domains as specified herein and additional C-terminal glycine residues (G446, numbered according to the EU index of Kabat); and molecules comprising heavy chains comprising subunits of Fc domains as specified herein and additional C-terminal glycine-lysine dipeptides (G446 and K447, numbered according to the EU index of Kabat). Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is numbered according to the EU numbering system (also referred to as the EU index), as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Edition Public Health Service, National Institutes of Health, Bethesda, MD, 1991 (see also above). As used herein, a "subunit" of an Fc domain refers to one of the two polypeptides that form a dimeric Fc domain, i.e., a polypeptide comprising the C-terminal constant region of an immunoglobulin heavy chain, which polypeptide is capable of stable self-association. For example, a subunit of an IgG Fc domain comprises the IgG CH2 and IgG CH3 constant domains.
[0092] "Framework" or "FR" refers to the variable domain residues excluding the complementarity determining regions (CDRs). The FR of a variable domain is usually composed of the following four FR domains: FR1, FR2, FR3, and FR4. Therefore, CDR and FR sequences usually appear in the following sequence in VH (or VL): FR1-CDR-H1 (CDR-L1)-FR2-CDR-H2 (CDR-L2)-FR3-CDR-H3 (CDR-L3)-FR4.
[0093] The terms "full length antibody," "intact antibody," and "whole antibody" are used interchangeably herein to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
[0094] "Fusion" means that the components (eg, Fab and transmembrane domain) are linked by peptide bonds, either directly or via one or more peptide linkers.
[0095] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and progeny derived from the primary transformed cell, regardless of the number of passages. Progeny may not be identical to the nucleic acid content of the parent cell, but may contain mutations. Mutant progeny as screened or selected for the same function or biological activity as in the original transformed cell are included herein.
[0096] A "human antibody" is an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by a human or human cell, or derived from a non-human antibody using a full repertoire of human antibodies or other human antibody coding sequences. This definition of a human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues.
[0097] A "human consensus framework" is a framework that represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. In general, the selection of human immunoglobulin VL or VH sequences is from a subset of variable domain sequences. In general, a subset of sequences is a subset as described in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), Volumes 1-3. In one aspect, for VL, the subgroup is subgroup κI as in Kabat et al., supra. In one aspect, for VH, the subgroup is subgroup III as in Kabat et al., supra.
[0098] "Humanized" antibody (e.g., humanized scFv fragment) refers to a chimeric antibody comprising amino acid residues from non-human CDRs and amino acid residues from human FRs. In certain aspects, a humanized antibody will substantially comprise at least one, usually two, variable domains, wherein all or substantially all CDRs correspond to the CDRs of non-human antibodies, and all or substantially all FRs correspond to the FRs of human antibodies. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. An antibody in "humanized form," such as a non-human antibody, refers to an antibody that has undergone humanization.
[0099] As used herein, the term "hypervariable region" or "HVR" refers to individual regions of an antibody variable domain that are hypervariable in sequence and determine antigen binding specificity, such as the "complementarity determining region" ("CDR").
[0100] Typically, antibodies contain six CDRs; three in VH (CDR-H1, CDR-H2, CDR-H3), and three in VL (CDR-L1, CDR-L2, CDR-L3). Exemplary CDRs herein include:
[0101] (a) hypervariable loops occurring at the following amino acid residues: 26 to 32 (L1), 50 to 52 (L2), 91 to 96 (L3), 26 to 32 (H1), 53 to 55 (H2), and 96 to 101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987));
[0102] (b) CDRs occurring at the following amino acid residues: 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991)); and
[0103] (c) Antigenic contact points occur at the following amino acid residues: 27c to 36 (L1), 46 to 55 (L2), 89 to 96 (L3), 30 to 35b (H1), 47 to 58 (H2), and 93 to 101 (H3) (MacCallum et al., J. Mol. Biol. 262:732-745 (1996)).
[0104] Unless otherwise indicated, CDRs are determined according to the method described in Kabat et al., supra. One skilled in the art will appreciate that CDR names may also be determined according to the method described in Chothia, supra, the method described in McCallum, supra, or any other scientifically accepted naming system.
[0105] As used herein, "immune activation part" refers to one or more polypeptides that induce activation of the immune cell (e.g., T cell) when interacting with an antigen, receptor or ligand (or other elements of induced activated cells) on an immune cell. An exemplary immune activation part is a cytokine (e.g., IL2), an antigen binding portion that can be combined with a co-stimulatory T cell antigen (e.g., CD28, 4-1BB) or a co-stimulatory ligand (e.g., 4-1BBL), as described herein and in WO2021 / 255138.
[0106] An "immunoconjugate" is an antibody conjugated to one or more heterologous molecules, including but not limited to a cytotoxic agent.
[0107] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain aspects, an individual or subject is a human.
[0108] An "isolated" antibody is one that has been separated from a component of its natural environment. In some aspects, the antibody is purified to a purity greater than 95% or 99% as determined by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed phase HPLC). For a review of methods for assessing antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007).
[0109] The term "immunoglobulin molecule" refers to a protein with the structure of a naturally occurring antibody. For example, the IgG class immunoglobulin is a heterotetrameric glycoprotein of about 150,000 daltons, which is composed of two light chains and two heavy chains bonded by disulfide bonds. From the N-terminus to the C-terminus, each heavy chain has a variable domain (VH) (also referred to as a variable heavy chain domain or a heavy chain variable region), followed by three constant domains (CH1, CH2, and CH3) (also referred to as a heavy chain constant region). Similarly, from the N-terminus to the C-terminus, each light chain has a variable domain (VL) (also referred to as a variable light chain domain or a light chain variable region), followed by a constant light chain (CL) domain (also referred to as a light chain constant region). The heavy chains of immunoglobulins can be assigned to one of five types: called α (IgA), δ (IgD), ε (IgE), γ (IgG) or μ (IgM), some of which can be further divided into subtypes, such as γ1 (IgG1), γ2 (IgG2), γ3 (IgG3), γ4 (IgG4), α1 (IgA1) and α2 (IgA2). The light chains of immunoglobulins can be assigned to one of two types based on the amino acid sequence of their constant domains: called kappa (κ) and lambda (λ). Immunoglobulins are essentially composed of two Fab molecules and an Fc domain connected by the immunoglobulin hinge region.
[0110] "Isolated nucleic acid" molecules or polynucleotides mean nucleic acid molecules, DNA or RNA that have been taken out of their natural environment. For example, recombinant polynucleotides encoding polypeptides contained in vectors are considered to be isolated for the purposes of the present invention. Other examples of isolated polynucleotides include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially purified) polynucleotides in solution. Isolated polynucleotides include polynucleotide molecules that are contained in cells that usually contain polynucleotide molecules, but the polynucleotide molecules are present outside the chromosome or in a chromosomal position different from its natural chromosomal position. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the present invention, as well as positive and negative strand forms and double-stranded forms. Isolated polynucleotides or nucleic acids according to the present invention further include such molecules produced by synthesis. In addition, polynucleotides or nucleic acids may be or may include regulatory elements, such as promoters, ribosome binding sites or transcription terminators.
[0111] With respect to a nucleic acid or polynucleotide having a nucleotide sequence that is at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is meant that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include mutations at most five points per 100 nucleotides of the reference nucleotide sequence. In other words, in order to obtain a polynucleotide having a nucleotide sequence that is at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These changes in the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, or may be interspersed individually among the residues of the reference sequence, or may be interspersed in one or more consecutive groups within the reference sequence. As a practical matter, known computer programs, such as those discussed below for polypeptides (e.g., ALIGN-2), can be used to routinely determine whether any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention.
[0112] By "isolated polypeptide" or variant or derivative thereof is meant a polypeptide that is not in its natural environment. No particular level of purification is required. For example, an isolated polypeptide may be removed from its native or natural environment. Recombinantly produced polypeptides and proteins expressed in host cells are considered isolated for purposes of the present invention, as are native or recombinant polypeptides that have been separated, fractionated, or partially or substantially purified by any suitable technique.
[0113] "Modifications that promote the association of the first and second subunits of the Fc domain" are manipulations of the peptide backbone or post-translational modifications of the Fc domain subunits that reduce or prevent the association of a polypeptide comprising the Fc domain subunit with the same polypeptide to form a homodimer. As used herein, modifications that promote association particularly include separate modifications to each of the two Fc domain subunits (i.e., the first and second subunits of the Fc domain) that are desired to associate, wherein the modifications complement each other to promote the association of the two Fc domain subunits. For example, modifications that promote association may change the structure or charge of one or both of the Fc domain subunits so as to make their association sterically or electrostatically favorable, respectively. Thus, (heterologous) dimerization occurs between a polypeptide comprising the first Fc domain subunit and a polypeptide comprising the second Fc domain subunit, which may be different in the sense that the additional components (e.g., antigen binding moieties) fused to each subunit are not the same. In some embodiments, modifications that promote association include amino acid mutations, particularly amino acid substitutions, in the Fc domain. In a specific embodiment, the modifications promoting association comprise individual amino acid mutations, in particular amino acid substitutions, of each of the two subunits of the Fc domain.
[0114] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous antibody population, that is, except for possible variant antibodies (e.g., containing naturally occurring mutations or produced during the production of monoclonal antibody preparations, such variants are usually present in small amounts), the individual antibodies comprising the population have identity and / or bind to the same epitope. Contrary to the polyclonal antibody preparations that typically include different antibodies for different determinants (epitopes), each monoclonal antibody in the monoclonal antibody preparation is directed to a single determinant on the antigen. Therefore, the modifier "monoclonal" represents that the feature of the antibody is obtained from a substantially homogeneous antibody population, and should not be interpreted as requiring antibody to be produced by any ad hoc method. For example, the monoclonal antibody according to the present invention can be prepared by a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of human immunoglobulin loci, such methods and other exemplary methods for preparing monoclonal antibodies are described herein.
[0115] A "naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (eg, a cytotoxic moiety) or a radiolabel. Naked antibodies can be present in pharmaceutical compositions.
[0116] "Native antibodies" refer to naturally occurring immunoglobulin molecules with different structures. For example, natural IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, consisting of two identical light chains and two identical heavy chains that are disulfide bonded. From the N-terminus to the C-terminus, each heavy chain has a variable domain (VH), also known as a variable heavy chain domain or a heavy chain variable region, followed by three constant heavy chain domains (CH1, CH2, and CH3). Similarly, from the N-terminus to the C-terminus, each light chain has a variable domain (VL), also known as a variable light chain domain or a light chain variable region, followed by a constant light chain (CL) domain.
[0117] "Amino acid sequence identity percentage (%)" relative to a reference polypeptide sequence is defined as the percentage of amino acid residues in the candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence after aligning the candidate sequence with the reference polypeptide sequence and introducing spaces (if necessary) to achieve maximum sequence identity percentage, and for the purpose of alignment without considering any conservative substitutions as components of sequence identity. Alignment for determining amino acid sequence identity percentage can be achieved in various ways within the technical scope of the art, for example, using publicly available computer software, such as BLAST, BLAST-2, Clustal W, Megalign (DNASTAR) software or FASTA program package. Those skilled in the art can determine the appropriate parameters for aligning sequences, including any algorithm required for achieving maximum alignment over the full length of the compared sequence. Alternatively, the sequence comparison computer program ALIGN-2 can be used to generate identity percentage values. The ALIGN-2 sequence comparison computer program was written by Genentech, Inc. and the source code has been filed with user documentation in the US Copyright Office, Washington DC, 20559, where it is registered under US Copyright Registration No. TXU510087 and is described in WO 2001 / 007611.
[0118] Unless otherwise indicated, for the purposes of this article, the values of percent amino acid sequence identity are generated using the BLOSUM50 comparison matrix using the ggsearch program of the FASTA package version 36.3.8c or higher. The FASTA package is by W.R. Pearson and D.J. Lipman (1988), "Improved Tools for Biological Sequence Analysis", PNAS 85:2444-2448; W.R. Pearson (1996) "Effective protein sequence comparison" Meth. Enzymol. 266:227-258; and Pearson et al., (1997) Genomics 46:24-36 creation and publicly available from www.fasta.bioch.virginia.edu / fasta_www2 / fasta_down.shtml or http: / / www.ebi.ac.uk / Tools / sss / fasta. Alternatively, sequences can be compared using a public server accessible at fasta.bioch.virginia.edu / fasta_www2 / index.cgi, using the ggsearch (global protein:protein) program and default options (BLOSUM50; open: -10; ext: -2; Ktup=2) to ensure that a global rather than a local alignment is performed. The percentage of amino acid identity is given in the output alignment title. The term "nucleic acid molecule" refers to a base sequence consisting of a polynucleotide containing purine and pyrimidine bases, wherein the bases represent the primary structure of the nucleic acid molecule. Here, the term nucleic acid molecule includes DNA, cDNA, genomic DNA, RNA, synthetic forms of DNA, and mixed polymers containing two or more of these molecules. In addition, the term nucleic acid molecule includes both the sense strand and the antisense strand. In addition, as readily understood by those skilled in the art, the nucleic acid molecules described herein may contain non-natural or derived nucleotide bases.
[0119] The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and / or warnings concerning the use of such therapeutic products.
[0120] The term "pharmaceutical composition" refers to a preparation which is in such form that the biological activity of the active ingredient contained therein is effective and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered. Pharmaceutical compositions typically contain one or more pharmaceutically acceptable carriers.
[0121] "Pharmaceutically acceptable carrier" refers to a component of a pharmaceutical composition other than the active ingredient that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.
[0122] As used herein, the term "polypeptide" refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also called peptide bonds).
[0123] The term "polypeptide" refers to any chain of two or more amino acids, rather than the specific length of the product. Therefore, peptides, dipeptides, tripeptides, oligopeptides, "proteins", "amino acid chains" or any other terms used to refer to chains with two or more amino acids are included in the definition of "polypeptide", and the term "polypeptide" can be used instead of any of these terms, or can be used interchangeably with any of these terms. The term "polypeptide" is also intended to refer to the post-expression modification product of the polypeptide, which post-expression modification includes but is not limited to glycosylation, acetylation, phosphorylation, amidation, derivatization with known protection / blocking groups, proteolytic cleavage, or modification with non-naturally occurring amino acids. The polypeptide can be derived from a natural biological source or produced by recombinant technology, and is not necessarily translated from a specified nucleic acid sequence. It can be generated in any way, including by chemical synthesis. The size of a polypeptide of the invention can be about 3 or more, 5 or more, 10 or more, 20 or more, 25 or more, 50 or more, 75 or more, 100 or more, 200 or more, 500 or more, 1,000 or more, or 2,000 or more amino acids. Polypeptides can have a defined three-dimensional structure, but they do not necessarily have such a structure. Polypeptides with a defined three-dimensional structure are referred to as folded; and polypeptides that do not have a defined three-dimensional structure, but can adopt a large number of different conformations, are referred to as unfolded.
[0124] The term "polynucleotide" refers to an isolated nucleic acid molecule or construct, such as messenger RNA (mRNA), virally derived RNA, or plasmid DNA (pDNA). A polynucleotide may contain conventional phosphodiester bonds or unconventional bonds (e.g., amide bonds, such as those present in peptide nucleic acids (PNA)). The term nucleic acid molecule refers to any one or more nucleic acid segments, such as DNA or RNA fragments, present in a polynucleotide.
[0125] "Decreased binding" (e.g., reduced binding to an Fc receptor) refers to a decrease in affinity for the corresponding interaction, as measured, for example, by SPR. For clarity, the term also includes a decrease in affinity to zero (or below the detection limit of the analytical method), i.e., complete elimination of the interaction. Conversely, "increased binding" refers to an increase in binding affinity for the corresponding interaction.
[0126] The term "regulatory sequence" refers to a DNA sequence that is necessary for achieving expression of the coding sequence to which it is linked. The nature of such control sequences varies depending on the host organism. In prokaryotes, control sequences typically include promoters, ribosome binding sites, and terminators. In eukaryotes, control sequences typically include promoters, terminators, and in some cases enhancers, transactivators, or transcription factors. The term "control sequence" is intended to include at least all components necessary for expression, and may also include other advantageous components.
[0127] As used herein, the term "single chain" refers to a molecule comprising amino acid monomers linearly linked by peptide bonds. In certain embodiments, one of the antigen binding moieties is a single-chain Fab molecule, i.e., a Fab molecule in which a Fab light chain and a Fab heavy chain are connected by a peptide linker to form a single peptide chain. In a specific embodiment of this type, the C-terminus of the Fab light chain in the single-chain Fab molecule is connected to the N-terminus of the Fab heavy chain.
[0128] As used herein, the term "SSD" refers to a "stimulatory signaling domain." An example of a stimulatory signaling domain is the intracellular domain of CD3z, or a fragment thereof.
[0129] As used herein, "treatment" (and grammatical variants thereof such as treat or treat) refers to an attempt to alter the natural course of the disease in the individual being treated, and may be performed for prevention or clinical interventions that may be performed during clinical pathology. Desired effects of treatment include, but are not limited to, preventing the occurrence or recurrence of the disease, alleviating symptoms, attenuating any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, ameliorating or alleviating the disease state, and alleviating or improving prognosis. In some aspects, the antibodies of the invention are used to delay the development of a disease or slow the progression of a disease.
[0130] As used herein, "T cell activation" refers to one or more cellular responses of T lymphocytes, particularly cytotoxic T lymphocytes, selected from: proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, and expression of activation markers. The immunoactivating Fc domain binding molecules of the present invention are capable of inducing T cell activation. Suitable assays for measuring T cell activation are known in the art as described herein.
[0131] A "therapeutically effective amount" of an agent (e.g., a pharmaceutical composition) is an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or preventive result. A therapeutically effective amount of an agent, for example, eliminates, reduces, delays, minimizes, or prevents an adverse effect of a disease.
[0132] The term "valency" as used herein means that there is a specified number of antigen binding sites in an antigen binding molecule. Thus, the term "monovalently binds to an antigen" means that there is one (and no more than one) antigen binding site specific for an antigen in an antigen binding molecule.
[0133] The term "variable region" or "variable domain" refers to the domain of an antibody heavy chain or light chain that participates in the binding of an antibody to an antigen. The variable domains of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have similar structures, wherein each domain comprises four conserved framework regions (FRs) and three complementary determining regions (CDRs). (See, e.g., Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co., p. 91 (2007).) A single VH or VL domain may be sufficient to confer antigen binding specificity. In addition, antibodies that bind to a specific antigen can be isolated using the VH or VL domains from antibodies that bind to the antigen, respectively, to screen for libraries of complementary VL or VH domains. See, e.g., Portolano et al., J. Immunol. 150: 880-887 (1993); Clarkson et al., Nature 352: 624-628 (1991).
[0134] The term "vector" as used herein refers to a nucleic acid molecule capable of carrying another nucleic acid to which it is linked. The term includes vectors that are self-replicating nucleic acid structures, as well as vectors that are incorporated into the genome of a host cell into which they have been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operably linked. Such vectors are referred to herein as "expression vectors."
[0135] Chimeric receptors of the present invention
[0136] The present invention relates to chimeric receptors comprising an extracellular domain comprising a mutated Fc domain, or fragments thereof (such as a CH2 and / or CH3 domain).
[0137] Provided herein is a chimeric receptor comprising a mutated Fc domain or fragment thereof and a transmembrane domain.
[0138] The mutated Fc domain can specifically interact with an antigen binding molecule (e.g., an antibody according to the present invention) to target cells expressing the chimeric receptor of the present invention to target cells (e.g., tumor cells) or to deliver effector molecules (e.g., cytokines) to cells expressing the chimeric receptor of the present invention.
[0139] In one embodiment, the extracellular domain comprises a mutated CH2 domain and / or a mutated CH3 domain. In one embodiment, the extracellular domain comprises a mutated CH2 domain.
[0140] The intracellular portion of the chimeric receptor can provide stimulation and co-stimulatory activity to cells (e.g., T cells) comprising the chimeric receptor. Therefore, further provided herein is a chimeric receptor comprising at least one intracellular stimulatory signaling domain and / or at least one co-stimulatory signaling domain.
[0141] The chimeric receptors of the invention can be used in a variety of therapeutic and non-therapeutic applications.
[0142] For example, the chimeric receptors of the present invention can be used to guide (or target) immune cells (such as T cells) to target cells through therapeutic antibodies, which include at least one antigen binding portion that can bind to the mutated Fc domain of the chimeric receptor but cannot bind to the non-mutated parent Fc domain. In a preferred embodiment, the antibody is a multispecific antibody, that is, the antibody includes at least one antigen binding portion that can bind to a target cell antigen and at least one antigen binding portion that can bind to the mutated Fc domain of the chimeric receptor. The therapeutic antibody can bind to the target cell and the immune cell containing the chimeric receptor located on the immune cell at the same time, whereupon the immune cell is activated (see, e.g., Figure 3A and Fig. 6A ).
[0143] According to this concept, a chimeric receptor comprising a mutated Fc domain is used to guide effector cells to target cells based on the target specificity of therapeutic antibodies. The chimeric receptor becomes inactive in the absence of therapeutic antibodies, and importantly, shows improved safety. The chimeric receptor of the present invention comprising a mutated Fc domain is not able to bind, for example, in the patient's tissue. This is in contrast to a CAR comprising an antigen binding portion (eg, scFv), which may show off-target or target off-tumor binding, which may lead to unnecessary toxicity.
[0144] Another exemplary use of the chimeric receptors of the invention is to specifically target effector molecules (e.g., cytokines) to cells, particularly T cells, comprising the chimeric receptors of the invention (see, e.g., Figure 7 ).
[0145] Notably, a CH2 domain comprising the P329G substitution (EU numbering) has been tested in clinical trials without inducing anti-drug antibodies. Furthermore, the P329G substitution prevents interaction with activating Fcγ receptors that are abundantly expressed by a variety of innate immune cells.
[0146] Thus, the present invention provides improved chimeric receptors for use in improving the treatment of, for example, cancer.
[0147] The present invention further relates to transducing T cells, such as CD8+ T cells, CD4+ T cells, CD3+ T cells, γδ T cells, natural killer (NK) cells, NKT cells or macrophages, preferably CD8+ T cells, with a chimeric receptor as described herein, and targeting their recruitment (for example) to a tumor, by an antibody molecule (e.g., a therapeutic antibody capable of binding to a mutated Fc domain).
[0148] As shown in the accompanying examples, as a proof of concept, a chimeric receptor comprising a CH2 domain comprising the P329G substitution according to the present invention (SEQ ID NO:87, as encoded by the DNA sequence shown in SEQ ID NO:96 and as Figure 1A ), which is capable of binding to a therapeutic antibody as described herein. Transduced T cells expressing a construct according to SEQ ID NO: 87 (Jurkat NFAT T cells) can be strongly activated by co-incubation with an antibody comprising two antigen binding portions capable of binding to FolR1 and one antigen binding portion capable of binding to a CH2 domain comprising a P329G substitution, but not capable of binding to a non-mutated parental Fc domain (see, e.g., FIG. 3 ). The antibody may further comprise a substitution other than glycine (G) at position P329 in the Fc domain to prevent multimerization of the therapeutic antibody (e.g., the antibody may further comprise a P329R substitution).
[0149] As a further proof of concept, a chimeric receptor was constructed comprising a CH2-CH3 domain comprising an AAA substitution according to the present invention (SEQ ID NO: 105, as encoded by the DNA sequence set forth in SEQ ID NO: 107 and as Figure 1B ), which can bind to a therapeutic antibody as described herein. Transduced T cells expressing a construct according to SEQ ID NO: 105 (Jurkat NFAT T cells) can be strongly activated by co-incubation with an antibody comprising two antigen binding portions capable of binding to FolR1 and one antigen binding portion capable of binding to a CH2-CH3 domain comprising I253A, H310A, H435A substitutions, but not capable of binding to a non-mutated parental Fc domain (see, e.g., FIG6 ).
[0150] The concepts and components of the present invention will be described in further detail below.
[0151] In one aspect of the invention, pairing a tumor-specific antibody as described herein with a T cell transduced with a chimeric receptor as described herein results in specific activation of the T cell and subsequent lysis of the tumor cell. As described above, this approach has significant safety advantages over traditional T cell-based approaches. Importantly, in the absence of an antibody capable of binding to a mutated Fc domain, the T cell is inert.
[0152] For many antigen binding moieties, it is difficult to completely avoid nonspecific binding in patients, which may lead to unnecessary toxicity. The present invention provides a two-component system in which a molecule (e.g., a therapeutic antibody) with an antigen binding moiety has a defined half-life in vivo. This is in contrast to, for example, CAR-T cells, which are permanently present in patients after application. Therefore, unnecessary toxicity in the treatment of CAR-T methods is limited. In contrast, the chimeric receptors provided herein do not include an antigen binding moiety, but rather a mutated Fc domain that exhibits very well-known in vivo activity characteristics. This method provides the potential to greatly reduce side effects and increase treatment safety based thereon.
[0153] The extent of T cell activation can be further modulated by adjusting the dose of the co-administered therapeutic antibody or by switching to a different antibody specificity or format.
[0154] Mutated Fc domain or fragment thereof
[0155] In one aspect, a chimeric receptor is provided, which comprises a mutated Fc domain or a fragment thereof. The Fc domain and its subdomains are well known in the art and are also described herein. The Fc domain is composed of a pair of polypeptide chains comprising the heavy chain constant domain of an immunoglobulin molecule. For example, the Fc domain of an immunoglobulin G (IgG) molecule is a dimer, and each subunit of the dimer comprises CH2 and CH3 IgG heavy chain constant domains. The two subunits of the Fc domain can stably associate with each other. The extracellular domain according to the present invention comprises one or two subunits of an IgG Fc domain or a fragment thereof (or a dimer of its fragment, such as, a CH2 dimer). In one aspect, the extracellular domain comprises an IgG Fc domain or a fragment thereof. In a specific embodiment, the extracellular domain comprises an IgG1 Fc domain or a fragment thereof, or an IgG4 Fc domain or a fragment thereof.
[0156] In one embodiment, the mutated Fc domain is a mutated CH2 domain and / or a mutated CH3 domain. In one embodiment, the mutated Fc domain is a mutated CH2 domain. In one embodiment, the extracellular domain comprises a mutated CH2 domain and / or a mutated CH3 domain. In one embodiment, the extracellular domain comprises a mutated CH2 domain.
[0157] In one embodiment, the mutated Fc domain comprises at least one amino acid substitution at a position selected from the group consisting of: L234, L235, I253, H310, P331, P329 and H435 (numbered according to the Kabat EU index), in particular, wherein the amino acid substitution is L234A, L235A, I253A, N297A, H310A, P329G and / or H435A.
[0158] In a preferred embodiment, the extracellular domain comprises a mutated CH2 domain, in particular, wherein the mutated CH2 domain comprises the amino acid substitution P329G (numbering according to the Kabat EU index).
[0159] In another preferred embodiment, the extracellular domain comprises a mutated CH2 domain and / or a mutated CH3 domain, in particular, wherein the mutated CH2 domain and / or the mutated CH3 domain comprises an amino acid substitution (numbered according to the KabatEU index):
[0160] (a) I253A, H310A and H435A;
[0161] (b)I253A
[0162] (c) I253A and H310A
[0163] (d) I253A and H435A
[0164] (e)H310A and H435A
[0165] (f) H310A, or
[0166] (g)H435A.
[0167] In another preferred embodiment, the extracellular domain comprises a mutated CH2 domain and / or a mutated CH3 domain, in particular, wherein the mutated CH2 domain and / or the mutated CH3 domain comprises an amino acid substitution (numbered according to the KabatEU index):
[0168] (a) I253A, H310A and H435A;
[0169] (b)I253A
[0170] (c) I253A and H310A
[0171] (d) I253A and H435A
[0172] (e)H310A and H435A
[0173] (f) H310A;
[0174] (g) H435A;
[0175] (h) L234A, L235A and P329G; or (i) L234A, L235A, I253A, H310A, P329G and H435A.
[0176] In one embodiment, the extracellular domain comprising a mutated CH2 domain and / or a mutated CH3 domain further comprises an amino acid substitution selected from the group consisting of P329G, P329L, P329I, P329R and P329A (numbered according to the Kabat EU index).
[0177] In a preferred embodiment, the extracellular domain comprises a mutated CH2 domain and a mutated CH3 domain, wherein the mutated CH2 domain and the mutated CH3 domain comprise amino acid substitutions I253A, H310A, P329G and H435A (numbered according to the Kabat EU index). In one such embodiment, the chimeric receptor is combined with a therapeutic antibody as described herein comprising a P329R substitution (numbered according to Kabat) and an antigen binding portion capable of binding to a CH2 domain comprising a P329R substitution.
[0178] In another preferred embodiment, the extracellular domain comprises a mutated CH2 domain and a mutated CH3 domain, wherein the mutated CH2 domain and the mutated CH3 domain comprise amino acid substitutions I253A, H310A, P329R and H435A (numbered according to the Kabat EU index). In one such embodiment, the chimeric receptor is combined with a therapeutic antibody as described herein comprising a P329G substitution (numbered according to Kabat) and an antigen binding portion capable of binding to a CH2 domain comprising a P329R substitution.
[0179] In one embodiment, the extracellular domain does not comprise a VH and / or VL domain.
[0180] In the context of the present invention, the antigen binding receptor comprises an extracellular domain that is not naturally present in or on a T cell. Thus, the antigen binding receptor is able to provide customized binding specificity for a cell expressing an antigen binding receptor according to the present invention. In one embodiment, the extracellular domain comprises a mutated CH2 domain. In one embodiment, the extracellular domain comprises a mutated Fc domain or a fragment thereof, wherein the mutated Fc domain or a fragment thereof comprises or consists of one of the following mutated CH2 domains (1) to (18).
[0181] (1) In one embodiment, the mutated CH2 domain comprises or consists of an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 20, wherein the mutated CH2 domain comprises amino acid G329 (according to Kabat numbering).
[0182] (2) In one embodiment, the mutated CH2 domain comprises or consists of an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:20, wherein the mutated CH2 domain comprises glycine (G) at position 99, wherein the numbering is relative to the sequence of SEQ ID NO:20.
[0183] (3) In one embodiment, the mutated CH2 domain comprises or consists of the amino acid sequence of SEQ ID NO: 20.
[0184] (4) In one embodiment, the mutated CH2 domain comprises or consists of an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:21, wherein the mutated CH2 domain comprises amino acid L329 (according to Kabat numbering).
[0185] (5) In one embodiment, the mutated CH2 domain comprises or consists of an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:21, wherein the mutated CH2 domain comprises a leucine (L) at position 99, wherein the numbering is relative to the sequence of SEQ ID NO:21.
[0186] (6) In one embodiment, the mutated CH2 domain comprises or consists of the amino acid sequence of SEQ ID NO:21.
[0187] (7) In one embodiment, the mutated CH2 domain comprises or consists of an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:22, wherein the mutated CH2 domain comprises amino acid I329 (according to Kabat numbering).
[0188] (8) In one embodiment, the mutated CH2 domain comprises or consists of an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:22, wherein the mutated CH2 domain comprises isoleucine (I) at position 99, wherein the numbering is relative to the sequence of SEQ ID NO:22.
[0189] (9) In one embodiment, the mutated CH2 domain comprises or consists of the amino acid sequence of SEQ ID NO:22.
[0190] (10) In one embodiment, the mutated CH2 domain comprises or consists of an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:23, wherein the mutated CH2 domain comprises amino acid R329 (according to Kabat numbering).
[0191] (11) In one embodiment, the mutated CH2 domain comprises or consists of an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:23, wherein the mutated CH2 domain comprises arginine (R) at position 99, wherein the numbering is relative to the sequence of SEQ ID NO:23.
[0192] (12) In one embodiment, the mutated CH2 domain comprises or consists of the amino acid sequence of SEQ ID NO:23.
[0193] (13) In one embodiment, the mutated CH2 domain comprises or consists of an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:24, wherein the mutated CH2 domain comprises amino acid A329 (according to Kabat numbering).
[0194] (14) In one embodiment, the mutated CH2 domain comprises or consists of an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:24, wherein the mutated CH2 domain comprises an alanine (A) at position 99, wherein the numbering is relative to the sequence of SEQ ID NO:24.
[0195] (15) In one embodiment, the mutated CH2 domain comprises or consists of the amino acid sequence of SEQ ID NO:24.
[0196] (16) In one embodiment, the mutated CH2 domain comprises or consists of an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:86, wherein the mutated CH2 domain comprises amino acids A234, A235 and G329 (according to Kabat numbering).
[0197] (17) In one embodiment, the mutated CH2 domain comprises or consists of an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:86, wherein the mutated CH2 domain comprises alanine (A) at positions 4 and 5 and glycine (G) at position 99, wherein the numbering is relative to the sequence of SEQ ID NO:86.
[0198] (18) In a preferred embodiment, the mutated CH2 domain comprises or consists of the amino acid sequence of SEQ ID NO:86.
[0199] In a specific preferred embodiment, a chimeric receptor is provided, which comprises an extracellular domain and a transmembrane domain, wherein the extracellular domain comprises a mutated CH2 domain, and the mutated CH2 domain comprises or consists of the amino acid sequence of SEQ ID NO: 86.
[0200] Optionally, the mutated CH2 domain as described above further comprises a CH3 domain. As can be seen in Example 7, the inclusion of a CH3 domain can produce a stronger effect (even if the antibody capable of binding to the chimeric receptor of the present invention is directed against the mutated CH2 domain). Without being bound by theory, the inventors believe that the inclusion of a CH2-CH3 domain in the extracellular domain will result in stronger expression of the chimeric receptor. The expression of the chimeric receptor can be measured using methods known in the art such as those described in the accompanying examples.
[0201] In one embodiment, the CH3 domain is a mutated CH3 domain.In one embodiment, the extracellular domain comprises a mutated CH2-CH3 domain (ie, a CH2 domain fused to a CH3 domain, optionally via a peptide linker).
[0202] In one embodiment, the extracellular domain comprises a mutated Fc domain or a fragment thereof, wherein the mutated Fc domain or a fragment thereof comprises or consists of one of the following mutated CH2-CH3 domains (1) to (4).
[0203] (1) In one embodiment, the mutated CH2-CH3 domain comprises or consists of the amino acid sequence of SEQ ID NO: 27.
[0204] (2) In one embodiment, the mutated CH2-CH3 domain comprises or consists of the amino acid sequence of SEQ ID NO: 105.
[0205] (3) In one embodiment, the mutated CH2-CH3 domain comprises or consists of the amino acid sequence of SEQ ID NO: 124.
[0206] (4) In one embodiment, the mutated CH2-CH3 domain comprises or consists of the amino acid sequence of SEQ ID NO: 126.
[0207] Transmembrane domain (TD)
[0208] In the context of the present invention, any transmembrane domain of a transmembrane protein specified by the CD-nomenclature can be used to generate a chimeric receptor according to the invention.
[0209] Thus, in the context of the present invention, the transmembrane domain may comprise a portion of a murine / mouse or preferably human transmembrane domain. An example of such a transmembrane domain is the transmembrane domain of CD8, for example, having an amino acid sequence as shown in SEQ ID NO: 89 herein (as encoded by the DNA sequence as shown in SEQ ID NO: 98). In the context of the present invention, the transmembrane domain of the chimeric receptor of the present invention may comprise or consist of an amino acid sequence as shown in SEQ ID NO: 89 (as encoded by the DNA sequence as shown in SEQ ID NO: 98).
[0210] In another embodiment, the chimeric receptor provided herein can comprise the transmembrane domain of CD28, which is located in the human full-length CD28 protein as shown in SEQ ID NO: 41 (as shown by SEQ ID to 179, 170 to 179, 171 to 179, 172 to 179, 173 to 179, 174 to 179, 175 to 179, 176 to 179, 177 to 179 or 178 to 179 of the cDNA shown in NO:40).
[0211] Alternatively, any protein having a transmembrane domain, as provided by the CD nomenclature, can be used as the transmembrane domain of the chimeric receptor protein of the present invention.
[0212] In some embodiments, the transmembrane domain comprises a transmembrane domain of any one of the group consisting of CD27 (SEQ ID NO:37, encoded by SEQ ID NO:36), CD137 (SEQ ID NO:45, encoded by SEQ ID NO:44), OX40 (SEQ ID NO:49, encoded by SEQ ID NO:48), ICOS (SEQ ID NO:53, encoded by SEQ ID NO:52), DAP10 (SEQ ID NO:57, encoded by SEQ ID NO:56), DAP12 (SEQ ID NO:61, encoded by SEQ ID NO:60), CD3z (SEQ ID NO:64, encoded by SEQ ID NO:65), FCGR3A (SEQ ID NO:68, encoded by SEQ ID NO:69), NKG2D (SEQ ID NO:72, encoded by SEQ ID NO:73), CD8 (SEQ ID NO:82, encoded by SEQ ID NO:83), or a transmembrane fragment thereof that retains the ability to anchor the chimeric receptor to a membrane.
[0213] Human sequences may be beneficial in the context of the co-invention, for example because (part of) the transmembrane domain may be accessible from the extracellular space and thus to the patient's immune system.
[0214] Signaling domain (SSD) and co-stimulatory domain (CSD)
[0215] Preferably, the chimeric receptor of the present invention comprises at least one stimulatory signaling domain and / or at least one co-stimulatory signaling domain. Thus, the chimeric receptor provided herein preferably comprises a stimulatory signaling domain that provides T cell activation. The chimeric receptor provided herein may comprise a stimulatory signaling domain which is a fragment / polypeptide portion of rat / mouse or human CD3z (the UniProt entry for human CD3z is P20963 (version 177, sequence number 2); the UniProt entry for rat / mouse CD3z is P24161 (primary citable accession number) or Q9D3G3 (secondary citable accession number), version 143, sequence number 1)), Fcgr3A (the UniProt entry for human FCGR3A is P08637 (version 178, sequence number 2)) or NKG2D (the UniProt entry for human NKG2D is P26718 (version 151, sequence number 1); the UniProt entry for rat / mouse NKG2D is O54709 (version 132, sequence number 2)).
[0216] Thus, the stimulatory signaling domain included in the chimeric receptors provided herein can be a fragment / polypeptide portion of full-length CD3z, Fcgr3A or NKG2D. The amino acid sequence of mouse / mouse full-length CD3z or NKG2D is shown herein as SEQ ID NO: 66 (CD3z), 70 (Fcgr3A) or 74 (NKG2D) (mouse / mouse such as encoded by the DNA sequence shown in SEQ ID NO: 67 (CD3z), 71 (FCGR3A) or 75 (NKG2D)). The amino acid sequence of human full-length CD3z, Fcgr3A or NKG2D is shown herein as SEQ ID NO: 64 (CD3z), 68 (FCGR3A) or 72 (NKG2D) (human such as encoded by the DNA sequence shown in SEQ ID NO: 65 (CD3z), 69 (FCGR3A) or 73 (NKG2D)). The chimeric receptor of the present invention may comprise a fragment of CD3z, Fcgr3A or NKG2D as a stimulatory domain, provided that at least one signaling domain is included. In particular, any part / fragment of CD3z, Fcgr3A or NKG2D is suitable as a stimulatory domain as long as it comprises at least one signaling motif. However, more preferably, the chimeric receptor of the present invention comprises a polypeptide derived from human origin.
[0217] In a preferred embodiment, the one or more stimulatory signaling domains contained in the chimeric receptor comprise or consist of the amino acid sequence set forth in SEQ ID NO: 91 (e.g., encoded by the DNA sequence set forth in SEQ ID NO: 100). In a further embodiment, the chimeric receptor comprises a sequence set forth in SEQ ID NO: 91 or a sequence having at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 23, 24, 25, 26, 27, 28, 29 or 30 substitutions, deletions or insertions compared to SEQ ID NO: 91 and characterized in that it has (or retains) stimulatory signaling activity. Specific configurations of chimeric receptors comprising stimulatory signaling domains (SSDs) are provided below and in the Examples and Figures. Stimulatory signaling activity can be determined; for example, increased cytokine release as measured by ELISA (IL-2, IFNγ, TNFα), increased proliferative activity (as measured by increased cell number), or increased lytic activity as measured by an LDH release assay.
[0218] In addition, the chimeric receptor provided herein preferably comprises at least one co-stimulatory signaling domain, which provides additional activity for T cells. The chimeric receptor provided herein may comprise a co-stimulatory signaling domain, which is mouse / mouse or human CD28 (the UniProt entry of human CD28 is P10747 (version number 173, sequence number 1); the UniProt entry of mouse / mouse CD28 is P31041 (version number 134, sequence number 2)), CD137 (the UniProt entry of human CD137 is Q07011 (version number 145, sequence number 1); the UniProt entry of mouse / mouse CD137 is P20334 (version number 139, sequence number 1)) , OX40 (UniProt entry for human OX40 is P23510 (version 138, sequence number 1); UniProt entry for rat / mouse OX40 is P43488 (version 119, sequence number 1)), ICOS (UniProt entry for human ICOS is Q9Y6W8 (version 126, sequence number 1)); UniProt entry for rat / mouse ICOS is Q9WV40 (primary citable accession number) or Q9JL17 (secondary citable accession number), version 102, sequence version 2)), CD27 ( The UniProt entry for human CD27 is P26842 (version 160, sequence number 2); the UniProt entry for mouse / rat CD27 is P41272 (version 137, sequence version 1)), 4-1-BB (the UniProt entry for mouse / rat 4-1-BB is P20334 (version 140, sequence version 1); the UniProt entry for human 4-1-BB is Q07011 (version 146, sequence version)), DAP10 (the UniProt entry for human DAP10 is Q9UBJ5 (version No. 25, SEQ ID NO. 1); the UniProt entry of mouse / mouse DAP10 is Q9QUJ0 (primary citable accession number) or Q9R1E7 (auxiliary citable accession number), version 101, SEQ ID NO. 1)) or DAP12 (the UniProt entry of human DAP12 is O43914 (version 146, SEQ ID NO. 1); the UniProt entry of mouse / mouse DAP12 is O054885 (primary citable accession number) or Q9R1E7 (auxiliary citable accession number), version 123, SEQ ID NO. 1) fragment / polypeptide portion. In certain embodiments of the present invention, the chimeric receptor of the present invention may comprise one or more, i.e., 1, 2, 3, 4, 5, 6 or 7 co-stimulatory signaling domains as defined herein.Thus, in the context of the present invention, the chimeric receptor of the present invention may comprise a fragment / polypeptide portion of murine / mouse or preferably human CD137 as a first co-stimulatory signaling domain, and the second co-stimulatory signaling domain is selected from the group consisting of murine / mouse or preferably human CD27, CD28, CD137, OX40, ICOS, DAP10 and DAP12, or a fragment thereof. Preferably, the chimeric receptor of the present invention comprises a co-stimulatory signaling domain derived from human origin.
[0219] In a preferred embodiment, one or more co-stimulatory signaling domains contained in the chimeric receptor of the present invention may comprise or consist of the amino acid sequence shown in SEQ ID NO:90 (eg, encoded by the DNA sequence shown in SEQ ID NO:99).
[0220] Thus, the co-stimulatory signaling domain that can be optionally included in the chimeric receptors provided herein is a fragment / polypeptide portion of full-length CD27, CD28, CD137, OX40, ICOS, DAP10 or DAP12. The amino acid sequences of murine / mouse full-length CD27, CD28, CD137, OX40, ICOS, CD27, DAP10 and DAP12 are shown herein as SEQ ID NO: 39 (CD27), 43 (CD28), 47 (CD137), 51 (OX40), 55 (ICOS), 59 (DAP10) or 63 (DAP12) (murine / mouse as encoded by the DNA sequence shown in SEQ ID NO: 38 (CD27), 42 (CD28), 46 (CD137), 50 (OX40), 54 (ICOS), 58 (DAP10) or 62 (DAP12)). However, since human sequences are most preferred in the context of the present invention, the co-stimulatory signaling domain that can be optionally included in the chimeric receptor proteins provided herein is a fragment / polypeptide portion of human full-length CD27, CD28, CD137, OX40, ICOS, DAP10 or DAP12. The amino acid sequence of human full-length CD27, CD28, CD137, OX40, ICOS, DAP10 or DAP12 is shown herein as SEQ ID NO: 37 (CD27), 41 (CD28), 45 (CD137), 49 (OX40), 53 (ICOS), 57 (DAP10) or 61 (DAP12) (human as encoded by the DNA sequence shown in SEQ ID NO: 36 (CD27), 40 (CD28), 44 (CD137), 48 (OX40), 52 (ICOS), 56 (DAP10) or 60 (DAP12)).
[0221] In one embodiment, the chimeric receptor comprises CD28 or a fragment thereof as a co-stimulatory signaling domain. The chimeric receptor provided herein may comprise a fragment of CD28 as a co-stimulatory signaling domain, provided that at least one signaling domain of CD28 is included. In particular, any part / fragment of CD28 is suitable for the chimeric receptor of the present invention as long as at least one signaling motive of the signaling motive of CD28 is included. The co-stimulatory signaling domains PYAP (AA 208 to 211 of CD28) and YMNM (AA 191 to 194 of CD28) are beneficial to the function of the CD28 polypeptide and the functional effects listed above. The amino acid sequence of the YMNM domain is shown in SEQ ID NO: 76; the amino acid sequence of the PYAP domain is shown in SEQ ID NO: 77. Therefore, in the chimeric receptor of the present invention, the CD28 polypeptide preferably comprises a sequence derived from the intracellular domain of the CD28 polypeptide having the sequence YMNM (SEQ ID NO: 76) and / or PYAP (SEQ ID NO: 77). In other embodiments, in the chimeric receptors of the present invention, one or both of these domains are mutated to FMNM (SEQ ID NO: 78) and / or AYAA (SEQ ID NO: 79), respectively. Any of these mutations reduces the ability of transduced cells containing the chimeric receptor to release cytokines without affecting their proliferative capacity, and can be advantageously used to prolong viability and thus prolong the therapeutic potential of the transduced cells. Or, in other words, such non-functional mutations preferably enhance the persistence of cells transduced with the chimeric receptors provided herein in vivo. However, these signaling motives can be present at any site within the intracellular domain of the chimeric receptors provided herein.
[0222] In a preferred embodiment, the chimeric receptor comprises CD137 or a fragment thereof as a co-stimulatory signaling domain. The chimeric receptor provided herein may comprise a fragment of CD137 as a co-stimulatory signaling domain, provided that at least one signaling domain of CD137 is included. In particular, any part / fragment of CD137 is suitable for the chimeric receptor of the present invention as long as at least one signaling motive of the signaling motive of CD137 is included. In a preferred embodiment, the CD137 polypeptide contained in the chimeric receptor protein of the present invention comprises an amino acid sequence shown in SEQ ID NO: 90 (such as encoded by a DNA sequence shown in SEQ ID NO: 99) or consists of it.
[0223] Specific configurations of chimeric receptors comprising a co-stimulatory signaling domain (CSD) are provided below and in the Examples and Figures. Co-stimulatory signaling activity can be determined; for example, increased cytokine release measured by ELISA (IL-2, IFNγ, TNFα), increased proliferation activity (measured by increased cell number), or increased lytic activity measured by LDH release assay. CD28 and / or CD137 activity can be measured by ELISA release of cytokines or cytokine flow cytometry, such as interferon-γ (IFN-γ) or interleukin 2 (IL-2), T cell proliferation measurement, for example by ki67 measurement, cell quantification by flow cytometry, or by real-time impedance measurement of target cells to assess lytic activity (by using, for example, an ICELLligence instrument, as described in, for example, Thakur et al., Biosens Bioelectron. 35(1) (2012), 503-506; Krutzik et al., Methods Mol Biol. 699 (2011), 179-202; Ekkens et al., Infect Immun. 75(5) (2007), 2291-2296; Ge et al., Proc Natl Acad Sci US A. 99(5) (2002), 2983-2988; Düwell et al., Cell Death Res. 106(4) (2003), 2983-2988; Düwell et al., Cell Death Res. 106(4) (2003), 2983-2988; Düwell et al., Cell Death Res. 106(4) (2003), 2983-2988. Differ.21(12)(2014),1825-1837, errata: Cell Death Differ.21(12)(2014),161).
[0224] Additional linkers and signal peptides
[0225] In addition, the chimeric receptors provided herein may include at least one linker (or "spacer"). The linker is typically a peptide of up to 20 amino acids in length. Therefore, in the context of the present invention, the length of the linker may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids. For example, the chimeric receptors provided herein may include a linker between an extracellular domain, a transmembrane domain, a co-stimulatory signaling domain and / or a stimulatory signaling domain. The advantage of such a linker is that they can increase the possibility that different polypeptides of the chimeric receptor (i.e., an extracellular domain, a transmembrane domain, a co-stimulatory signaling domain and / or a stimulatory signaling domain) are independently folded and run as expected. In the context of the present invention, the extracellular domain, the transmembrane domain, the co-stimulatory signaling domain and the stimulatory signaling domain may be included in a single-chain multifunctional polypeptide. Single-chain fusion constructs can be composed of, for example, one or more polypeptides comprising one or more extracellular domains, one or more transmembrane domains, one or more co-stimulatory signaling domains and / or one or more stimulatory signaling domains. Thus, the extracellular domain, transmembrane domain, co-stimulatory signaling domain and stimulatory signaling domain can be connected by one or more identical or different peptide linkers as described herein. For example, in the chimeric receptors provided herein, the linker between the extracellular domain and the transmembrane domain can comprise or consist of an amino acid sequence as shown in SEQ ID NO: 97. Thus, the transmembrane domain, co-stimulatory signaling domain and / or stimulatory domain can be connected to each other by a peptide linker or alternatively by direct fusion of the domains.
[0226] The chimeric receptors provided herein or portions thereof may include a signal peptide. Such signal peptides will bring the protein to the surface of the T cell membrane. For example, in the chimeric receptors provided herein, the signal peptide may have an amino group and an amino acid sequence as shown in SEQ ID NO: 80 (as encoded by the DNA sequence shown in SEQ ID NO: 81).
[0227] Specific chimeric receptors capable of binding to mutated Fc domains
[0228] The components of the chimeric receptors described above can be fused to each other in a variety of configurations.
[0229] In some embodiments, the chimeric receptor comprises an extracellular domain comprising a mutated Fc domain. In one embodiment, the chimeric receptor comprises a mutated CH2 domain and / or a mutated CH3 domain as described above. In a preferred embodiment, the Fc domain is optionally fused to the N-terminus of the transmembrane domain at the C-terminus via a peptide linker. In other embodiments, the chimeric receptor further comprises a stimulatory signaling domain and / or a co-stimulatory signaling domain.
[0230] In a specific such embodiment, the chimeric receptor comprises (or consists essentially of) an extracellular domain comprising a mutated Fc domain (e.g., a CH2 and / or CH3 domain) fused at the C-terminus to the N-terminus of a transmembrane domain, wherein the transmembrane domain is fused at the C-terminus to the N-terminus of a stimulatory signaling domain.
[0231] Optionally, the chimeric receptor further comprises a co-stimulatory signaling domain. In one such specific embodiment, the chimeric receptor comprises (or consists essentially of) an extracellular domain comprising a mutated Fc domain (e.g., a CH2 and / or CH3 domain) fused at the C-terminus to the N-terminus of a transmembrane domain, wherein the transmembrane domain is fused at the C-terminus to the N-terminus of a stimulatory signaling domain, wherein the stimulatory signaling domain is fused at the C-terminus to the N-terminus of a co-stimulatory signaling domain.
[0232] In an alternative embodiment, the costimulatory signaling domain is linked to a transmembrane domain rather than a stimulatory signaling domain. In a specific such embodiment, the chimeric receptor comprises (or consists essentially of) an extracellular domain comprising a mutated Fc domain (e.g., a CH2 and / or CH3 domain) fused at the C-terminus to the N-terminus of a transmembrane domain, wherein the transmembrane domain is fused at the C-terminus to the N-terminus of the costimulatory signaling domain, wherein the costimulatory signaling domain is fused at the C-terminus to the N-terminus of the stimulatory signaling domain.
[0233] In a preferred embodiment, the chimeric receptor comprises (or consists essentially of) the following items from N-terminus to C-terminus in this order: an extracellular domain comprising a mutated Fc domain (e.g., a CH2 and / or CH3 domain); a transmembrane domain; a co-stimulatory signaling domain; and a stimulatory signaling domain, the above items being connected by one or more peptide linkers. In a preferred embodiment, the mutated Fc domain is a CH2 domain.
[0234] The Fc domain, transmembrane domain, stimulatory signaling and / or co-stimulatory signaling domain can be fused to each other directly or through one or more peptide linkers comprising one or more amino acids, typically about 2-20 amino acids. Peptide linkers are known in the art and described herein. Suitable non-immunogenic peptide linkers include, for example, (G4S) n 、(SG4) n 、(G4S) n or G4(SG4) nA peptide linker, wherein "n" is typically a number between 1 and 10, typically between 2 and 4. A preferred peptide linker for connecting the antigen binding portion and the anchoring transmembrane portion is (G4S). Another preferred peptide linker for connecting the antigen binding portion and the anchoring transmembrane portion is the amino acid sequence of SEQ ID NO 88 (CD8 stem). In addition, the linker may comprise (a portion of) an immunoglobulin hinge region.
[0235] In one embodiment, the Fc domain (e.g., a mutated CH2 domain) is an IgG Fc domain or a fragment thereof, particularly an IgG1 or IgG4 Fc domain or a fragment thereof. In one embodiment, the extracellular domain comprises a CH2 domain, a CH3 domain and / or a CH4 domain, preferably a CH2 domain. In one embodiment, the Fc domain comprises at least one amino acid substitution compared to a native Fc domain. In one embodiment, at least one amino acid substitution reduces binding to an Fc receptor and / or reduces effector function. In one embodiment, at least one amino acid substitution is selected from a list consisting of 233, 234, 235, 238, 253, 265, 269, 270, 297, 310, 331, 327, 329 and 435 (numbered according to the Kabat EU index). In one embodiment, at least one amino acid substitution is included in a substitution at position P329 (numbered according to the Kabat EU index). In one embodiment, at least one amino acid substitution includes a substitution at position P329 (numbered according to the Kabat EU index) by an amino acid selected from the list consisting of alanine (A), arginine (R), leucine (L), isoleucine (I) and proline (P). In one embodiment, at least one amino acid substitution includes the amino acid substitution P329G (numbered according to the Kabat EU index).
[0236] In a specific embodiment, the chimeric receptor comprises a mutated Fc domain, in particular an IgG1 Fc domain, comprising a P329G substitution (according to EU numbering).
[0237] In one embodiment, the Fc domain comprises a P329G substitution (according to EU numbering). In one embodiment, the Fc domain is optionally fused to the N-terminus of the transmembrane domain at the C-terminus via a peptide linker. In one embodiment, the peptide linker comprises the amino acid sequence of SEQ ID NO:88. In one embodiment, the transmembrane domain is a transmembrane domain selected from the group consisting of CD8, CD4, CD3z, FCGR3A, NKG2D, CD27, CD28, CD137, OX40, ICOS, DAP10 or DAP12 transmembrane domain or a fragment thereof. In a preferred embodiment, the transmembrane domain is a CD8 transmembrane domain or a fragment thereof. In a specific embodiment, the transmembrane domain comprises or consists of the amino acid sequence of SEQ ID NO:89. In one embodiment, the chimeric receptor further comprises a costimulatory signaling domain (CSD). In one embodiment, the transmembrane domain of the chimeric receptor is fused to the N-terminus of the costimulatory signaling domain at the C-terminus. In one embodiment, the costimulatory signaling domain is individually selected from the group consisting of the intracellular domain of CD27, the intracellular domain of CD28, the intracellular domain of CD137, the intracellular domain of OX40, the intracellular domain of ICOS, the intracellular domain of DAP10 and the intracellular domain of DAP12, or a fragment thereof, as described above. In one embodiment, the costimulatory signaling domain is the intracellular domain of CD28 or a fragment thereof. In one embodiment, the costimulatory signaling domain comprises the intracellular domain of CD28 or a fragment thereof, which retains CD28 signaling. In a preferred embodiment, the costimulatory signaling domain comprises the intracellular domain of CD137 or a fragment thereof, which retains CD137 signaling. In a specific such embodiment, the costimulatory signaling domain comprises SEQ ID NO: 90 or consists thereof. In one embodiment, the chimeric receptor further comprises a stimulatory signaling domain. In one embodiment, the costimulatory signaling domain of the chimeric receptor is fused at the C-terminus to the N-terminus of the stimulatory signaling domain. In one embodiment, at least one stimulatory signaling domain is individually selected from the group consisting of: the intracellular domain of CD3z, the intracellular domain of FCGR3A, and the intracellular domain of NKG2D, or a fragment thereof. In a preferred embodiment, the stimulatory signaling domain is the intracellular domain of CD3z, or a fragment thereof, which retains CD3z signaling. In a specific embodiment, the stimulatory signaling domain comprises or consists of SEQ ID NO: 91.
[0238] In one embodiment, the chimeric receptor is fused to a reporter protein, in particular to GFP or an enhanced analog thereof. In one embodiment, the chimeric receptor is optionally fused to the N-terminus of eGFP (enhanced green fluorescent protein) at the C-terminus via a peptide linker as described herein. In a preferred embodiment, the peptide linker is GEGRGSLLTCGDVEENPGP (T2A) according to SEQ ID NO: 95.
[0239] In a specific embodiment, the chimeric receptor comprises a transmembrane domain and an extracellular domain comprising a mutated CH2 domain, wherein the mutated CH2 domain comprises a P329G substitution (according to EU numbering). The P329G substitution reduces Fcγ receptor binding. In one embodiment, the chimeric receptor of the present invention comprises a transmembrane domain (TD), a costimulatory signaling domain (CSD) and a stimulatory signaling domain (SSD). In one such embodiment, the chimeric receptor has the configuration CH2-TD-CSD-SSD. In another embodiment, the chimeric receptor has the configuration CH2-TD-SSD-CSD. In a preferred embodiment, the chimeric receptor has the configuration CH2 (P329G) -TD-CSD-SSD. In a more specific embodiment of this type, the chimeric receptor has the configuration CH2 (P329G) -linker -TD-CSD-SSD, wherein the "linker" is a linker as described herein before.
[0240] In one embodiment, the present invention provides a chimeric receptor, which comprises or consists of the following items from N-terminus to C-terminus: an extracellular domain, which comprises a CH2 domain, wherein the CH2 domain comprises an amino acid substitution P329G (numbered according to the Kabat EU index); and a transmembrane domain. In a specific embodiment, the CH2 domain comprises or consists of the sequence of SEQ ID NO: 86.
[0241] In one embodiment, the present invention provides a chimeric receptor comprising, from N-terminus to C-terminus:
[0242] (i) an extracellular domain comprising a CH2 domain, wherein the CH2 domain comprises the amino acid substitution P329G (numbering according to the Kabat EU index),
[0243] (ii) a transmembrane domain, and
[0244] (iii) at least one intracellular stimulatory signaling domain and / or at least one co-stimulatory signaling domain.
[0245] In one embodiment, the present invention provides a chimeric receptor comprising, from N-terminus to C-terminus:
[0246] (i) an extracellular domain comprising a CH2 domain of SEQ ID NO: 86; and an optional linker, in particular a linker of SEQ ID NO: 88,
[0247] (ii) a transmembrane domain, in particular a transmembrane domain of SEQ ID NO: 89,
[0248] (iii) a co-stimulatory signaling domain, in particular a co-stimulatory signaling domain of SEQ ID NO:90, and (iv) a stimulatory signaling domain, in particular a stimulatory signaling domain of SEQ ID NO:91.
[0249] In one embodiment, a chimeric receptor is provided, comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the following amino acid sequence: SEQ ID NO: 87. In one embodiment, a chimeric receptor is provided, comprising or consisting of the following amino acid sequence: SEQ ID NO: 87.
[0250] In one embodiment, the present invention provides a chimeric receptor, which comprises or consists of the following items from N-terminus to C-terminus: an extracellular domain, which comprises a CH2-CH3 domain, wherein the CH2-CH3 domain comprises amino acid substitutions I253A, H310A and H435A (numbered according to the Kabat EU index); and a transmembrane domain. In a specific embodiment, the CH2-CH3 domain comprises or consists of the amino acid sequence of SEQ ID NO: 105.
[0251] In one embodiment, the present invention provides a chimeric receptor comprising, from N-terminus to C-terminus:
[0252] (i) an extracellular domain comprising a CH2-CH3 domain, wherein the CH2-CH3 domain comprises amino acid substitutions I253A, H310A and H435A (numbering according to the Kabat EU index),
[0253] (ii) a transmembrane domain, and
[0254] (iii) at least one intracellular stimulatory signaling domain and / or at least one co-stimulatory signaling domain.
[0255] In one embodiment, the present invention provides a chimeric receptor comprising, from N-terminus to C-terminus:
[0256] (i) an extracellular domain comprising the CH2-CH3 domain of SEQ ID NO: 105; and an optional linker, in particular a linker of SEQ ID NO: 88,
[0257] (ii) a transmembrane domain, in particular a transmembrane domain of SEQ ID NO: 89,
[0258] (iii) a co-stimulatory signaling domain, in particular a co-stimulatory signaling domain of SEQ ID NO:90, and (iv) a stimulatory signaling domain, in particular a stimulatory signaling domain of SEQ ID NO:91.
[0259] In one embodiment, a chimeric receptor is provided, comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the following amino acid sequence: SEQ ID NO: 106. In one embodiment, a chimeric receptor is provided, comprising or consisting of the following amino acid sequence: SEQ ID NO: 106.
[0260] In one embodiment, a chimeric receptor is provided, comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the following amino acid sequence: SEQ ID NO: 125. In one embodiment, a chimeric receptor is provided, comprising or consisting of the following amino acid sequence: SEQ ID NO: 125.
[0261] In one embodiment, a chimeric receptor is provided, comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the following amino acid sequence: SEQ ID NO: 126. In one embodiment, a chimeric receptor is provided, comprising or consisting of the following amino acid sequence: SEQ ID NO: 126.
[0262] Transduced cells capable of expressing the chimeric receptor of the present invention
[0263] Another aspect of the present invention is a transduced T cell capable of expressing a chimeric receptor of the present invention. The chimeric receptors described herein relate to molecules that are not naturally contained in T cells and / or on the surface of T cells and are not expressed (endogenously) in normal (non-transduced) T cells or on T cells. Therefore, the chimeric receptors in T cells and / or on T cells are artificially introduced into T cells. In the context of the present invention, the T cells, preferably CD8+ T cells, can be isolated / obtained from a subject to be treated as defined herein. In the context of the present invention, the chimeric receptors are presented in the T cells and / or on the surface of the T cells after (retroviral, lentiviral or non-viral) transduction as described below. Therefore, after transduction, the T cells according to the present invention can be activated by an immunoglobulin (preferably a (therapeutic) antibody) that comprises at least one antigen binding portion capable of binding to a target cell antigen, and at least one antigen binding portion capable of binding to a mutated Fc domain but not capable of binding to a corresponding non-mutated parent Fc domain.
[0264] The present invention also relates to transduced T cells expressing a chimeric receptor encoded by one or more nucleic acid molecules encoding a chimeric receptor of the present invention. Thus, in the context of the present invention, a transduced cell may comprise a nucleic acid molecule encoding a chimeric receptor of the present invention or a vector of the present invention expressing a chimeric receptor of the present invention.
[0265] In the context of the present invention, the term "transduced T cells" refers to genetically modified T cells (i.e., T cells into which nucleic acid molecules are intentionally introduced). The transduced T cells provided herein may comprise a vector of the present invention. Preferably, the transduced T cells provided herein comprise nucleic acid molecules encoding the chimeric receptor of the present invention and / or the vector of the present invention. The transduced T cells of the present invention may be T cells that transiently or stably express exogenous DNA (i.e., nucleic acid molecules that have been introduced into T cells). In particular, nucleic acid molecules encoding the chimeric receptor of the present invention may be stably integrated into the genome of T cells using retroviral or lentiviral transduction. By using mRNA transfection, nucleic acid molecules encoding the chimeric receptor of the present invention may be transiently expressed. Preferably, the transduced T cells provided herein have been genetically modified by introducing nucleic acid molecules into T cells by viral vectors (e.g., retroviral vectors or lentiviral vectors). Therefore, the expression of the chimeric receptor may be constitutive, and the extracellular domain (and mutated Fc domain) chimeric receptor may be detected on the cell surface.
[0266] In the case where the chimeric receptor is introduced into T cells under the control of an inducible or repressible promoter, expression can also be conditional or inducible. Examples of such inducible or repressible promoters can be transcription systems comprising alcohol dehydrogenase I (alcA) gene promoters and transactivator AlcR. Different formulations based on agricultural alcohol are used to control the expression of target genes connected to the alcA promoter. In addition, tetracycline responsive promoter systems can work by activating or repressing gene expression systems in the presence of tetracycline. Some elements of the system include tetracycline repressor protein (TetR), tetracycline operator sequence (tetO) and tetracycline transactivator fusion protein (tTA), which is a fusion of TetR and herpes simplex virus protein 16 (VP16) activation sequence. In addition, steroid response promoters, metal regulation or pathogenesis-related (PR) protein-related promoters can be used.
[0267] Depending on the system used, expression can be constitutive or constitutive. The chimeric receptor of the present invention can be expressed on the surface of the transduced T cells provided herein. The extracellular portion of the chimeric receptor (i.e., the extracellular domain of the chimeric receptor) can be detected on the cell surface, while the intracellular portion (i.e., one or more co-stimulatory signaling domains and stimulatory signaling domains) cannot be detected on the cell surface. Detection of the extracellular domain of the chimeric receptor can be performed by using antibodies that specifically bind to the extracellular domain and / or mutated Fc domains (e.g., by flow cytometry or microscopy).
[0268] Other cells can also be transduced with the chimeric receptor of the present invention, so as to directly target the target cells. These other cells include but are not limited to B cells, natural killer (NK) cells, innate lymphoid cells, macrophages, monocytes, dendritic cells or neutrophils. Preferably, the immune cell is a lymphocyte. Triggering the chimeric receptor of the present invention on the surface of leukocytes will cause the cells to produce cytotoxicity to the target cells together with the therapeutic antibodies as described herein, regardless of which lineage the cells originate from. Regardless of the stimulation signal transduction domain or the costimulatory signal transduction domain selected for the chimeric receptor, and independent of the exogenous supply of other cytokines, cytotoxicity will be produced. Therefore, the transduced cells of the present invention can be, for example, CD4+T cells, CD8+-T cells, γδT cells, natural killer (NK) T cells, natural killer (NK) cells, tumor-infiltrating lymphocytes (TIL) cells, bone marrow cells or mesenchymal stem cells. Preferably, the transduced cells provided herein are T cells (e.g., autologous T cells), and more preferably, the transduced cells are CD8+ T cells. Therefore, in the context of the present invention, the transduced cells are CD8+ T cells. Further, in the context of the present invention, the transduced cells are autologous T cells. Therefore, in the context of the present invention, the transduced cells are preferably autologous CD8+ T cells. In addition to using autologous cells (e.g., T cells) separated from a subject, the present invention also includes the use of allogeneic cells. Therefore, in the context of the present invention, the transduced cells can also be allogeneic cells, such as allogeneic CD8+ T cells. The term allogeneic refers to cells from unrelated donor individuals / subjects, which are human leukocyte antigens (HLA) compatible with the individual / subject to be treated by, for example, the transduced cells expressing the chimeric receptor described herein. Autologous cells refer to cells separated / obtained from a subject to be treated with the transduced cells described herein as described above.
[0269] The transduced cells of the present invention can be co-transduced with other nucleic acid molecules, for example, with nucleic acid molecules encoding cytokines.
[0270] The present invention also relates to a method for producing transduced T cells expressing the chimeric receptor of the present invention, comprising the steps of transducing T cells with the vector of the present invention, culturing the transduced T cells under conditions that allow the expression of the chimeric receptor in or on the surface of the transduced cells and recovering the transduced T cells.
[0271] In the context of the present invention, the transduced cells of the present invention are preferably produced by isolating cells (e.g., T cells, preferably CD8+ T cells) from a subject (preferably a human patient). Methods for isolating / obtaining cells (e.g., T cells, preferably CD8+ T cells) from a patient or donor are well known in the art and in the present invention for cells (e.g., T cells, preferably CD8+ T cells) from a patient or donor, for example, cells can be isolated by drawing blood or removing bone marrow. After isolating / obtaining cells as a patient sample, the cells (e.g., T cells) are separated from the other components of the sample. Several methods for isolating cells (e.g., T cells) from a sample are known, including, but not limited to, for example, leukapheresis for obtaining cells from a peripheral blood sample of a patient or donor, by isolating / obtaining cells using a FACS cell sorter. The isolated / obtained cellular T cells are then cultured and expanded, for example, by using anti-CD3 antibodies, by using anti-CD3 and anti-CD28 monoclonal antibodies and / or by using anti-CD3 antibodies, anti-CD28 antibodies and interleukin 2 (IL-2) (see, e.g., Dudley, Immunother. 26 (2003), 332-342 or Dudley, Clin. Oncol. 26 (2008), 5233-5239).
[0272] In a subsequent step, cells (e.g., T cells) are artificially / genetically modified / transduced by methods known in the art (see, e.g., Lemoine, J Gene Med 6 (2004), 374-386). Methods for transducing cells (e.g., T cells) are known in the art and include, but are not limited to, electroporation, calcium phosphate, cationic lipid, or liposome methods, for example, in the case of transducing nucleic acids or recombinant nucleic acids. The nucleic acid to be transduced can be routinely and efficiently transduced using commercially available transfection reagents such as Lipofectamine (manufactured by Invitrogen, catalog number: 11668027). In the case of using a vector, the vector can be transduced in the same manner as the above-mentioned nucleic acid, as long as the vector is a plasmid vector (i.e., a vector that is not a viral vector). In the context of the present invention, methods for transducing cells (e.g., T cells) include retroviral or lentiviral T cell transduction, non-viral vectors (such as Sleeping Beauty minicircle vectors), and mRNA transfection. "mRNA transfection" refers to a method well known to those skilled in the art for transiently expressing a target protein (such as, in this case, a chimeric receptor of the present invention) in a cell to be transduced. In short, cells can be electroporated with mRNA encoding a chimeric receptor of the present invention using an electroporation system (such as, for example, Gene Pulser, Bio-Rad), and then cultured using a standard cell (e.g., T cell) culture protocol as described above (see Zhao et al., Mol Ther. 13(1) (2006), 151-159). The transduced cells of the present invention can be produced by lentiviral or, most preferably, retroviral transduction.
[0273] In this case, suitable retroviral vectors for transducing cells are known in the art, such as SAMEN CMV / SRa (Clay et al., J. Immunol. 163 (1999), 507-513), LZRS-id3-IHRES (Heemskerk et al., J. Exp. Med. 186 (1997), 1597-1602), FeLV (Neil et al., Nature 308 (1984), 814-820), SAX (Kantoff et al., Proc. Natl. Acad. Sci. USA 83 (1986), 6563-6567), pDOL (Desiderio, J. Exp. Med. 167 (1988), 372-388), N2 (Kasid et al., Proc. Natl. Acad. Sci. USA 87 (1990), 473-477), LNL6 (Tiberghien et al., Blood 84 (1994), 1333-1341), pZipNEO (Chen et al., J. Immunol. 153 (1994), 3630-3638), LASN (Mullen et al., Hum. Gene Ther. 7 (1996), 1123-1129), pG1XsNa (Taylor et al., J. Exp. Med. 184 (1996), 2031-2036), LCNX (Sun et al., Hum. Gene Ther. 8 (1997), 1041-1048), SFG (Gallardo et al., Blood 90 (1997), and LXSN (Sun et al., Hum. Gene Ther. 8 (1997), 1041-1048), SFG (Gallardo et al., Blood 90 (1997), 952-957), HMB-Hb-Hu (Vieillard et al., Proc. Natl. Acad. Sci. USA 94 (1997), 11595-11600), pMV7 (Cochlovius et al., Cancer Immunol. Immunother. 46 (1998), 61-66), pSTITCH (Weitjens et al., Gene Ther 5 (1998), 1195-1203), pLZR (Yang et al., Hum. Gene Ther. 10 (1999), 123-132), pBAG (Wu et al., Hum. Gene Ther.10(1999),977-982), rKat.43.267bn(Gilham et al., J.Immunother.25 (2002), 139-151), pLGSN (Engels et al., Hum. Gene Ther. 14 (2003), 1155-1168), pMP71 (Engels et al., Hum. Gene Ther. 14 (2003), 1155-1168), pGCSAM (Morgan et al., J. Immunol. 171 (2003), 3287-3295), pMSGV (Zhao et al., J. Immunol. 174 (2005), 4415-4423) or pMX (de Witte et al., J. Immunol. 181 (2008), 5128-5136). In the context of the present invention, suitable lentiviral vectors for transducing cells (e.g., T cells) are, for example, PL-SIN lentiviral vector (Hotta et al., Nat Methods. 6 (5) (2009), 370-376), p156RRL-sinPPT-CMV-GFP-PRE / NheI (Campeau et al., PLoS One 4 (8) (2009), e6529), pCMVR8.74 (Addgene Catalogoue No.: 22036), FUGW (Lois et al., Science 295 (5556) (2002), 868-872, pLVX-EF1 (Addgene Catalog No.: 64368), pLVE (Brunger et al., Proc Natl Acad Sci USA 111 (9) (2014), E798-806), pCDH1-MCS1-EF1 (Hu et al., Mol Cancer Res.7(11)(2009),1756-1770), pSLIK(Wang et al., Nat Cell Biol.16(4)(2014),345-356), pLJM1(Solomon et al., Nat Genet.45(12)(2013),1428-30), pLX302(Kang et al., Sci Signal.6(287)(2013),rs13), pHR-IG(Xie et al., J Cereb Blood Flow Metab.33(12)(2013),1875-85), pRRLSIN(Addgene Catalogue No.:62053), pLS(Miyoshi et al., J Virol.72(10)(1998),8150-8157), pLL3.7(Lazebnik et al., J Biol Chem.283(7)(2008), 11078-82), FRIG (Raissi et al., Mol Cell Neurosci. 57(2013), 23-32), pWPT (Ritz-Laser et al., Diabetologia. 46(6)(2003), 810-821), pBOB (Marr et al., J Mol Neurosci. 22(1-2)(2004), 5-11) or pLEX (Addgene Catalogue No.: 27976).
[0274] The transduced cells of the present invention are preferably grown under controlled conditions outside their natural environment. In particular, the term "culture" refers to the growth of cells (e.g., one or more transduced cells of the present invention) derived from multicellular eukaryotic organisms (preferably from human patients) in vitro. Cultivating cells is a laboratory technique that keeps cells separated from their original tissue source alive. In this article, the transduced cells of the present invention are cultured under conditions that allow the chimeric receptor of the present invention to be expressed in or on the transduced cells. Conditions that allow expression or transgenesis (i.e., chimeric receptors of the present invention) are well known in the art and include, for example, agonistic anti-CD3 antibodies and anti-CD28 antibodies and the addition of cytokines such as interleukin 2 (IL-2), interleukin 7 (IL-7), interleukin 12 (IL-12) and / or interleukin 15 (IL-15). After expressing the chimeric receptor of the present invention in the cultured transduced cells (e.g., CD8+ T), the transduced cells are recovered (i.e., re-extracted) from the culture (i.e., from the culture medium).
[0275] Therefore, the present invention also encompasses transduced cells obtainable by the method of the present invention, preferably T cells, in particular CD8+ T cells expressing the chimeric receptor encoded by the nucleic acid molecule of the present invention.
[0276] Nucleic acid molecules
[0277] Another aspect of the invention is nucleic acids and vectors encoding one or more chimeric receptors of the invention. Exemplary nucleic acid molecules encoding chimeric receptors of the invention are shown in SEQ ID NO:96 or SEQ ID NO:107. The nucleic acid molecules of the invention can be under the control of regulatory sequences. For example, promoters, transcription enhancers and / or sequences that allow for inducible expression of the chimeric receptors of the invention can be employed. In the context of the present invention, the nucleic acid molecules are expressed under the control of a constitutive or inducible promoter. Suitable promoters are, for example, CMV promoter (Qin et al., PLoS One 5(5)(2010), e10611), UBC promoter (Qin et al., PLoS One 5(5)(2010), e10611), PGK (Qin et al., PLoS One 5(5)(2010), e10611), EF1A promoter (Qin et al., PLoS One 5(5)(2010), e10611), CAGG promoter (Qin et al., PLoS One 5(5)(2010), e10611), SV40 promoter (Qin et al., PLoS One 5(5)(2010), e10611), COPIA promoter (Qin et al., PLoS One 5(5)(2010), e10611), ACT5C promoter (Qin et al., PLoS One 5(5)(2010), e10611), TRE promoter (Qin et al., PLoS One.5(5)(2010), e10611), Oct3 / 4 promoter (Chang et al., Molecular Therapy 9(2004), S367–S367 (doi:10.1016 / j.ymthe.2004.06.904)) or Nanog promoter (Wu et al., Cell Res.15(5)(2005), 317-24). Therefore, the present invention also relates to one or more vectors comprising one or more nucleic acid molecules described in the present invention. As used herein, the term vector refers to a circular or linear nucleic acid molecule that can replicate autonomously in a cell into which it has been introduced. Many suitable vectors are known to those skilled in the art of molecular biology, and their selection depends on the desired function, including plasmids, cosmids, viruses, bacteriophages and other vectors conventionally used in genetic engineering. Methods well known to those skilled in the art can be used to construct a variety of plasmids and vectors; see, for example, the techniques described in Sambrook et al. (cited above) and Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, NY (1989), (1994).Alternatively, the polynucleotides and vectors of the present invention can be reconstituted into liposomes for delivery to target cells. As discussed in further detail below, cloning vectors are used to isolate individual DNA sequences. Related sequences can be transferred to expression vectors that require specific polypeptide expression. Typical cloning vectors include pBluescript SK, pGEM, pUC9, pBR322, pGA18, and pGBT9. Typical expression vectors include pTRE, pCAL-n-EK, pESP-1, and pOP13CAT.
[0278] The present invention also relates to one or more vectors comprising one or more nucleic acid molecules, which are regulatory sequences operably connected to the one or more nucleic acid molecules, which encode chimeric receptors as defined herein. In the context of the present invention, the vector can be a polycistronic. Such regulatory sequences (control elements) are known to the technician and may include promoters, splicing boxes, translation start codons, translation and insertion sites for introducing insertion sequences into one or more vectors. In the context of the present invention, the one or more nucleic acid molecules are operably linked to the expression control sequences to allow expression in eukaryotic or prokaryotic cells. It is envisioned that the one or more vectors are one or more expression vectors, which contain one or more nucleic acid molecules encoding chimeric receptors as defined herein. Operably connected refers to juxtaposition, wherein the components described are in a relationship that allows them to function in their intended manner. The control sequence operably connected to the coding sequence is connected so that the expression of the coding sequence is achieved under conditions compatible with the control sequence. In the case where the control sequence is a promoter, it is obvious to the technician that double-stranded nucleic acids are preferably used.
[0279] In the context of the present invention, the one or more vectors are one or more expression vectors. An expression vector is a construct that can be used to transform a selected cell and provide a coding sequence to be expressed in a selected cell. One or more expression vectors can be, for example, cloned one or more vectors, one or more binary vectors or one or more integration vectors. Expression includes preferably transcribing a nucleic acid molecule into a translatable mRNA. Regulatory elements that ensure expression in prokaryotes and / or eukaryotic cells are well known to those skilled in the art. In the case of eukaryotic cells, they generally include promoters that ensure transcription initiation and optionally include poly-A signals that ensure transcription termination and transcript stability. Possible regulatory elements that allow expression in prokaryotic host cells include, for example, PL, lac, trp or tac promoters in Escherichia coli, and examples of regulatory elements that allow expression in eukaryotic host cells are CMV promoters, SV40 promoters, RSV promoters (Rous sarcoma virus), CMV enhancers, SV40 enhancers or globin introns in yeast or mammals and other animal cells.
[0280] In addition to the elements responsible for transcription initiation, such regulatory elements may also comprise transcription termination signals downstream of the polynucleotide, such as SV40-poly-A sites or tk-poly-A sites. In addition, depending on the expression system used, a leader sequence encoding a signal peptide capable of directing the polypeptide to a cell compartment or secreting it into the culture medium may be added to the coding sequence of the nucleic acid sequence, as is well known in the art, see also, for example, the attached examples.
[0281] One or more leader sequences are assembled with the translation, initiation and termination sequences at appropriate stages, preferably the leader sequence is capable of directing secretion of the translated protein or part thereof to the periplasmic space or the extracellular medium. Optionally, the heterologous sequence may encode a chimeric receptor comprising an N-terminal recognition peptide that confers desired characteristics, such as stabilization or simplified purification of the expressed recombinant product, see above. In this context, suitable expression vectors are known in the art, such as the Okayama-Berg cDNA expression vector pcDV1 (Pharmacia), pCDM8, pRc / CMV, pcDNA1, pcDNA3 (In-vitrogene), pEF-DHFR, pEF-ADA or pEF-neo (Raum et al., Cancer Immunol Immunother 50 (2001), 141-150) or pSPORT1 (GIBCO BRL).
[0282] In the context of the present invention, the expression control sequence will be a eukaryotic promoter system in a vector capable of transforming or transfecting eukaryotic cells, but prokaryotic control sequences may also be used. Once the vector has been incorporated into an appropriate cell, the cell is maintained under conditions suitable for high-level expression of the nucleotide sequence and as desired. Other regulatory elements may include transcriptional and translational enhancers. Advantageously, the above-mentioned vectors of the present invention include selectable and / or scorable markers. Selectable marker genes for selection of transformed cells and, for example, plant tissues and plants are well known to those skilled in the art and include, for example, antimetabolite resistance as the basis for selection for dhfr, which confers resistance to methotrexate (Reiss, Plant Physiol. (Life Sci. Adv.) 13 (1994), 143-149), npt, which confers resistance to the aminoglycosides neomycin, kanamycin and paromomycin (Herrera-Estrella, EMBO J. 2 (1983), 987-995), and hygro, which confers resistance to hygromycin (Marsh, Gene 32 (1984), 481-485). Other selectable genes have been described, namely trpB, which allows cells to utilize indole instead of tryptophan; hisD, which allows cells to utilize histinol instead of histidine (Hartman, Proc. Natl. Acad. Sci. USA 85 (1988), 8047); mannose-6-phosphate isomerase, which allows cells to utilize mannose (WO 94 / 20627) and ODC (ornithine decarboxylase), which confers resistance to the ornithine decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO (McConlogue, 1987, In: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory ed.) or a deaminase from Aspergillus terreus, which confers resistance to blasticidin (Tamura, Biosci. Biotechnol. Biochem. 59 (1995), 2336-2338).
[0283] Useful labelable markers are also known to those skilled in the art and are commercially available. Advantageously, the marker is a gene encoding luciferase (Giacomin, Pl. Sci. 116 (1996), 59-72; Scikantha, J. Bact. 178 (1996), 121), green fluorescent protein (Gerdes, FEBS Lett. 389 (1996), 44-47) or beta-glucuronidase (Jefferson, EMBO J. 6 (1987), 3901-3907). This embodiment is particularly useful for simple and rapid screening of cells, tissues and organisms containing the vector.
[0284] As described above, the nucleic acid molecules can be used alone or as part of one or more vectors to express the chimeric receptors of the invention in cells for, for example, adoptive T cell therapy, but also for gene therapy purposes. Nucleic acid molecules or one or more vectors containing the DNA sequence encoding any of the chimeric receptors described herein are introduced into cells, which in turn produce the polypeptide of interest. Gene therapy based on the introduction of therapeutic genes into cells by ex vivo or in vivo techniques is one of the most important applications of gene transfer. Suitable vectors, methods or gene delivery systems for in vitro or in vivo gene therapy methods or gene delivery systems are described in the literature and are known to those skilled in the art; see, for example, Giordano, Nature Medicine 2 (1996), 534-539; Schaper, Circ. Res. 79 (1996), 911-919; Anderson, Science 256 (1992), 808-813; Verma, Nature 389 (1994), 239; Isner, Lancet 348 (1996), 370-374; Muhlhauser, Circ. Res. 77 (1995), 1077-1086; Onodera, Blood 91 (1998), 30-36; Verma, Gene Ther.5 (1998), 692-699; Nabel, Ann. NY Acad. Sci. 811 (1997), 289-292; Verzeletti, Hum. Gene Ther. 9 (1998), 2243-51; Wang, Nature Medicine 2 (1996), 714-716; WO 94 / 29469; WO 97 / 00957; US 5,580,859; US 5,589,466; or Schaper, Current Opinion in Biotechnology 7 (1996), 635-640. The one or more nucleic acid molecules and one or more vectors can be designed for direct introduction into cells or introduction into cells via liposomes or viral vectors (e.g., adenoviral vectors, retroviral vectors). In the context of the present invention, the cell is a T cell, such as a CD8+ T cell, a CD4+ T cell, a CD3+ T cell, a γδ T cell or a Natural Killer (NK) T cell, preferably a CD8+ T cell.
[0285] According to the above, the present invention relates to a method of deriving a vector, in particular a plasmid, cosmid and phage conventionally used in genetic engineering, which vector comprises a nucleic acid molecule encoding the polypeptide sequence of the chimeric receptor defined herein. In the context of the present invention, the vector is an expression vector and / or a gene transfer or targeting vector. Expression vectors derived from viruses, such as retroviruses, vaccinia viruses, adeno-associated viruses, herpes viruses or bovine papilloma viruses, can be used to deliver the polynucleotide or vector to a target cell population.
[0286] Methods well known to those skilled in the art can be used to construct one or more recombinant vectors; see, for example, Sambrook et al. (loc cit.), Ausubel (1989, loc cit.) or other standard textbooks. Alternatively, the nucleic acid molecule and the vector can be reconstituted into liposomes for delivery to target cells. The vector containing the nucleic acid molecule of the present invention can be transferred into a host cell by well-known methods, depending on the type of cell host. For example, calcium chloride transfection is commonly used for prokaryotic cells, while calcium phosphate treatment or electroporation can be used for other cell hosts; see Sambrook, supra. The vector can be pEF-DHFR, pEF-ADA or pEF-neo in particular. The vectors pEF-DHFR, pEF-ADA and pEF-neo have been described in the art, for example, in Mack et al. Proc. Natl. Acad. Sci. USA 92 (1995), 7021-7025 and Raum et al. Cancer Immunol Immunother 50 (2001), 141-150.
[0287] The present invention also provides a T cell transduced with a vector as described herein. The T cell can be produced by introducing at least one of the above vectors or at least one of the above nucleic acid molecules into a T cell or a precursor cell thereof. The presence of the at least one vector or at least one nucleic acid molecule in the T cell mediates the expression of the gene encoding the chimeric receptor. The vector of the present invention can be polycistronic.
[0288] The one or more nucleic acid molecules or one or more vectors introduced into the T cell or its precursor cell may be integrated into the genome of the cell or may be maintained extrachromosomally.
[0289] Antibodies capable of binding to the chimeric receptor of the present invention
[0290] The chimeric receptors of the invention can be used, for example, in methods of treating various diseases (eg, cancer) or delaying their progression, particularly in combination with antibodies capable of binding to the chimeric receptors of the invention.
[0291] In one embodiment, a method for treating a disease in a subject is provided, the method comprising: administering to the subject transduced T cells, the transduced T cells being capable of expressing a chimeric receptor as described herein, wherein the chimeric receptor comprises an extracellular domain comprising a mutated Fc domain or a fragment thereof; and administering a therapeutically effective amount of a molecule (e.g., an antibody) prior to, simultaneously with, or after administering the transduced T cells, the molecule comprising at least one antigen binding portion that is capable of binding to a mutated Fc domain but not to a non-mutated parent Fc domain. In one embodiment, the antibody comprises at least one effector portion.
[0292] In one embodiment, the effector moiety is an antigen binding moiety capable of binding to a target cell antigen.
[0293] In one embodiment, the effector moiety is an immune activation moiety. In one embodiment, the immune activation moiety is a cytokine (e.g., IL2). In a specific embodiment, the cytokine is IL2 or a derivative thereof. In one embodiment, the immune activation moiety is a co-stimulatory T cell antigen (e.g., CD28, 4-1BB) or a co-stimulatory ligand (e.g., 4-1BBL).
[0294] Antigen binding portions, target antigens, and immune activating portions capable of binding to a mutated Fc domain are further described below.
[0295] Antigen binding portion capable of binding to a mutated Fc domain
[0296] The present invention further provides an antibody comprising at least one antigen binding portion capable of binding to a mutated Fc domain (e.g., comprising a P329G substitution according to EU numbering). The antigen binding portion capable of binding to (modified / engineered) Fc domains or fragments thereof can be produced, for example, by immunizing a mammalian immune system, for example, with an Fc domain or fragment thereof comprising a relevant mutation. Such methods are known in the art and are described, for example, in Burns, Methods in Molecular Biology 295: 1-12 (2005). Alternatively, the antigen binding portion of the present invention can be separated by screening a combinatorial library for antigen binding portions with one or more desired activities. Methods for screening combinatorial libraries are summarized in, for example, Lerner et al., Nature Reviews 16: 498-508 (2016). For example, various methods are known in the art for generating phage display libraries and screening such libraries to obtain antigen binding portions with desired binding characteristics. Such methods are reviewed, for example, in Frenzel et al., mAbs 8:1177-1194 (2016); Bazan et al., Human Vaccines and Immunotherapeutics 8:1817-1828 (2012) and Zhao et al., Critical Reviews in Biotechnology 36:276-289 (2016), and in Hoogenboom et al., Methods in Molecular Biology 178:1-37 (O'Brien et al., eds., Human Press, Totowa, NJ, 2001) and further described, for example, in McCafferty et al., Nature 348:552-554; Clackson et al., Nature 352:624-628 (1991); Marks et al., J. Mol. Biol. 222:581-597 (1992) and Marks and Bradbury, Methods in Molecular Biology 248:161-175 (Lo ed., Human Press, Totowa, NJ, 2003).; Sidhu et al., J. Mol. Biol. 338(2):299-310 (2004); Lee et al., J. Mol. Biol. 340(5):1073-1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34):12467-12472 (2004); and Lee et al., J. Immunol. Methods 284(1-2):119-132 (2004). In some phage display methods, the repertoire of VH and VL genes are individually cloned by polymerase chain reaction (PCR) and randomly recombined in a phage library, which can then be screened for antigen-binding phage, as described in Winter et al., Annual Review of Immunology 12:433-455 (1994). Phages usually display antibody fragments as single-chain Fv (scFv) fragments or Fab fragments. Libraries from immunized sources provide high-affinity antigen-binding moieties without the need to construct hybridomas. Alternatively, natural constituents (e.g., natural constituents from people) can be cloned to provide a single source of antigen-binding moieties for a wide range of antigens without any immunization, as described by Griffiths et al. in EMBO Journal 12:725-734 (1993). In addition, natural libraries are also synthesized in the following manner: cloning unrearranged V gene segments from stem cells; and using PCR primers containing random sequences to encode highly variable CDR3 regions and complete in vitro rearrangement, as described by Hoogenboom and Winter in Journal of Molecular Biology 227:381-388 (1992). Patent publications describing human antibody phage libraries include, for example, U.S. Pat. Nos. 5,750,373; 7,985,840; 7,785,903 and 8,679,490 and U.S. Patent Publication Nos. 2005 / 0079574, 2007 / 0117126, 2007 / 0237764 and 2007 / 0292936 and 2009 / 0002360. Other examples of methods known in the art for screening combinatorial libraries of antigen-binding portions having one or more desired activities include ribosome and mRNA display, and methods for antibody display and selection in bacteria, mammalian cells, insect cells or yeast cells.Methods for yeast surface display are reviewed in, for example, Scholler et al., Methods in Molecular Biology 503: 135-56 (2012) and Cherf et al., Methods in Molecular biology 1319: 155-175 (2015) and Zhao et al., Methods in Molecular Biology 889: 73-84 (2012). Methods for ribosome display are described in, for example, He et al., Nucleic Acids Research 25: 5132-5134 (1997) and Hanes et al., PNAS 94: 4937-4942 (1997).
[0297] In an illustrative example of the invention, as a proof of concept, an antigen binding portion is provided which is capable of binding to a mutated Fc domain comprising the amino acid substitution P329G.
[0298] More generally, antibodies are provided that are capable of binding to a mutated Fc domain comprising a substitution at position P329 (numbered according to the Kabat EU index). In one embodiment, at least one amino acid substitution comprises a substitution at position P329 (numbered according to the Kabat EU index) by an amino acid selected from the list consisting of alanine (A), arginine (R), leucine (L), isoleucine (I) and proline (P). In one embodiment, at least one amino acid substitution comprises the amino acid substitution P329G (numbered according to the Kabat EU index).
[0299] In one embodiment, the antigen binding portion is capable of binding to a mutated Fc domain. In one embodiment, the Fc domain is an IgG, particularly an IgG1 or IgG4 Fc domain. In one embodiment, the Fc domain is a human Fc domain. In one embodiment, the mutated Fc domain exhibits reduced binding affinity to an Fc receptor and / or reduced effector function compared to a native IgG1 Fc domain. In one embodiment, the Fc domain comprises one or more amino acid mutations that reduce binding to an Fc receptor and / or effector function.
[0300] In a preferred embodiment, the mutated Fc domain comprises a P329G substitution.
[0301] In one embodiment, an antibody is provided wherein at least one antigen binding portion is capable of binding to a mutated Fc domain comprising a P329G substitution (EU numbering), but is unable to bind to the non-mutated parental Fc domain.
[0302] In one embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising at least one of:
[0303] (a) the heavy chain complementarity determining region (CDR H) 1 amino acid sequence of SEQ ID NO: 1;
[0304] (b) a CDR H2 amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 9, SEQ ID NO: 12 or SEQ ID NO: 15; and
[0305] (c) CDR H3 amino acid sequence of SEQ ID NO:3.
[0306] In one embodiment, the antigen binding portion comprises a light chain variable domain (VL) comprising at least one of:
[0307] (d) the light chain (CDR L) 1 amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 18;
[0308] (e) the CDR L2 amino acid sequence of SEQ ID NO: 5; and
[0309] (f) CDR L3 amino acid sequence of SEQ ID NO:6.
[0310] In a preferred embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising:
[0311] (a) the heavy chain complementarity determining region (CDR H) 1 amino acid sequence of SEQ ID NO: 1;
[0312] (b) a CDR H2 amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 9, SEQ ID NO: 12 or SEQ ID NO: 15; and
[0313] (c) the CDR H3 amino acid sequence of SEQ ID NO: 3;
[0314] and a light chain variable domain (VL) comprising:
[0315] (d) the light chain (CDR L) 1 amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 18;
[0316] (e) the CDR L2 amino acid sequence of SEQ ID NO: 5; and
[0317] (f) CDR L3 amino acid sequence of SEQ ID NO:6.
[0318] In a specific embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising:
[0319] (a) the heavy chain complementarity determining region (CDR H) 1 amino acid sequence of SEQ ID NO: 1;
[0320] (b) the CDR H2 amino acid sequence of SEQ ID NO: 2;
[0321] (c) the CDR H3 amino acid sequence of SEQ ID NO: 3;
[0322] and a light chain variable domain (VL) comprising:
[0323] (d) light chain (CDR L) 1 amino acid sequence of SEQ ID NO: 4;
[0324] (e) the CDR L2 amino acid sequence of SEQ ID NO: 5; and
[0325] (f) CDR L3 amino acid sequence of SEQ ID NO:6.
[0326] In another specific embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising:
[0327] (a) the heavy chain complementarity determining region (CDR H) 1 amino acid sequence of SEQ ID NO: 1;
[0328] (b) the CDR H2 amino acid sequence of SEQ ID NO:9;
[0329] (c) the CDR H3 amino acid sequence of SEQ ID NO: 3;
[0330] and a light chain variable domain (VL) comprising:
[0331] (d) light chain (CDR L) 1 amino acid sequence of SEQ ID NO: 4;
[0332] (e) the CDR L2 amino acid sequence of SEQ ID NO: 5; and
[0333] (f) CDR L3 amino acid sequence of SEQ ID NO:6.
[0334] In another specific embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising:
[0335] (a) the heavy chain complementarity determining region (CDR H) 1 amino acid sequence of SEQ ID NO: 1;
[0336] (b) the CDR H2 amino acid sequence of SEQ ID NO: 12;
[0337] (c) the CDR H3 amino acid sequence of SEQ ID NO: 3;
[0338] and a light chain variable domain (VL) comprising:
[0339] (d) light chain (CDR L) 1 amino acid sequence of SEQ ID NO: 4;
[0340] (e) the CDR L2 amino acid sequence of SEQ ID NO: 5; and
[0341] (f) CDR L3 amino acid sequence of SEQ ID NO:6.
[0342] In another specific embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising:
[0343] (g) the heavy chain complementarity determining region (CDR H) 1 amino acid sequence of SEQ ID NO: 1;
[0344] (h) the CDR H2 amino acid sequence of SEQ ID NO: 15;
[0345] (i) the CDR H3 amino acid sequence of SEQ ID NO: 3;
[0346] and a light chain variable domain (VL) comprising:
[0347] (j) light chain (CDR L) 1 amino acid sequence of SEQ ID NO: 4;
[0348] (k) the CDR L2 amino acid sequence of SEQ ID NO:5; and
[0349] (l) CDR L3 amino acid sequence of SEQ ID NO:6.
[0350] In another specific embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising:
[0351] (a) the heavy chain complementarity determining region (CDR H) 1 amino acid sequence of SEQ ID NO: 1;
[0352] (b) the CDR H2 amino acid sequence of SEQ ID NO:9;
[0353] (c) the CDR H3 amino acid sequence of SEQ ID NO: 3;
[0354] and a light chain variable domain (VL) comprising:
[0355] (d) light chain (CDR L) 1 amino acid sequence of SEQ ID NO: 18;
[0356] (e) the CDR L2 amino acid sequence of SEQ ID NO: 5; and
[0357] (f) CDR L3 amino acid sequence of SEQ ID NO:6.
[0358] In one embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:16.
[0359] In one embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:7.
[0360] In one embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:10.
[0361] In one embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:13.
[0362] In one embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:14.
[0363] In one embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:16.
[0364] In one embodiment, the antigen binding portion comprises a light chain variable domain (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to a sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:17 and SEQ ID NO:19.
[0365] In one embodiment, the antigen binding portion comprises a light chain variable domain (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:8.
[0366] In one embodiment, the antigen binding portion comprises a light chain variable domain (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:11.
[0367] In one embodiment, the antigen binding portion comprises a light chain variable domain (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:17.
[0368] In one embodiment, the antigen binding portion comprises a light chain variable domain (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:19.
[0369] In one embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:7, and a light chain variable domain (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:8.
[0370] In one embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 10, and a light chain variable domain (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 11.
[0371] In one embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 13, and a light chain variable domain (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 11.
[0372] In one embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 14, and a light chain variable domain (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 11.
[0373] In one embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 16, and a light chain variable domain (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 11.
[0374] In one embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 10, and a light chain variable domain (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 17.
[0375] In one embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 10, and a light chain variable domain (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 19.
[0376] In a preferred embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) and a light chain variable domain (VL), wherein the heavy chain variable domain (VH) comprises the amino acid sequence of SEQ ID NO: 14, and the light chain variable domain (VL) comprises the amino acid sequence of SEQ ID NO: 11.
[0377] In one embodiment, the mutated Fc domain comprises I253A, H310A and H435A ("AAA") substitutions. In one embodiment, an antibody is provided comprising at least one antigen binding portion that is capable of binding to a mutated Fc domain comprising I253A, H310A and H435A substitutions (EU numbering), but is unable to bind to a non-mutated parental Fc domain.
[0378] In one embodiment, the antigen binding portion comprises a heavy chain variable region comprising at least one of:
[0379] (a) the heavy chain complementarity determining region (CDR H) 1 amino acid sequence of SEQ ID NO: 28;
[0380] (b) the CDR H2 amino acid sequence of SEQ ID NO: 29; and
[0381] (c) CDR H3 amino acid sequence of SEQ ID NO: 30).
[0382] In one embodiment, the antigen binding portion comprises at least one of:
[0383] (d) light chain (CDR L) 1 amino acid sequence of SEQ ID NO:31;
[0384] (e) the CDR L2 amino acid sequence of SEQ ID NO:32; and
[0385] (f) CDR L3 amino acid sequence of SEQ ID NO:33.
[0386] In one embodiment, the antigen binding portion comprises at least one heavy chain complementary determining region (CDR), which comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of: SEQ ID NO:28, SEQ ID NO:29 and SEQ ID NO:30, and at least one light chain CDR selected from the group consisting of: SEQ ID NO:31, SEQ ID NO:32 and SEQ ID NO:33.
[0387] In one embodiment, the antigen binding portion comprises the heavy chain complementarity determining regions (CDRs) of SEQ ID NO:28, SEQ ID NO:29, and SEQ ID NO:30 and the light chain CDRs of SEQ ID NO:31, SEQ ID NO:32, and SEQ ID NO:33.
[0388] In one embodiment, the antigen binding portion comprises a heavy chain variable region comprising:
[0389] (a) the heavy chain complementarity determining region (CDR H) 1 amino acid sequence of SEQ ID NO: 28;
[0390] (b) the CDR H2 amino acid sequence of SEQ ID NO:29;
[0391] (c) the CDR H3 amino acid sequence of SEQ ID NO: 30; and a light chain variable region comprising:
[0392] (d) light chain (CDR L) 1 amino acid sequence of SEQ ID NO:31;
[0393] (e) the CDR L2 amino acid sequence of SEQ ID NO:32; and
[0394] (f) CDR L3 amino acid sequence of SEQ ID NO:33.
[0395] In one embodiment, the antigen binding portion comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:34, and the light chain variable region comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from SEQ ID NO:35.
[0396] In one embodiment, the antigen binding portion comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:34 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:35.
[0397] In one embodiment, the antigen binding portion comprises a heavy chain variable region comprising at least one of:
[0398] (d) the heavy chain complementarity determining region (CDR H) 1 amino acid sequence of SEQ ID NO: 130;
[0399] (e) the CDR H2 amino acid sequence of SEQ ID NO: 131; and
[0400] (f) CDR H3 amino acid sequence of SEQ ID NO: 132).
[0401] In one embodiment, the antigen binding portion comprises at least one of:
[0402] (g) light chain (CDR L) 1 amino acid sequence of SEQ ID NO: 133;
[0403] (h) the CDR L2 amino acid sequence of SEQ ID NO: 134; and
[0404] (i) CDR L3 amino acid sequence of SEQ ID NO:135.
[0405] In one embodiment, the antigen binding portion comprises at least one heavy chain complementary determining region (CDR), which comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of: SEQ ID NO: 130, SEQ ID NO: 131 and SEQ ID NO: 132, and at least one light chain CDR selected from the group consisting of: SEQ ID NO: 133, SEQ ID NO: 134 and SEQ ID NO: 135.
[0406] In one embodiment, the antigen binding portion comprises the heavy chain complementarity determining regions (CDRs) of SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:132 and the light chain CDRs of SEQ ID NO:133, SEQ ID NO:134, and SEQ ID NO:135.
[0407] In one embodiment, the antigen binding portion comprises a heavy chain variable region comprising:
[0408] (g) the heavy chain complementarity determining region (CDR H) 1 amino acid sequence of SEQ ID NO: 130;
[0409] (h) the CDR H2 amino acid sequence of SEQ ID NO: 131;
[0410] (i) the CDR H3 amino acid sequence of SEQ ID NO: 132; and a light chain variable region comprising:
[0411] (j) light chain (CDR L) 1 amino acid sequence of SEQ ID NO: 133;
[0412] (k) the CDR L2 amino acid sequence of SEQ ID NO: 134; and
[0413] (l) CDR L3 amino acid sequence of SEQ ID NO:135.
[0414] In one embodiment, the antigen binding portion comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 136, and the light chain variable region comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from SEQ ID NO: 35.
[0415] In one embodiment, the antigen binding portion comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 136 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 35.
[0416] Target cell antigen
[0417] As described above, in addition to an antigen binding portion that is capable of binding to a mutated Fc domain but not to a non-mutated parent Fc domain (i.e., capable of binding to a chimeric receptor of the invention), the (therapeutic) antibodies described herein may also comprise at least one antigen binding portion that is capable of binding to a target cell antigen (e.g., a tumor-specific antigen naturally present on the surface of a tumor cell). In the context of the present invention, such antibodies will bring a transduced T cell as described herein comprising a chimeric receptor of the invention into physical contact with a target cell (e.g., a tumor cell), wherein the transduced T cell is activated. Activation of the transduced T cells of the present invention preferentially results in lysis of the target cell as described herein.
[0418] Examples of target cell antigens (e.g., tumor markers) naturally present on the surface of target (e.g., tumor) cells are given below and include, but are not limited to, FAP (fibroblast activation protein), CEA (carcinoembryonic antigen), p95 (p95HER2), BCMA (B cell maturation antigen), EpCAM (epithelial cell adhesion molecule), MSLN (mesothelin), MCSP (melanoma chondroitin sulfate proteoglycan), HER-1 (human epidermal growth factor 1), HER-2 (human epidermal growth factor 2), HER-3 (human epidermal growth factor 3), CD19, CD20, CD22, CD33, CD38, CD 52Flt3, folate receptor 1 (FOLR1), human trophoblast cell surface antigen 2 (Trop-2) cancer antigen 12-5 (CA-12-5), human leukocyte antigen-antigen D related (HLA-DR), MUC-1 (mucin-1), A33 antigen, PSMA (prostate-specific membrane antigen), FMS-like tyrosine kinase 3 (FLT-3), PSMA (prostate-specific membrane antigen), PSCA (prostate stem cell antigen), transferrin-receptor, TNC (tenascin), carbonic anhydrase IX (CA-IX) and / or peptides bound to molecules of the human major histocompatibility complex (MHC).
[0419] A33 antigen, BCMA (B cell maturation antigen), cancer antigen 12-5 (CA-12-5), carbonic anhydrase IX (CA-IX), CD19, CD20, CD22, CD33, CD38, CEA (carcinoembryonic antigen), EpCAM (epithelial cell adhesion molecule), FAP (fibroblast activation protein), FMS-like tyrosine kinase 3 (FLT-3), folate receptor 1 (FOLR1), HER-1 (human epidermal growth factor 1), HER-2 (human epidermal growth factor 2), HER-3 (human epidermal growth factor 3), human leukocyte antigen-related antigen D (HL Sequences of 5-mercaptoethanol (5-mercaptoethanol), ... One or more sequences of (human) FAP (fibroblast activation protein) can be obtained from Swiss-Prot database entry Q12884 (entry version 168, sequence version 5); one or more sequences of (human) CEA (carcinoembryonic antigen) can be obtained from Swiss-Prot database entry P06731 (entry version 171, sequence version 3); one or more sequences of (human) EpCAM (epithelial cell adhesion molecule) can be obtained from Swiss-Prot database entry P16422 (entry version 117, sequence version 2); one or more sequences of (human) MSLN (mesothelin) can be obtained from UniProt entry number Q13421 (version number 132; sequence version 2); one or more sequences of (human) FMS-like tyrosine kinase 3 (FLT-3) can be obtained from Swiss-Prot database entry P36888 (primary citable accession number) or Q13414 (secondary accession number) (version number 165 and sequence version 2);One or more sequences of (human) MCSP (melanoma chondroitin sulfate proteoglycan) can be obtained from UniProt entry number Q6UVK1 (version number 118; sequence version 2); one or more sequences of (human) folate receptor 1 (FOLR1) can be obtained from UniProt entry number P15328 (primary citable accession number) or Q53EW2 (secondary accession number) (version number 153, sequence version 3); one or more sequences of (human) trophoblast cell surface antigen 2 (Trop-2) can be obtained from UniProt entry number P09758 (primary citable accession number) or Q15658 (secondary accession number) (version number 172 and sequence version 3) One or more sequences of (human) PSCA (prostate stem cell antigen) can be obtained from UniProt entry number O43653 (primary citable accession number) or Q6UW92 (secondary accession number) (version number 134 and sequence version 1); one or more sequences of (human) HER-1 (epidermal growth factor receptor) can be obtained from Swiss-Prot database entry P00533 (entry version 177, sequence version 2); one or more sequences of (human) HER-2 (receptor tyrosine protein kinase erbB-2) can be obtained from Swiss-Prot database entry P04626 (entry version 161, sequence version 1); (human) H One or more sequences of ER-3 (receptor tyrosine protein kinase erbB-3) can be obtained from Swiss-Prot database entry P21860 (entry version 140, sequence version 1); one or more sequences of (human) CD20 (B lymphocyte antigen CD20) can be obtained from Swiss-Prot database entry P11836 (entry version 117, sequence version 1); one or more sequences of (human) CD22 (B lymphocyte antigen CD22) can be obtained from Swiss-Prot database entry P20273 (entry version 135, sequence version 2); one or more sequences of (human) CD33 (B lymphocyte antigen CD33) can be obtained from Swiss-Prot database entry P21860 (entry version 140, sequence version 1); one or more sequences of (human) CD20 (B lymphocyte antigen CD20) can be obtained from Swiss-Prot database entry P21836 (entry version 117, sequence version 1); one or more sequences of (human) CD22 (B lymphocyte antigen CD22) can be obtained from Swiss-Prot database entry P20273 (entry version 135, sequence version 2); one or more sequences of (human) CD33 (B lymphocyte antigen CD33) can be obtained from Swiss-Prot database entry P21860 (entry version 140, sequence version 1); one or more sequences of (human) CD33 (B lymphocyte antigen CD33) can be obtained from Swiss-Prot database entry P21836 (entry version 117 ...22 (B lymphocyte antigen CD22) can be obtained from Swiss-Prot database entry P21836 (entry version 117, sequence version 1); one or more Multiple sequences can be obtained from Swiss-Prot database entry P20138 (entry version 129, sequence version 2); one or more sequences of (human) CA-12-5 (mucin 16) can be obtained from Swiss-Prot database entry Q8WXI7 (entry version 66, sequence version 2); one or more sequences of (human) HLA-DR can be obtained from Swiss-Prot database entry Q29900 (entry version 59, sequence version 1); one or more sequences of (human) MUC-1 (mucin-1) can be obtained from Swiss-Prot database entry P15941 (entry version 135, sequence version 3);One or more sequences of (human) A33 (cell surface A33 antigen) can be obtained from Swiss-Prot database entry Q99795 (entry version 104, sequence version 1); one or more sequences of (human) PSMA (glutamate carboxypeptidase 2) can be obtained from Swiss-Prot database entry Q04609 (entry version 133, sequence version 1); one or more sequences of (human) transferrin receptor can be obtained from Swiss-Prot database entries Q9UP52 (entry version 99, sequence version 1) and P02786 (entry version 152, sequence version 2); one or more sequences of (human) TNC (tenascin) can be obtained from Swiss-Prot database entry P24821 (entry version 141, sequence version 3); or one or more sequences of (human) CA-IX (carbonic anhydrase IX) can be obtained from Swiss-Prot database entry Q16790 (entry version 115, sequence version 2). ;
[0420] In a specific embodiment, the target cell antigen is selected from the group consisting of fibroblast activation protein (FAP), carcinoembryonic antigen (CEA), mesothelin (MSLN), CD20, folate receptor 1 (FOLR1), and tenascin (TNC).
[0421] Antibodies capable of binding to any of the above target cell antigens can be generated using methods well known in the art, such as immunization of a mammalian immune system and / or phage display using a recombinant library as described above.
[0422] Immune Activation Fc Binding Molecules
[0423] The chimeric receptors of the invention can be combined with immune activating Fc binding molecules (which are capable of binding to mutated Fc domains). Suitable molecules are described below and in WO2021 / 255138.
[0424] In one embodiment, a chimeric receptor as described above is provided for use in a method for treating cancer or delaying its progression, wherein the chimeric receptor is used in combination with any one of the immune-activating Fc-binding molecules described in WO2021 / 255138.
[0425] In one embodiment, a chimeric receptor as described above is provided for use in a method for treating cancer or delaying its progression, wherein the chimeric receptor is used in combination with a molecule as described in Figure 29A and Example 5 of WO2021 / 255138.
[0426] Reagent test kit
[0427] Another aspect of the invention is a kit comprising or consisting of a nucleic acid encoding a chimeric receptor of the invention and / or a cell, preferably a T cell for transduction / transduced with a chimeric receptor of the invention, and optionally one or more (therapeutic) antibodies as described hereinbefore.
[0428] Thus, a kit is provided comprising transduced T cells capable of expressing a chimeric receptor according to the invention, wherein the chimeric receptor comprises an extracellular domain comprising a mutated Fc domain or a fragment thereof; and an antibody, in particular a therapeutic antibody, comprising at least one antigen binding portion capable of binding to the mutated Fc domain but not to the non-mutated parent Fc domain, wherein the antibody comprises at least one effector portion as described hereinbefore.
[0429] Further provided is a kit comprising an isolated polynucleotide encoding a chimeric receptor according to the invention.
[0430] In one embodiment, the effector moiety is an antigen binding moiety capable of binding to a target cell antigen as described above.
[0431] In one embodiment, the effector moiety is an immune activating moiety as described above, particularly a cytokine (eg, IL2 or a derivative thereof).
[0432] In one embodiment, the chimeric receptor comprises a mutated Fc domain, which comprises P329G substitution (according to Kabat EU index numbering). In a preferred such embodiment, the therapeutic antibody does not comprise P329G substitution (according to Kabat EU index numbering). This prevents the dimerization of the therapeutic antibody comprising the antigen binding portion that can replace specific binding with P329G. In one embodiment, the therapeutic antibody comprises an amino acid substitution selected from the group consisting of the following items: P329G, P329L, P329I, P329R and P329A (according to Kabat EU index numbering). In a preferred embodiment, the therapeutic antibody comprises P329R substitution (according to Kabat EU index numbering).
[0433] In another preferred embodiment, the chimeric receptor comprises a mutated Fc domain comprising amino acid substitutions I253A, H310A and H435A (numbered according to the Kabat EU index). In a preferred such embodiment, the therapeutic antibody comprises a P329G substitution (numbered according to the Kabat EU index).
[0434] In a specific embodiment, the antibody is a therapeutic antibody, such as a tumor-specific antibody or an immune-activating antibody as described above. Tumor-specific antigens and immune-activating moieties are known in the art and described above. In the context of the present invention, the antibody is administered before, simultaneously with, or after administration of transduced T cells expressing the chimeric receptor of the present invention.
[0435] In one embodiment of the present invention, a kit is provided, comprising transduced T cells capable of expressing the amino acid sequence of SEQ ID NO: 87, or alternatively, the kit comprises a polynucleotide encoding the amino acid sequence of SEQ ID NO: 87 (e.g., the kit comprises a polynucleotide comprising the sequence of SEQ ID NO: 96) in combination with an antibody comprising a heavy chain of SEQ ID NO: 109, a heavy chain of SEQ ID NO: 110, a light chain of SEQ ID NO: 11, and two light chains of SEQ ID NO: 108. The kit can be used to treat FolR-positive cancers.
[0436] In one embodiment of the present invention, a kit is provided, comprising transduced T cells capable of expressing the amino acid sequence of SEQ ID NO: 106, or alternatively, the kit comprises a polynucleotide encoding the amino acid sequence of SEQ ID NO: 106 (e.g., the kit comprises a polynucleotide comprising the sequence of SEQ ID NO: 107) in combination with an antibody comprising a heavy chain of SEQ ID NO: 112, a heavy chain of SEQ ID NO: 113, a light chain of SEQ ID NO: 114, and two light chains of SEQ ID NO: 108. The kit can be used to treat FolR1-positive cancers.
[0437] In one embodiment of the present invention, a kit is provided, comprising transduced T cells capable of expressing the amino acid sequence of SEQ ID NO: 87, or alternatively, the kit comprises a polynucleotide encoding the amino acid sequence of SEQ ID NO: 87 (e.g., the kit comprises a polynucleotide comprising the sequence of SEQ ID NO: 96) in combination with an antibody comprising a heavy chain of SEQ ID NO: 109, a heavy chain of SEQ ID NO: 115, a light chain of SEQ ID NO: 108, and a light chain of SEQ ID NO: 111. The kit can be used to treat FolR1-positive cancers.
[0438] In one embodiment of the present invention, a kit is provided, comprising transduced T cells capable of expressing the amino acid sequence of SEQ ID NO: 106, or alternatively, the kit comprises a polynucleotide encoding the amino acid sequence of SEQ ID NO: 106 (e.g., the kit comprises a polynucleotide comprising the sequence of SEQ ID NO: 107) in combination with an antibody comprising a heavy chain of SEQ ID NO: 112, a heavy chain of SEQ ID NO: 116, a light chain of SEQ ID NO: 114, and a light chain of SEQ ID NO: 108. The kit can be used to treat FolR1-positive cancers.
[0439] In one embodiment of the present invention, a kit is provided, comprising transduced T cells capable of expressing the amino acid sequence of SEQ ID NO: 87, or alternatively, the kit comprises a polynucleotide encoding the amino acid sequence of SEQ ID NO: 87 (e.g., the kit comprises a polynucleotide comprising the sequence of SEQ ID NO: 96) in combination with an antibody comprising a heavy chain of SEQ ID NO: 118, a heavy chain of SEQ ID NO: 119, a light chain of SEQ ID NO: 117, and two light chains of SEQ ID NO: 120. The kit can be used to treat CEA-positive cancers.
[0440] In one embodiment of the present invention, a kit is provided, comprising transduced T cells capable of expressing the amino acid sequence of SEQ ID NO: 106, or alternatively, the kit comprises a polynucleotide encoding the amino acid sequence of SEQ ID NO: 106 (e.g., the kit comprises a polynucleotide comprising the sequence of SEQ ID NO: 107) in combination with an antibody comprising a heavy chain of SEQ ID NO: 122, a heavy chain of SEQ ID NO: 123, a light chain of SEQ ID NO: 121, and two light chains of SEQ ID NO: 114. The kit can be used to treat CEA-positive cancers.
[0441] In addition, the components of the kit of the present invention can be packaged individually in vials or bottles or combined in containers or multi-container units. In addition, the kit of the present invention can include a (closed) bag cell incubation system, in which patient cells, preferably T cells as described herein, can be transduced with one or more chimeric receptors of the present invention and incubated under GMP (Good Manufacturing Practice, as described in the Good Manufacturing Practice Guide published by the European Commission at http: / / ec.europa.eu / health / documents / eudralex / index_en.htm) conditions. In addition, the kit of the present invention includes a (closed) bag cell incubation system, in which isolated / obtained patient T cells can be transduced with one or more chimeric receptors of the present invention and incubated under GMP. In addition, in the context of the present invention, the kit can also include a vector encoding a chimeric receptor as described herein. The kit of the present invention can be used in particular to advantageously implement the method of the present invention and can be used in various applications mentioned herein, for example as a research tool or a medical tool. The manufacture of the kit preferably follows standard procedures known to those skilled in the art.
[0442] In this context, cells (preferably T cells) derived from patients can be transduced with chimeric receptors as described herein using a kit as described above. The extracellular domain of the Fc domain comprising a mutation does not naturally exist in or on T cells. Therefore, cells derived from patients transduced with the kit of the present invention will acquire the ability to interact with therapeutic antibodies, and will become able to induce elimination / lysis of target cells via interaction with therapeutic antibodies, wherein therapeutic antibodies can bind to tumor-specific antigens naturally present (i.e., endogenously expressed) on the surface of tumor cells. The binding of the extracellular domain of the chimeric receptor as described herein activates the T cell and physically contacts it with tumor cells through therapeutic antibodies. Non-transduced or endogenous T cells (e.g., CD8+ T cells) cannot bind to therapeutic antibodies. Therefore, T cells expressing the chimeric receptor molecule of the present invention have the ability to lyse target cells in vivo and / or in vitro in the presence of antibodies as described herein. The corresponding target cells include cells expressing surface molecules (i.e., tumor-specific antigens naturally present on the surface of tumor cells), which are recognized by at least one, preferably two, binding domains of the therapeutic antibodies described herein.
[0443] The cracking of target cells can be detected by methods known in the art.Therefore, such methods especially include physiological in vitro assays.Such physiological assays can monitor cell death, such as monitoring (such as by the loss of cell membrane integrity, propidium iodide assay, trypan blue influx assay, photometric enzyme release assay (LDH), radiation 51Cr release assay, fluorescence europium release and calcein AM release assay) by the loss of cell membrane integrity.Further assay includes monitoring cell viability, such as by photometric MTT, XTT, WST-1 and alamarBlue assay, radiation 3H-Thd incorporation assay, measurement of cell division activity, measurement of clonal formation and measurement of mitochondrial transmembrane gradient, fluorescence rhodamine 123 assay.In addition, apoptosis can be monitored, such as by exposure assay of phosphatidylserine based on FACS, TUNEL test based on ELISA, caspase activity assay (based on photometer, fluorometer or based on ELISA) or analysis of the cell morphology (contraction, membrane blistering) of change.
[0444] Exemplary Therapeutic Uses and Methods of Treatment
[0445] The molecules or constructs (e.g., chimeric receptors, transduced T cells, and kits) provided herein are particularly useful in medical settings, particularly for the treatment of cancer. For example, tumors can be treated with transduced T cells expressing the chimeric receptors of the invention together with a therapeutic antibody comprising at least one antigen binding portion capable of binding to a target cell antigen and at least one antigen binding portion capable of binding to a mutated Fc domain (e.g., comprising a P329G substitution according to EU numbering) but not capable of binding to a non-mutated parental Fc domain. Thus, in certain embodiments, the chimeric receptors, transduced T cells, or kits are used to treat cancer, particularly cancers of epithelial, endothelial, or mesothelial origin and hematological cancers.
[0446] The tumor specificity of the treatment is provided by a therapeutic antibody that binds to a target cell antigen, wherein the antibody is administered before, simultaneously with, or after administration of transduced T cells expressing the chimeric receptor of the invention. In this case, the transduced T cells are universal T cells in that they are not specific for a given tumor, but can target any tumor, depending on the specificity of the therapeutic antibody used according to the invention.
[0447] Cancer can be a cancer / cancer of epithelial, endothelial or mesothelial origin or a blood cancer. In one embodiment, the cancer / cancer is selected from the group consisting of gastrointestinal cancer, pancreatic cancer, cholangiocellular carcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, oral cancer, gastric cancer, cervical cancer, B and T cell lymphoma, myeloid leukemia, ovarian cancer, leukemia, lymphatic leukemia, nasopharyngeal carcinoma, colon cancer, prostate cancer, renal cell carcinoma, head and neck cancer, skin cancer (melanoma), urogenital tract cancer (e.g., testicular cancer, ovarian cancer, endothelial carcinoma, cervical cancer and kidney cancer), bile duct cancer, esophageal cancer, salivary gland cancer and thyroid cancer or other neoplastic diseases, such as blood tumors, gliomas, sarcomas or osteosarcomas.
[0448] For example, tumor diseases and / or lymphomas can be treated with specific constructs directed to one or more of these medical indications. For example, gastrointestinal cancer, pancreatic cancer, cholangiocarcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer and / or oral cancer can be treated with antibodies directed to (human) EpCAM, as a tumor-specific antigen naturally present on the surface of tumor cells.
[0449] Gastrointestinal cancer, pancreatic cancer, cholangiocellular carcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer and / or oral cancer can be treated with the transduced T cells of the present invention, which are administered before, simultaneously or after the administration of therapeutic antibodies against HER1, preferably human HER1. In addition, gastrointestinal cancer, pancreatic cancer, cholangiocellular carcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, glioblastoma and / or oral cancer can be treated with the transduced T cells of the present invention, which are administered before, simultaneously or after the administration of therapeutic antibodies against MCSP, preferably human MCSP. Gastrointestinal cancer, pancreatic cancer, cholangiocellular carcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, glioblastoma and / or oral cancer can be treated with the transduced T cells of the present invention, which are administered before, simultaneously or after the administration of therapeutic antibodies against FOLR1, preferably human FOLR1. Gastrointestinal cancer, pancreatic cancer, cholangiocellular carcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, glioblastoma and / or oral cancer can be treated with the transduced T cells of the present invention, which are administered before, simultaneously or after the administration of therapeutic antibodies against Trop-2, preferably human Trop-2. Gastrointestinal cancer, pancreatic cancer, cholangiocellular carcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, glioblastoma and / or oral cancer can be treated with the transduced T cells of the present invention, which are administered before, simultaneously or after the administration of therapeutic antibodies against PSCA, preferably human PSCA. Gastrointestinal cancer, pancreatic cancer, cholangiocellular carcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, glioblastoma and / or oral cancer can be treated with the transduced T cells of the present invention, which are administered before, simultaneously or after the administration of therapeutic antibodies against EGFRvIII, preferably human EGFRvIII. Gastrointestinal cancer, pancreatic cancer, cholangiocarcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, glioblastoma and / or oral cancer can be treated with the transduced T cells of the present invention, which are administered before, simultaneously or after the administration of therapeutic antibodies against MSLN, preferably human MSLN. Gastric cancer, breast cancer and / or cervical cancer can be treated with the transduced T cells of the present invention, which are administered before, simultaneously or after the administration of therapeutic antibodies against HER2, preferably human HER2. Gastric cancer and / or lung cancer can be treated with the transduced T cells of the present invention, which are administered before, simultaneously or after the administration of therapeutic antibodies against HER3, preferably human HER3. B-cell lymphoma and / or T-cell lymphoma can be treated with the transduced T cells of the present invention, which are administered before, simultaneously or after the administration of therapeutic antibodies against CD20, preferably human CD20.B cell lymphoma and / or T cell lymphoma can be treated with the transduced T cells of the present invention, which are administered before, simultaneously or after the administration of therapeutic antibodies against CD22, preferably human CD22. Myeloid leukemia can be treated with the transduced T cells of the present invention, which are administered before, simultaneously or after the administration of therapeutic antibodies against CD33, preferably human CD33. Ovarian cancer, lung cancer, breast cancer and / or gastrointestinal cancer can be treated with the transduced T cells of the present invention, which are administered before, simultaneously or after the administration of therapeutic antibodies against CA12-5, preferably human CA12-5. Gastrointestinal cancer, leukemia and / or nasopharyngeal cancer can be treated with the transduced T cells of the present invention, which are administered before, simultaneously or after the administration of therapeutic antibodies against HLA-DR, preferably human HLA-DR. Colon cancer, breast cancer, ovarian cancer, lung cancer and / or pancreatic cancer can be treated with the transduced T cells of the present invention, which are administered before, simultaneously with, or after the administration of a therapeutic antibody against MUC-1, preferably human MUC-1. Colon cancer can be treated with the transduced T cells of the present invention, which are administered before, simultaneously with, or after the administration of a therapeutic antibody against A33, preferably human A33. Prostate cancer can be treated with the transduced T cells of the present invention, which are administered before, simultaneously with, or after the administration of a therapeutic antibody against PSMA, preferably human PSMA. Gastrointestinal cancer, pancreatic cancer, cholangiocellular carcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, and / or oral cancer can be treated with the transduced T cells of the present invention, which are administered before, simultaneously with, or after the administration of a therapeutic antibody against transferrin receptor, preferably human transferrin receptor. Pancreatic cancer, lung cancer and / or breast cancer can be treated with the transduced T cells of the present invention, which are administered before, simultaneously or after the administration of therapeutic antibodies against transferrin receptor, preferably human transferrin receptor. Kidney cancer can be treated with the transduced T cells of the present invention, which are administered before, simultaneously or after the administration of therapeutic antibodies against CA-IX, preferably human CA-IX.
[0450] The invention also relates to methods of treating diseases, malignancies such as cancers of epithelial, endothelial or mesothelial origin and / or hematological cancers.In the context of the present invention, the subject is a human.
[0451] In the context of the present invention, a specific method for treating a disease comprises the following steps:
[0452] (a) isolating T cells, preferably CD8+ T cells, from a subject;
[0453] (b) transducing said isolated T cells, preferably CD8+ T cells, with a chimeric receptor as described herein; and
[0454] (c) administering the transduced T cells, preferably CD8+ T cells, to the subject.
[0455] In the context of the present invention, said transduced T cells, preferably CD8+ T cells, and / or therapeutic antibody / antibodies are co-administered to said subject by intravenous infusion.
[0456] Furthermore, in the context of the present invention, there is provided a method for treating a disease, comprising the following steps:
[0457] (a) isolating T cells, preferably CD8+ T cells, from a subject;
[0458] (b) transducing said isolated T cells, preferably CD8+ T cells, with a chimeric receptor as described herein;
[0459] (c) expanding T cells, preferably CD8+ T cells, by anti-CD3 and anti-CD28 antibodies; and
[0460] (d) administering the transduced T cells, preferably CD8+ T cells, to the subject.
[0461] The above step (c) (referring to the step of amplifying T cells such as TIL by anti-CD3 and / or anti-CD28 antibodies) can also be carried out in the presence of (stimulating) cytokines such as interleukin 2 and / or interleukin 15 (IL-15). In the context of the present invention, the above step (d) (referring to the step of amplifying T cells such as TIL by anti-CD3 and / or anti-CD28 antibodies) can also be carried out in the presence of interleukin 12 (IL-12), interleukin 7 (IL-7) and / or interleukin 21 (IL-21).
[0462] In addition, the method of treatment includes the administration of antibodies used according to the present invention. The antibodies can be administered before, simultaneously with, or after the administration of the transduced T cells. In the context of the present invention, the administration of the transduced T cells will be performed by intravenous infusion. In the context of the present invention, the transduced T cells are isolated / obtained from the subject to be treated.
[0463] The present invention also contemplates a co-administration scheme with other compounds (e.g., molecules that can provide activation signals for immune effector cells, cell proliferation or cell stimulation). The molecule can be, for example, other primary activation signals of T cells (e.g., other costimulatory molecules: B7 family, Ox40L, 4.1BBL, CD40L, anti-CTLA-4, anti-PD-1 molecules), or other cytokine interleukins (e.g., IL-2).
[0464] The composition of the present invention as described above may also be a diagnostic composition, which further optionally comprises means and methods for detection.
[0465] Composition
[0466] In addition, the present invention provides a composition (drug) comprising one or more antibody molecules, and / or one or more T cells transduced comprising a chimeric receptor of the present invention, and / or one or more nucleic acid molecules and one or more vectors encoding a chimeric receptor according to the present invention. In addition, the present invention provides a kit comprising one or more of the compositions. In the context of the present invention, the composition is a pharmaceutical composition, further optionally comprising a formulation of a suitable carrier, stabilizer and / or excipient. Therefore, in the context of the present invention, a pharmaceutical composition (drug) is provided, comprising an antibody molecule as described herein, which will be administered in combination with a transduced T cell comprising a chimeric receptor as described herein and / or a composition comprising the transduced T cell, wherein the antibody molecule is administered before, simultaneously with or after the administration of the transduced T cell comprising the chimeric receptor of the present invention.
[0467] The use of the term "combination" does not limit the order in which the components of the treatment regimen are administered to a subject. Thus, the pharmaceutical compositions / medicaments described herein encompass the administration of an antibody as defined above, administered before, simultaneously with, or after administration of a transduced T cell comprising a chimeric receptor of the present invention. "Combination" as used herein also does not limit the time between administration of an antibody as defined above and a transduced T cell comprising a chimeric receptor as defined above. Thus, when the two components are not administered simultaneously / in parallel, the administration may be separated by 1 minute, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, or 72 hours or any suitable time difference readily determined by a person skilled in the art and / or described herein.
[0468] In the context of the present invention, the term "combination" also encompasses situations in which an antibody as defined herein and a transduced T cell comprising a chimeric receptor according to the present invention are pre-incubated together prior to administration to a subject. Thus, the two components may be pre-incubated prior to administration, for example, for 1 minute, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 45 minutes or 1 hour or any suitable time readily determined by a skilled person. In another embodiment, the invention relates to a treatment regimen in which an antibody as defined herein and a transduced T cell comprising a chimeric receptor as defined herein are administered simultaneously / in parallel. In the context of the present invention, an antibody as defined herein may be administered after the transduced T cell comprising a chimeric receptor has been administered.
[0469] Further, "combination" as used herein does not limit the disclosed treatment regimen to the administration of the antibody as defined herein and the transduced T cells, preferably CD8+ T cells, comprising the chimeric receptor of the present invention, in an immediate order (i.e., administration of one of the two components, followed by administration of the other (after a certain time interval), without administration and / or implementation of any other treatment regimen in between). Thus, the present treatment regimen also encompasses the separate administration of the antibody molecule as defined herein and the transduced T cells, preferably CD8+ T cells, comprising the chimeric receptor according to the present invention, wherein the administration is separated by one or more treatment regimens necessary and / or appropriate for the treatment or prevention of the disease or its symptoms. Examples of such intervention treatment regimens include, but are not limited to, the administration of analgesics; the administration of chemotherapeutic drugs, surgical treatment of the disease or its symptoms. Thus, the treatment regimen as disclosed herein encompasses the administration of the antibody as defined herein and the transduced T cells, preferably CD8+ T cells, comprising the chimeric receptor as defined herein, and not administered together with a treatment regimen suitable for the treatment or prevention of a disease or its symptoms as described herein or known in the art, and administered together with one or more than one treatment regimen suitable for the treatment or prevention of a disease or its symptoms as described herein or known in the art.
[0470] It is particularly envisaged that the one or more pharmaceutical compositions / one or more drugs will be administered to the patient by infusion or injection. In the context of the present invention, transduced T cells comprising a chimeric receptor as described herein will be administered to the patient via infusion or injection. The administration of a suitable composition / drug can be achieved by different means (intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration).
[0471] The pharmaceutical composition / medicine of the present invention may further comprise a pharmaceutical carrier. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline, water, emulsions, such as oil / water emulsions, various types of wetting agents, sterile solutions, etc. Compositions comprising such carriers may be prepared by well-known conventional methods. These pharmaceutical compositions may be administered to subjects at suitable doses. The dosage regimen will be determined by the attending physician and clinical factors. As is well known in the medical field, the dosage of any one patient depends on many factors, including the patient's body size, body surface area, age, specific compound to be administered, sex, administration time and route, general health and other drugs administered simultaneously. Typically, the conventional administration regimen of the pharmaceutical composition should be within the range of 1 μg to 5g units per day. However, a more preferred dosage for continuous infusion may be within the range of 0.01 μg to 2 mg, preferably 0.01 μg to 1 mg, more preferably 0.01 μg to 100 μg, even more preferably 0.01 μg to 50 μg and most preferably 0.01 μg to 10 μg units per kilogram of body weight per hour. Particularly preferred dosages are listed below. Progress can be monitored with periodic assessments. Dosages vary, but the preferred dose for intravenous administration of DNA is approximately 10 6 Up to 10 12 Copying DNA molecules.
[0472] The composition of the present invention can be administered locally or systemically. Administration is usually parenteral (e.g., intravenous); transduced T cells can also be administered directly to the target site, such as by catheter administration to a site in an artery. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate). Aqueous carriers include water, alcohol / aqueous solutions, emulsions, or suspensions, including saline and buffered media. Parenteral carriers include sodium chloride solution, Ringer's dextrose, glucose and sodium chloride, lactated Ringer's solution, or fixed oil. Intravenous injection carriers include fluid and nutrient supplements, electrolyte supplements (such as supplements based on Ringer's dextrose), etc. Preservatives and other additives, such as antimicrobials, antioxidants, chelating agents, and inert gases, etc., may also be present. In addition, the pharmaceutical composition of the present invention may include a protein carrier, such as serum albumin or immunoglobulin, preferably human. It is envisioned that in addition to protein antibody constructs or nucleic acid molecules or vectors (such as described in the present invention) and / or cells encoding them, the pharmaceutical composition of the present invention may also include other bioactive agents, depending on the intended use of the pharmaceutical composition. Such drugs may be drugs acting on the gastrointestinal system, drugs as cell inhibitors, drugs for preventing hyperuricemia, drugs (such as corticosteroids) that suppress immune responses, drugs acting on the circulatory system and / or medicaments known in the art such as T cell costimulatory molecules or cytokines.
[0473] Other exemplary embodiments:
[0474] 1. A chimeric receptor comprising
[0475] (i) an extracellular domain comprising a mutated Fc domain or a fragment thereof, and
[0476] (ii) Transmembrane domain.
[0477] 2. The chimeric receptor of embodiment 1, further comprising (iii) at least one intracellular stimulatory signaling domain and / or at least one co-stimulatory signaling domain.
[0478] 3. The chimeric receptor of embodiment 1 or 2, wherein the extracellular domain comprises a mutated CH2 domain and / or a mutated CH3 domain.
[0479] 4. The chimeric receptor of any one of embodiments 1 to 3, wherein the extracellular domain comprises a mutated CH2 domain.
[0480] 5. The chimeric receptor of any one of embodiments 1 to 4, wherein the mutated Fc domain comprises at least one amino acid substitution at a position selected from the group consisting of: L234, L235, 1253, H310, P331, P329 and H435 (numbered according to the Kabat EU index), in particular, wherein the amino acid substitution is selected from the group consisting of: L234A, L235A, 1253A, N297A, H310A, P329G and / or H435A.
[0481] 6. The chimeric receptor of any one of embodiments 1 to 5, wherein the extracellular domain comprises a mutated CH2 domain, wherein the mutated CH2 domain comprises the amino acid substitution P329G (numbered according to the Kabat EU index).
[0482] 7. The chimeric receptor of any one of embodiments 1 to 6, wherein the extracellular domain comprises a mutated CH2 domain and / or a mutated CH3 domain, wherein the mutated CH2 domain and / or the mutated CH3 domain comprises an amino acid substitution (numbered according to the Kabat EU index):
[0483] (a) I253A, H310A and H435A;
[0484] (b)I253A
[0485] (c) I253A and H310A
[0486] (d) I253A and H435A
[0487] (e)H310A and H435A
[0488] (f) H310A;
[0489] (g) H435A;
[0490] (h) L234A, L235A and P329G; or (i) L234A, L235A, I253A, H310A, P329G and H435A.
[0491] 8. The chimeric receptor of any one of embodiments 1 to 7, wherein the extracellular domain does not comprise a heavy chain variable domain (VH) and / or a light chain variable domain (VL).
[0492] 9. The chimeric receptor of any one of embodiments 1 to 8, wherein the transmembrane domain is selected from the group consisting of: CD8, CD4, CD3z, FCGR3A, NKG2D, CD27, CD28, CD137, OX40, ICOS, DAP10 or DAP12 transmembrane domains or fragments thereof.
[0493] 10. The chimeric receptor of any one of embodiments 2 to 9, wherein the transmembrane domain is a CD8 transmembrane domain, particularly wherein the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 11.
[0494] 11. The chimeric receptor of any one of embodiments 2 to 10, wherein the stimulatory signaling domain is selected from the group consisting of: an intracellular domain of CD3z, an intracellular domain of FCGR3A, and an intracellular domain of NKG2D, or a fragment thereof that retains stimulatory signaling activity.
[0495] 12. The chimeric receptor of any one of embodiments 2 to 11, wherein the stimulatory signaling domain is the intracellular domain of CD3z, or a fragment thereof that retains stimulatory signaling activity, particularly wherein the stimulatory signaling domain comprises the amino acid sequence of SEQ ID NO: 13.
[0496] 13. The chimeric receptor of any one of embodiments 2 to 12, wherein the costimulatory signaling domain is selected from the group consisting of an intracellular domain of CD27, an intracellular domain of CD28, an intracellular domain of CD137, an intracellular domain of OX40, an intracellular domain of ICOS, an intracellular domain of DAP10, and an intracellular domain of DAP12, or a fragment thereof that retains costimulatory signaling activity.
[0497] 14. The chimeric receptor of any one of embodiments 2 to 13, wherein the co-stimulatory signaling domain is the CD137 intracellular domain, or a fragment thereof, which retains the CD137 co-stimulatory activity, particularly wherein the co-stimulatory signaling domain comprises the amino acid sequence of SEQ ID NO: 12.
[0498] 15. The chimeric receptor of any one of embodiments 2 to 14, wherein the co-stimulatory signaling domain is: the CD28 intracellular domain, or a fragment thereof that retains the CD28 co-stimulatory activity.
[0499] 16. A chimeric receptor according to any one of embodiments 2 to 15, wherein the chimeric receptor comprises a stimulatory signaling domain, the one stimulatory signaling domain comprising: the intracellular domain of CD3z, or a fragment thereof, which retains the CD3z stimulatory signaling activity, and wherein the chimeric receptor comprises a co-stimulatory signaling domain, the one co-stimulatory signaling domain comprising: the intracellular domain of CD137, or a fragment thereof, which retains the CD137 co-stimulatory signaling activity.
[0500] 17. The chimeric receptor of any one of embodiments 2 to 16, wherein the stimulatory signaling domain comprises the amino acid sequence of SEQ ID NO: 13, and the co-stimulatory signaling domain comprises the amino acid sequence of SEQ ID NO: 12.
[0501] 18. The chimeric receptor of any one of embodiments 1 to 17, wherein the extracellular domain is linked to the transmembrane domain, optionally via a peptide linker.
[0502] 19. The chimeric receptor of any one of embodiments 1 to 18, wherein the transmembrane domain is linked at the N-terminus to the C-terminus of the extracellular domain.
[0503] 20. The chimeric receptor of any one of embodiments 2 to 19, wherein the transmembrane domain is linked to the co-stimulatory signaling domain or the stimulatory signaling domain, optionally via a peptide linker.
[0504] 21. The chimeric receptor of any one of embodiments 2 to 20, wherein the co-stimulatory signaling domain is linked at the N-terminus to the C-terminus of the transmembrane domain.
[0505] 22. The chimeric receptor of embodiment 21, wherein the chimeric receptor comprises a stimulatory signaling domain, wherein the stimulatory signaling domain is linked at the N-terminus to the C-terminus of the co-stimulatory signaling domain.
[0506] 23. The chimeric receptor of any one of embodiments 1 to 22, wherein the chimeric receptor comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:125.
[0507] 24. A chimeric receptor comprising the amino acid sequence of SEQ ID NO:7; or a chimeric receptor comprising the amino acid sequence of SEQ ID NO:125.
[0508] 25. The chimeric receptor of any one of embodiments 1 to 22, wherein the chimeric receptor comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:87, SEQ ID NO:106, SEQ ID NO:125, and SEQ ID NO:126.
[0509] 26. A chimeric receptor comprising or consisting of the amino acid sequence of SEQ ID NO: 87.
[0510] 27. A chimeric receptor comprising or consisting of the amino acid sequence of SEQ ID NO: 106.
[0511] 28. A chimeric receptor comprising or consisting of the amino acid sequence of SEQ ID NO: 125.
[0512] 29. A chimeric receptor comprising or consisting of the amino acid sequence of SEQ ID NO: 127.
[0513] 30. An isolated polynucleotide encoding the chimeric receptor of any one of embodiments 1 to 29.
[0514] 31. A polypeptide encoded by the isolated polynucleotide of embodiment 30.
[0515] 32. A vector, in particular an expression vector, comprising the polynucleotide according to embodiment 30.
[0516] 33. A transduced T cell comprising the polynucleotide of embodiment 30 or the vector of embodiment 32.
[0517] 34. A transduced T cell capable of expressing the chimeric receptor of any one of embodiments 1 to 29.
[0518] 35. A medicine kit comprising
[0519] (A) a transduced T cell capable of expressing the chimeric receptor according to any one of embodiments 1 to 30, wherein the chimeric receptor comprises an extracellular domain comprising a mutated Fc domain or a fragment thereof; and
[0520] (B) an antibody comprising at least one antigen binding portion capable of binding to said mutated Fc domain, but not capable of binding to a non-mutated parental Fc domain, wherein the antibody comprises at least one effector portion.
[0521] 36. A medicine kit comprising
[0522] (A) an isolated polynucleotide encoding the chimeric receptor according to any one of embodiments 1 to 30, wherein the chimeric receptor comprises an extracellular domain comprising a mutated Fc domain or a fragment thereof; and
[0523] (B) an antibody comprising at least one antigen binding portion capable of binding to said mutated Fc domain, but not capable of binding to a non-mutated parental Fc domain, wherein the antibody comprises at least one effector portion.
[0524] 37. A kit according to embodiment 36 or 37, wherein the effector moiety is: (i) an antigen binding moiety, which is capable of binding to a target cell antigen; or (ii) and an immune activating moiety, in particular a cytokine.
[0525] 38. The kit according to any one of embodiments 35 to 37 for use as a medicament.
[0526] 39. The chimeric receptor of any one of embodiments 1 to 29 or the transduced T cell of any one of embodiments 33 or 34 for use as a medicament, wherein the chimeric receptor comprises an extracellular domain comprising a mutated Fc domain, or a fragment thereof, wherein the transduced T cell expressing the chimeric receptor is administered before, simultaneously with, or after administration of an antibody comprising: at least one antigen binding portion capable of binding to a target cell antigen; and at least one antigen binding portion capable of binding to the mutated Fc domain but not to the non-mutated parental Fc domain.
[0527] 40. The kit according to any one of embodiments 35 to 36, for use in the treatment of a disease, in particular in the treatment of cancer.
[0528] 41. A method for treating a disease in a subject, the method comprising: administering to the subject transduced T cells, the transduced T cells being capable of expressing the chimeric receptor according to any one of embodiments 1 to 30, wherein the chimeric receptor comprises an extracellular domain, the extracellular domain comprising a mutated Fc domain or a fragment thereof; and administering before, simultaneously with, or after the administration of the transduced T cells, a therapeutically effective amount of an antibody comprising at least one antigen binding portion that is capable of binding to the mutated Fc domain but not to the non-mutated parental Fc domain, wherein the antibody comprises at least one effector portion.
[0529] 42. A method according to embodiment 41, wherein the effector portion is: (i) an antigen binding portion, which is capable of binding to a target cell antigen; or (ii) and an immune activation portion, in particular a cytokine.
[0530] 43. Use of the chimeric receptor of any one of embodiments 1 to 29, the polynucleotide of embodiment 30, or the transduced T cell of embodiment 33 or 34 for the manufacture of a medicament.
[0531] 44. The use according to embodiment 43, wherein the medicament is for the treatment of cancer.
[0532] 45. The use according to embodiment 44, characterized in that the cancer is selected from cancers of epithelial, endothelial or mesothelial origin and hematological cancers.
[0533] 46. The invention as hereinbefore described.
[0534] The above and other embodiments are disclosed and included in the description and examples of the present invention. Further relevant documents about any antibody, method, purpose and compound adopted according to the present invention can be retrieved in public libraries and databases by using, for example, electronic devices, etc. For example, the public database "Medline" on the Internet can be used, for example, at http: / / www.ncbi.nlm.nih.gov / PubMed / medline.html. More databases and addresses, such as http: / / www.ncbi.nlm.nih.gov / , http: / / www.infobiogen.fr / , http: / / www.fmi.ch / biology / research_tools.html, http: / / www.tigr.org / , are known to those skilled in the art, and can also be obtained using, for example, http: / / www.lycos.com.
[0535] Exemplary sequences
[0536] The CDR definitions in the sequence listing are according to Kabat.
[0537] Table 1: Exemplary anti-P329G antigen binding moieties
[0538]
[0539]
[0540]
[0541]
[0542] Table 2: Exemplary mutated CH2 domains
[0543]
[0544]
[0545] Table 3: Exemplary mutated CH2-CH3 domains
[0546]
[0547] Table 4: Other anti-AAA antigen binding moieties
[0548]
[0549] Table 5: Exemplary human and mouse sequences
[0550]
[0551]
[0552]
[0553]
[0554]
[0555]
[0556]
[0557]
[0558]
[0559]
[0560]
[0561]
[0562]
[0563]
[0564]
[0565]
[0566] Table 6: Exemplary CH2 P329G chimeric receptor amino acid sequences:
[0567]
[0568]
[0569] Table 7: Exemplary CH2 P329G chimeric receptor DNA sequences:
[0570]
[0571]
[0572]
[0573]
[0574] Table 8: Exemplary CH2-CH3 AAA chimeric acceptor amino acid sequences:
[0575]
[0576] Table 9: Exemplary CH2-CH3 AAA chimeric receptor DNA sequences:
[0577]
[0578]
[0579] Table 10: Exemplary CD28 co-stimulatory signaling domains
[0580]
[0581]
[0582] Table 11: Exemplary bispecific antibodies anti-PG x FolR1 2+1
[0583]
[0584]
[0585] Table 12: Exemplary bispecific antibodies anti-AAA x FolRI 2+1
[0586]
[0587]
[0588] Table 13: Exemplary bispecific antibodies anti-PG x FolR1 1+1
[0589]
[0590]
[0591] Table 14: Exemplary bispecific antibodies anti-AAA x FolR1 1+1
[0592]
[0593]
[0594] Table 15: Exemplary bispecific antibodies anti-PG x CEA 2+1
[0595]
[0596]
[0597] Table 16: Exemplary bispecific antibodies anti-AAA x CEA 2+1
[0598]
[0599]
[0600] Table 17: Exemplary CH2-CH3 AAA P329R chimeric receptor amino acid sequences:
[0601]
[0602]
[0603] Table 18: Exemplary CH2-CH3 AAA P329G chimeric receptor amino acid sequences:
[0604]
[0605] Table 19: Other anti-AAA antigen binding moieties
[0606]
[0607]
[0608] Table 20: Exemplary anti-P329G-IL2v
[0609]
[0610]
[0611] Examples
[0612] The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced given the general description provided above.
[0613] Recombinant DNA technology
[0614] Standard methods were used to manipulate DNA, such as described in Sambrook et al., Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Molecular biology reagents were used according to the manufacturer's instructions. General information on the nucleotide sequences of human immunoglobulin light and heavy chains is given in: Kabat, EA et al., (1991) Sequences of Proteins of Immunological Interest, 5th Edition, NIH Publication No. 91-3242.
[0615] DNA Sequencing
[0616] The DNA sequence was determined by double-stranded Sanger sequencing.
[0617] Gene synthesis
[0618] When necessary, the desired gene segments are generated by PCR using appropriate templates, or the desired gene segments are synthesized from synthetic oligonucleotides and PCR products by Genscript Biotech (New Jersey, US) through automated gene synthesis. The gene segments flanked by a single restriction endonuclease cleavage site are cloned into standard cloning / sequencing vectors. Plasmid DNA is purified from transformed bacteria and the concentration is determined by ultraviolet spectroscopy. The DNA sequence of the subcloned gene fragments is confirmed by DNA sequencing. The gene segments with suitable restriction sites are designed to allow subcloning into corresponding expression vectors. All constructs are designed with a 5' end DNA sequence that encodes a leader peptide that targets proteins secreted by eukaryotic cells.
[0619] Production of IgG-like proteins in Expi293F cells
[0620] By transient transfection Expi293F cells, antibody and bispecific antibody are produced.Cells are seeded in Expi293 culture medium (Gibco, catalog number 1435101) with a density of 2.5x 106 / ml.Expression vector and ExpiFectamine (Gibco, ExpiFectamine transfection kit, catalog number 13385544) are mixed in OptiMEM (Gibco, catalog number 11520386) respectively.After 5 minutes, two solutions are merged, mixed by pipetting and incubated at room temperature for 25 minutes.Cells are added to carrier / ExpiFectamine solution, and incubated at 37 ℃ for 24 hours in a shaking incubator with 5% CO2 atmosphere.One day after transfection, supplement (enhancer 1+2, ExpiFectamine transfection kit) is added.After 4 to 5 days, cell supernatant is harvested by centrifugation and subsequent filtration (0.2 μm filter), and protein is purified from the supernatant harvested by the standard method as shown below.
[0621] Production of IgG-like proteins in CHO K1 cells
[0622] Alternatively, the antibodies and bispecific antibodies described herein are prepared by Evitria using its proprietary vector system by conventional (non-PCR-based) cloning techniques and using suspension-adapted CHO K1 cells (originally received from ATCC and adapted for serum-free growth in Evitria's suspension culture). During production, Evitria used its proprietary animal component-free and serum-free culture media (eviGrow and eviMake2) and its proprietary transfection reagent (eviFect). Cell supernatants were harvested by centrifugation and subsequent filtration (0.2 μm filter), and proteins were purified from the harvested supernatants using standard methods.
[0623] Purification of IgG-like proteins
[0624] Proteins were purified from filtered cell culture supernatants according to standard protocols. Briefly, Fc-containing proteins were purified from filtered cell culture supernatants using protein A affinity chromatography (equilibration buffer: 20 mM sodium citrate, 20 mM sodium phosphate, pH 7.5; elution buffer: 20 mM sodium citrate, pH 3.0). Elution was achieved at pH 3.0, followed by immediate pH neutralization of the sample. The elution was performed by centrifugation (Millipore The proteins were concentrated using ULTRA-15 (Art. Nr.: UFC903096) and aggregated proteins were separated from monomeric proteins using size exclusion chromatography in 20 mM histidine, 140 mM sodium chloride (pH 6.0).
[0625] Analysis of IgG-like proteins
[0626] According to Pace et al., Protein Science, 1995, 4, 2411-1423, the concentration of purified protein was determined by measuring the absorbance at 280 nm using the mass extinction coefficient calculated based on the amino acid sequence. In the presence and absence of a reducing agent, the purity and molecular weight of the protein were analyzed by CE-SDS using LabChip GXII or LabChip GX Touch (Perkin Elmer) (Perkin Elmer). Aggregation content was determined by HPLC chromatography at 25 ° C using an analytical size exclusion column (TSKgel G3000 SW XL or UP-SW3000) balanced in running buffer (200 mM KH2PO4, 250 mM KCl pH 6.2, 0.02% NaN3).
[0627] Preparation of lentiviral supernatant and transduction of Jurkat cells
[0628] Use Lenti-X at about 70% confluence TM 293T cells (Takara, #632180) and the chimeric receptor encoding transfer vector and packaging vector pCAG-VSVG and psPAX2 were used in a molar ratio of 2:1:2 for Lipofectamine LTX-based TMTransfection (Giry-Laterriere M et al. Methods Mol Biol. 2011; 737: 183-209, Myburgh R et al. Mol Ther Nucleic Acids. 2014). As a control for each experiment, simulated virus-like particles (VLPs) using only packaging vectors without transfer vectors were also produced. After 48 h, the supernatant was collected and centrifuged at 350 × g for 5 min to remove the remaining cells and purify the virus particles. VLPs were used directly or concentrated 10-fold (Lenti-x concentrator, Takara, #631231) and added to 24-well plates with 8ug / ml polybrene (Sigma Aldrich) and Lentiboost P (1:100) (Sirion Biotech, #SB-P-LV-101-12) for Jurkat NFAT (GloResponse Jurkat NFAT-RE-luc2P, Promega #CS176501) or Jurkat TCRab-KO CD4+ (T cell activation bioassay (TCRαβ-KO), Promega #GA1172) cells at 1100×g and 31° C. for 99 min spinfection. Cells were incubated for at least 72 hours before the transduction was examined by flow cytometry.
[0629] Sorting of transduced cells
[0630] If the ratio of transduced cells is less than 90%, cells are sorted to find eGFP positive cells. Collect 3 million to 10 million cells and decelerate and spin (400x g, 4min). Remove the culture medium, and resuspend the cells in MACS buffer (Miltenyi Biotec, #130-091-222) supplemented with 5% BSA (Miltenyi Biotec, #130-091-376). On BD FACSAriaIII, cells are sorted in pools to find eGFP positive cells. For the sorting of Jurkat cells, a 100 micron nozzle was used and a 4-way purity precision mode was applied.
[0631] Jurkat NFAT activation assay
[0632] Jurkat activation assay measures T cell activation of human acute lymphoblastic leukemia reporter cell line (GloResponse JurkatNFAT-RE-luc2P, Promega#CS176501 or T cell activation bioassay TCRαβ-KO CD4+, Promega#GA1172). This immortalized T cell line is genetically engineered to stably express a luciferase reporter gene driven by T cell activation via CD3. After transduction, the cell line expresses a chimeric antigen receptor construct with a CD3z signaling domain. The combination of constructs and immobilized adapter molecules (such as tumor antigen binding adapter molecules) results in cross-linking, thereby resulting in T cell activation and luciferase expression. After adding substrate, the cell changes of NFAT activity can be measured as relative luminescent units. The assay is carried out in 384 plates (Falcon#353988 white, white flat bottom). Target cells (transduced Jurkat cells) and effector cells (20 000 effector cells and 8000 target cells) at a ratio of 2.5:1 were inoculated in RPMI-1640+10% FCS+1% Glutamax (growth medium) in triplicate at 20 μl or 10 ul, respectively. For Jurkat NFAT assays, GloSensor cAMP reagent (Promega, #E1291) was used for readings, and 2% of the final volume (here: 40 ul, resulting in 0.8 ul / well) was added to the wells. Further, serial dilutions of the antibody of interest were prepared in growth medium, and 10 ul was added to the wells to obtain a final concentration of 20 nM to 0.00122 nM in the assay plate, with a final total volume of 40 μl per well. The 384-well plate was centrifuged at 300 g and room temperature for 1 min and incubated in a humidified atmosphere at 37°C and 5% CO2. After 4h to 6h incubation, the plate was adjusted to room temperature before measurement for 10 minutes. For JurkatTCRab-KO CD4+ cells, a final volume of 100% Bio-Glo-NL reagent (Promega, #J3082) was added, and the plate was centrifuged at 350 × g for 1 min and incubated for 5 minutes to 10 minutes. In the assay using Jurkat NFAT cells, cAMP reagent (see above) was added when the cells were inoculated. Afterwards, the relative luminescence units (RLU) of each well were measured using a Tecan microplate reader immediately. Concentration-response curves were fitted using GraphPadPrism version 8 and EC was calculated. 50 value.
[0633] Isolation of primary T cells from buffy coats
[0634] Buffy coat is ordered from Blutspende Zürich (Rütistrasse 19,8952 Schlieren).Prepare the Leucosep tube with 15mL of room temperature Histopaque density gradient medium (Sigma-Aldrich, #10771), and it is centrifuged 5 minutes with 400x g, until Histopaque passes through filter.Blood is transferred in T75 flask and isopyknic DPBS is added.The blood / buffer mixture of 30ml is added to Leucosep tube, and they are accelerated centrifuged 20 minutes with 1200xg, and interrupted.The band containing peripheral blood mononuclear cell (PBMC) is carefully moved in fresh 50ml falcon tube, and is filled to 50ml with DPBS.Pipe is centrifuged 10 minutes (under the situation of low interruption (withlow breaks)) with 350x g, then discard supernatant. The cells were washed three more times with DPBS (1.250xg, 10 minutes; 2.250xg, 10 minutes; 3.120xg, 10 minutes), and then the cells were resuspended and counted. CD4+ and CD8+ T cell separation kits (Miltenyi, #130-096-533, #130-096-495) were used for negative selection according to the manufacturer's instructions. After separation, the cells were frozen or used directly. The cells were cultured in Advanced RPMI (Gibco, #11530446), 10% FBS (Sigma, #F4135-500ML), 1% Glutamax (Gibco, #35050-038), 50 IU / Proleukin (Novartis), 25 ng / ml IL-7 (Miltenyi, #130-095-364) and 50 ng / ml IL-15 (Miltenyi, #130-095-766) (T cell culture medium).
[0635] Preparation of virus-like particles (VLPs)
[0636] Use Lenti-X at about 70% confluence TM 293T cells (Takara, #632180) and constructs encoding transfer vector and packaging vector pCAG-VSVG and psPAX2 were used in a 2:1:2 molar ratio for Lipofectamine LTX-based TMTransfection (Thermo Fisher, #15338-100) (Giry-Laterriere M et al. Methods Mol Biol. 2011; 737: 183-209, Myburgh R et al. Mol Ther Nucleic Acids. 2014). As a control for each experiment, a simulated virus-like particle (VLP) using only a packaging vector without a transfer vector was produced. After 48 hours, the supernatant was collected and centrifuged at 500 × g for 10 minutes to remove the remaining cells. According to the manufacturer's instructions, the VLP was concentrated 10 times by using a Lenti-X concentrator (Takara, #631231). For storage, the VLP was aliquoted in Eppendorf tubes and flash-frozen in liquid nitrogen, and then stored at -80 ° C.
[0637] Transduction of primary T cells
[0638] CD4+ and CD8+ T cells were thawed, mixed 1:1, and cultured using ImmunoCult TM Human CD3 / CD28 / CD2 T cell activator (StemCell, #10990) is directly activated for 24 hours.Then the activated cells are resuspended, counted, and 1 million cells / well / ml are seeded in 24-well plates.VLP is thawed at 37 ° C, and 150 μ l is added to the activated cells in 24-well plates together with 8 μ g / ml polycondensate (Sigma Aldrich) and Lentiboost P (1: 100) (Sirion Biotech, #SB-P-LV-101-12).Cells are incubated at 37 ° C, 5% CO2 for 24 hours, then they are resuspended in 4 ml of fresh T cell culture medium and added to gREX plates (Wilson Wolf, #MSPP-80192M), for amplification.From 72 hours after transduction, the expression of constructs is checked by flow cytometry.
[0639] STAT5 phosphorylation assay
[0640] Non-transduced and transduced T cells were spun down, washed with DPBS, and seeded in cytokine-free medium (advanced RPMI, 10% FBS, 1x Glutamax (assay medium)) for starvation (4 hours to overnight). Before the assay, fix buffer I (BD, #557870) was placed at 37°C, and Perm Buffer III (BD, #558050) was placed at -20°C. Starved T cells were spun down and resuspended in assay medium. Depending on the expression rate of the transduced T cell pool, T cells were mixed with non-transduced cells to ensure that the distribution of non-transduced cells (eGFP-) and construct-expressing cells (eGFP+) in each well was similar. 150,000 to 300,000 cells were seeded in 96-well V-bottom plates with 25 μl. Cytokines or molecules were diluted in assay medium, and 50 μl of dilutions were added to T cells in duplicate. The plate was incubated at 37°C for 15 minutes, and then 75 μl of fixation buffer I was added to the wells. After the plate was incubated at 37°C for another 30 minutes, the plate was spun down (400 x g, 3 min) and the supernatant was discarded. The cells were resuspended in 100 μl of ice-cold Perm Buffer III and incubated on ice for 30 minutes. At this stage, the cells were stained directly or stored at -20°C for up to two weeks.
[0641] For staining, the plate was washed twice with DPBS (400 x g, 3 min), and the cells were then resuspended in 50 μl of diluted AF647 mouse anti-Stat5 (pY694) staining antibody (1:20 in FACS buffer, BD, #562076) and incubated at 4°C for 1 hour. The cells were then washed twice with FACS buffer and samples were collected on a BD FACS Fortessa. To compare the effects of cytokine fusion molecules on non-transduced (eGFP-) cells with those on transduced (eGFP+) cells, the median fluorescence intensity of the two populations was analyzed.
[0642] Immune cell killing assay
[0643] Cancer cell lines (HeLa and MKN45) were used NucLight Red lentivirus (EF1α, Puro, #4476) is transduced internally, and stable cell lines (HeLa NLR, MKN45 NLR) are produced under puromycin selection. Human CD4+ / CD8+ T cells are separated and transduced with the desired construct as described above. For determination, HeLa NLR or MKN45 NLR cells are resuspended in RPMI-1640 (Gibco, #42401-018) + 2% FCS (Sigma, #F4135-500ML) + 1% Glutamax (Gibco, #35050-038) (killing medium), and 10,000 cells are seeded in each well of a flat-bottomed 96-well plate with 100 μl. The plate is incubated at 37°C, 5% CO2 for 4 to 24 hours until the cells are attached. Transduced T cells were counted, adjusted to 10,000 eGFP+ cells / 50 μl in Kill Medium, and added to attached cancer cells. Adaptor and control antibodies were diluted to the desired concentration in Kill Medium and 50 μl was added to the wells. Each condition was pipetted in duplicate. Air bubbles were removed from the well surface and the plate was placed on S3 machine. Five images of each well were captured every 4 hours over the course of 5 to 6 days. The reduction in the number of cancer cells was quantified using an analysis mask that counted the number of red blood cells.
[0644] Example 1
[0645] Generation and characterization of humanized anti-P329G antibodies
[0646] Parental and humanized anti-P329G antibodies were produced in HEK cells and purified by protein A affinity chromatography and size exclusion chromatography. All antibodies were purified with good quality (Table 13).
[0647] Table 13 - Biochemical analysis of anti-P329G antibodies. Monomer content was determined by analytical size exclusion chromatography. Purity was determined by non-reducing SDS capillary electrophoresis.
[0648] molecular monomer[%] purity[%] Anti-P329G (M-1.7.24) huIgG1 100 85 Anti-P329G (VH1VL1) huIgG1 100 97 Anti-P329G (VH2VL1) huIgG1 100 87 Anti-P329G (VH3VL1) huIgG1 100 97
[0649] Binding of the parental and six humanized variants of the anti-P329G binder M-1.7.24 to human Fc(P329G)
[0650] Instrument: Biacore T200
[0651] Chip: CM5(#772)
[0652] Fc1 to Fc4: anti-human Fab specific (GE Healthcare 28-9583-25)
[0653] Capture: 50nM IgG, for 60s
[0654] Analyte: Human Fc (P329G) (P1AD9000-004)
[0655] Running buffer: HBS-EP
[0656] T°: 25℃
[0657] Dilution: 2-fold dilution in HBS-EP from 0.59 to 37.5 nM
[0658] Flow rate: 30 μl / min
[0659] Association: 240sec
[0660] Dissociation: 800 sec
[0661] Regeneration: 10 mM glycine pH 2.1, 2x60 sec
[0662] SPR experiments were all performed on a Biacore T200 using HBS-EP as a running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% surfactant P20 (BR-1006-69, GE Healthcare)). Anti-human Fab-specific antibodies (GE Healthcare 28-9583-25) were directly immobilized on a CM5 chip (GE Healthcare) by amine coupling. IgG was captured at 50 nM for 60 s. A two-fold dilution series of human Fc (P329G) was passed over the ligand at a speed of 30 μl / min for 240 seconds to record the association phase. The dissociation phase was monitored for 800 s and triggered by switching from the sample solution to HBS-EP+. After each cycle, the chip surface was regenerated using two 10 mM glycine pH 2.1 injections for 60 sec. Bulk refractive index differences were corrected by subtracting the response obtained on the reference flow cell 1. Affinity constants were derived from kinetic rate constants by fitting to 1 :1 Langmuir binding using Biaeval software (GE Healthcare). Measurements were performed in triplicate in independent dilution series.
[0663] The following samples were analyzed for binding to human Fc(P329G) (Table 14).
[0664] Table 14: Description of samples analyzed for binding to human Fc(P329G).
[0665] Conjugate TAPIR ID form Anti-P329G (M-1.7.24) (parent) P1AE9963 IgG, supernatant / purified Anti-P329G (VH3VL1) P1AE9957 IgG, supernatant / purified Anti-P329G (VH1VL1) P1AE9955 IgG, supernatant / purified Anti-P329G (VH2VL1) P1AE9956 IgG, supernatant / purified Anti-P329G (VH4VL1) P1AE9958 IgG, supernatant Anti-P329G (VH1VL2) P1AE9959 IgG, supernatant Anti-P329G (VH1VL3) P1AE9960 IgG, supernatant Human Fc(P329G) P1AD9000-004 Antigen used as analyte
[0666] Human Fc(P329G) was prepared by plasmin digestion of human IgG1 followed by affinity purification by protein A and size exclusion chromatography.
[0667] Binding of the parental and six humanized variants of the anti-P329G binder M-1.7.24 to human Fc(P329G)
[0668] The dissociation phase was fitted to a single curve to help characterize the dissociation rate. The ratio between the binding and capture response levels was calculated. (Table 15).
[0669] Table 15: Binding assessment of the six humanized variants to human Fc (P329G).
[0670]
[0671]
[0672] Affinity of the parental and three humanized variants of the anti-P329G binder M-1.7.24 to human Fc(P329G)
[0673] Three humanized variants with similar binding modes to the parent were evaluated in more detail. Table 16 summarizes the kinetic constants for 1:1 Langmuir binding.
[0674] Table 16: Kinetic constants (1:1 Langmuir binding). Means and standard deviations (in brackets) of independent triplicates (independent dilution series in the same run).
[0675]
[0676] in conclusion
[0677] Six humanized variants were generated. Three of them (VH4VL1, VH1VL2, VH1VL3) showed reduced binding to human Fc (P329G) compared to the parent M-1.7.24. The other three humanized variants (VH1VL1, VH2VL1, VH3VL1) had very similar binding kinetics to the parent binder and did not lose affinity due to humanization.
[0678] Example 2
[0679] Preparation of CH2 or CH2-CH3 chimeric antigen receptors
[0680] DNA sequences encoding constant heavy chain 2 (CH2) with a P329G substitution or CH2 constant heavy chain 3 (CH3) fusions containing P329R and AAA substitutions (I253A, H310A, H435A) were cloned and used as targeting domains of adaptor molecules in chimeric receptors according to the invention.
[0681] The C-terminus of CH2 or CH2-CH3 is linked via a G4S linker to the stem and transmembrane domain of CD8a (Uniprot P01732[183-203]), which is fused to the intracellular co-stimulatory signaling domain (CSD) CD137 (Uniprot Q07011AA214-255), which in turn is fused to the stimulatory signaling domain (SSD) CD3ζ (Uniprot P20963 AA 52–164) ( Figure 1A and Figure 1B ). A graphical representation of an exemplary expression construct comprising an eGFP reporter gene and an RQR8 purification tag is shown in Figure 1C (and for the CH2 P329G construct) and in Figure 1D (for CH2-CH3 AAA construct).
[0682] Example 3
[0683] Expression of CH2 or CH2-CH3 chimeric antigen receptors in Jurkat-NFAT or Jurkat TCRab KO CD4+ cells
[0684] CH2 or CH2-CH3 receptors were virally transduced into Jurkat NFAT (GloResponse Jurkat NFAT-RE-luc2P, Promega #CS176501) or Jurkat TCRab-KO CD4+ (T cell activation bioassay (TCRαβ-KO), Promega #GA1172) cells.
[0685] Expression of chimeric receptors was assessed by flow cytometry. Jurkat cells characterized by the CH2 P329G construct or the CH2-CH3 AAA construct were harvested, washed with PBS and seeded at 100.000 cells per well in 96-well U-bottom plates. Cells were cultured with LIVE / DEAD at 4°C. TMFixable Near-IR Dead (Invitrogen, #L34976) dye (1:1000 in PBS) was stained for 20 minutes and washed twice with FACS buffer (1xPBS, 2% FBS, 5mM EDTA pH8.0, 0.05% NaN3). Cells transduced with CH2-CH3 AAA constructs were incubated with anti-AAA x FolR1 2+1 antibodies at different concentrations (1:4 serial dilutions from 500nM to 0nM) and incubated at 4°C for 30 minutes. The samples were washed twice with FACS buffer and then stained with R-phycoerythrin AffiniPure F(ab')2 fragment goat anti-human IgG, F(ab')2 fragment specific antibody (1:50 dilution) in the dark at 4°C for 30min ( Figure 4A and Figure 4B For analysis of receptor expression, anti-AAA x FolR1 2+1 antibody was selected at a concentration of 2 nM and is depicted in Figure 5B The CH2 P329G construct expression was also analyzed via FACS staining. Thus, as described above for live cells, cells were harvested, washed and stained. The CH2 P329G construct was detected by staining with 100 nM anti-P329G VH3xVL1 AF647 labeled IgG ( Figure 2A and Figure 2B In addition, the expression of the intracellular eGFP reporter gene was also analyzed (see Figure 2C and Figure 5C ).
[0686] Both the CH2 P329G construct and the CH2-CH3 AAA construct were shown to be expressed on the surface of Jurkat cells, and this expression correlated with intracellular eGFP expression.
[0687] To test the functionality of the CARs, they were assessed in the Jurkat activation assay.
[0688] Example 4
[0689] Specific T cell activation in the presence of targeting antibodies comprising anti-P329G or anti-AAA conjugates
[0690] To assess specific T cell activation, FolR1-positive target cells and anti-PG x FolRI 2+1 antibodies ( Figure 3A ) or anti-AAA x FolRI 2+1 antibody ( Fig. 6A) were evaluated for activation of CH2 P329G Jurkat cells and CH2-CH3 AAAJurkat cells in the presence of . CH2 P329G Jurkat cells were tested with high (HeLa), medium (Ovcar-3) and low (HT29) FolR1 positive target cells. Mock-transduced Jurkat cells (transduced with VLPs and without transgenic vectors) were used as negative controls. Dose-dependent and antigen-level-dependent activation of CH2 P329G Jurkat cells was observed. Mock-transduced control cells did not show activation by anti-PG x FolRI 2+1 antibodies with any of the tested target cells ( FIG. 3B to FIG. 3D ). CH2-CH3 AAA Jurkat cells were tested in the activation assay with high (HeLa) FolR1 positive target cells. Jurkat NFAT wild type cells were used as negative control. Dose dependent activation of CH2-CH3 AAA Jurkat cells was also observed here, while no activation of Jurkat NFAT wild type cells was observed ( Figure 6B ).
[0691] These results lead to the conclusion that the CH2 P329G construct as well as the CH2-CH3 AAA construct can be expressed in T cells, both are functional and can be selectively activated by antibodies comprising the cognate antibody binder.
[0692] Example 5
[0693] CH2-CH3 AAA P329G CAR, CH2-CH3 AAA P329R CAR or CH2 P329GCAR in primary T cells Expression in
[0694] As described above, CH2-CH3 AAA P329G CAR ( Figure 8B , SEQ ID NO:127), CH2-CH3 AAAP329R CAR( Figure 1B , SEQ ID NO: 125) or CH2P329G CAR ( Figure 1A , SEQ ID NO:87) receptor was transduced into human T cells (1:1CD4+:CD8+) using virus-like particles (VLPs).
[0695] The expression of chimeric receptors was assessed and compared by flow cytometry at day 7 after transduction as follows. Transduced T cells were harvested, washed with DPBS and seeded at 100.000 cells per well in 96-well U-bottom plates. T cells transduced with CAR containing the P329G mutation were cultured with LIVE / DEAD at 4°C. TMFixable Near-IR Dead (Invitrogen, #L34976) dye (1:1000 in DPBS) and 50 nM anti-PG VH3xVL1 huIgG-AF647 were stained for 20 minutes. The cells were then washed twice with FACS buffer (1x DPBS, 2% FBS, 5 mM EDTA pH 8.0, 0.05% NaN3), fixed (BD CytoFix, #554655) and analyzed on FACS.
[0696] Cells transduced with CAR containing the AAA mutation were treated with LIVE / DEAD TM Fixable Near-IR Dead (Invitrogen, #L34976) dye (1:1000 in DPBS) and 200nM anti-AAA x FolR1 2+1 TCB staining (20 minutes at 4°C). The cells were then washed twice with FACS buffer. The cell pellet was resuspended in 50ul secondary antibody (1:100, APC-F(ab)2 fragment anti-huIgG (Jackson ImmunoResearch, #109-136-097)) diluted in FACS buffer and incubated at 4°C for 30 minutes. After two additional washing steps, the cells were fixed (BD CytoFix, #554655) and analyzed on FACS.
[0697] Intracellular eGFP expression and anti-PG / anti-AAA staining are depicted in Fig. 9A and Fig. 9B Between 87% and 89% of the cells were eGFP positive and expressed the CAR construct on the cell surface.
[0698] To assess whether the P329G mutation and the AAA mutation could be simultaneously bound by the corresponding molecules, a second staining was performed as follows ( Fig. 12A ). Incubate the cells with LIVE / DEAD TMFixable Near-IR Dead (Invitrogen, #L34976) dye (1: 1000 in DPBS) and 50nM anti-PG VH3xVL1 huIgG-AF647 were incubated for 20 minutes. The cells were then washed twice with FACS buffer. In the second step, the cells were incubated with 100nM anti-AAA x FolR1-Avi-Biotin 1+1 TCB and 500nM Fc_P329LALA (20 minutes at 4°C). Fc_P329GLALA was used as a blocking molecule to prevent anti-PG VH3xVL1 huIgG-AF647 from binding to the PG mutation in anti-AAA x FolR1-Avi-Biotin 1+1 TCB. After incubation, the cells were washed twice with FACS buffer. In the third step, cells were resuspended in BV421 streptavidin (Biolegend, #405225) and 500 nM Fc_P329LALA (20 min, 4° C.) After two additional washing steps, cells were fixed (BD CytoFix, #554655) and analyzed on FACS.
[0699] CH2-CH3 AAA P329G CAR T cells showed double staining (BV421+, AF647+), indicating that AAA and P329G mutations can be simultaneously targeted in one CAR construct with anti-AAA and anti-PG adaptors ( Fig. 12B ). As expected, CH2-CH3 AAA P329R CAR or CH2 P329G CAR T cells showed only corresponding single staining.
[0700] To test the functionality of the constructs, they were To further evaluate the targeting of cytokines in cis to CAR T cells via the P329G mutation, a STAT5 phosphorylation assay was performed.
[0701] Example 6
[0702] Using CEA+ or FolR1+ target cells Immune cell killing assay
[0703] To evaluate the CH2-CH3 AAA P329G CAR ( Figure 8B , SEQ ID NO:127), CH2-CH3 AAA P329RCAR( Figure 1B , SEQ ID NO: 125) or CH2 P329G CAR ( Figure 1A, SEQ ID NO: 87) receptor cytotoxicity, killing assays were performed. To compare different constructs, the number of T cells per well was normalized to the same percentage of eGFP+ cells, resulting in 10.000 target cells and 10.000 eGFP+ T cells / well. Killing assays were performed as described above.
[0704] As adaptor molecules for HeLa NLR, anti-AAA x FolR1 2+1, anti-AAA x FolR1 1+1, anti-PG x FolRI 2+1 or anti-PG x FolRI 1+1 antibodies were titrated from 0 pM to 10 nM (1:10). As a positive control for killing, 10 nM anti-FolR1 2+1 TCB was used.
[0705] Dose-dependent killing was observed for all CAR constructs incubated with their corresponding adaptor molecules ( Fig. 10A , Fig. 10B , Fig. 10C , Fig.10F ). Incubation of T cells expressing CH2-CH3 AAA P329R CAR with anti-PG x FolR1 antibody did not result in any expected killing ( Fig. 10D The same situation was observed for CH2 P329GCAR T cells incubated with anti-AAA x FolR1 antibody ( Fig. 10E ).
[0706] In both approaches (anti-PG or anti-AAA), the 2+1 format showed more sensitive killing compared to the 1+1 format, which was independent of the CAR construct ( Fig. 10A , Fig. 10B , Fig. 10C , Fig.10F ). In direct comparison, the anti-AAA x FolRI molecule showed higher sensitivity compared to the anti-PG x FolRI adaptor.
[0707] MKN45 NLR cells were targeted with anti-AAA x CEA 2+1 or anti-PG x CEA 2+1 antibodies (0 pM to 10 nM, (1:10)). Dose-dependent growth inhibition was observed for all CAR constructs incubated with their corresponding adapter molecules ( Fig.11A , Fig. 11B (top), Fig. 11C (Bottom). As previously observed, the addition of an adaptor molecule with a binder that did not match the mutation present in the CAR construct did not result in any killing ( Fig. 11B (bottom) and Fig. 11C(Top)). Consistent with the HeLa NLR killing data, the anti-AAA x CEA molecule showed higher sensitivity compared to the anti-PG x CEA adaptor.
[0708] Example 7
[0709] STAT5 phosphorylation assay using anti-P329G-targeted IL2v
[0710] To assess the effects of cytokines on CH2-CH3 AAA P329G CAR ( Figure 8B , SEQ ID NO: 127) or CH2P329G CAR ( Figure 1A , SEQ ID NO:87) was selectively targeted and STAT5 phosphorylation assay was performed. In order to ensure that the distribution of non-transduced cells (eGFP-) and construct-expressing cells (eGFP+) in each well was similar, non-transduced cells and transduced cells were mixed 1:1 for the assay (>90% of transduced cells expressed the construct). Anti-P329G-IL2v or Proleukin (Novartis) was titrated on the cells, starting from 100nM (1:10). Assay was performed as described above. Samples were collected on BD FACSFortessa, and the median fluorescence intensity (MFI) of the pSTAT5 signal on the non-transduced (eGFP-) population and the transduced (eGFP+) population was plotted in GraphPad Prism 8.
[0711] Figure 13 shows the results of the pSTAT5 assay. In samples with CH2 P329G CAR T cells, a 50-fold increase in pSTAT5 MFI was observed in the eGFP+ population compared to the eGFP- population ( Fig.13A ). When T cells expressed CH2-CH3AAA P329G CAR (250 times, Fig. 13B ), the effect was even greater when IL2v was used to target the eGFP+ population. No cis effect was observed in CH2-CH3 AAA P329R CAR T cells, confirming that the effect was indeed due to P329G targeting. Looking at the data obtained with Proleukin, all samples and populations showed comparable STAT5 phosphorylation.
[0712] ***
Claims
1. A chimeric receptor comprising (i) an extracellular domain comprising a mutated Fc domain or a fragment thereof, and (ii) Transmembrane domain.
2. The chimeric receptor of claim 1, further comprising (iii) at least one intracellular stimulatory signaling domain and / or at least one co-stimulatory signaling domain.
3. The chimeric receptor according to claim 1 or 2, wherein the extracellular domain comprises a mutated CH2 domain and / or a mutated CH3 domain.
4. The chimeric receptor of any one of claims 1 to 3, wherein the extracellular domain comprises a mutated CH2 domain and / or a mutated CH3 domain, wherein the mutated CH2 domain and / or the mutated CH3 domain comprises an amino acid substitution (numbered according to the Kabat EU index): (a) I253A, H310A and H435A; (b) I253A; (c) I253A and H310A; (d) I253A and H435A; (e) H310A and H435A; (f) H310A; (g) H435A; (h) L234A, L235A and P329G; or (i) L234A, L235A, I253A, H310A, P329G and H435A.
5. The chimeric receptor of any one of claims 1 to 4, wherein the transmembrane domain is selected from the group consisting of CD8, CD4, CD3z, FCGR3A, NKG2D, CD27, CD28, CD137, OX40, ICOS, DAP10 or DAP12 transmembrane domains or fragments thereof.
6. The chimeric receptor of any one of claims 2 to 5, wherein the stimulatory signaling domain is selected from the group consisting of the intracellular domain of CD3z, the intracellular domain of FCGR3A, and the intracellular domain of NKG2D, or a fragment thereof that retains stimulatory signaling activity.
7. The chimeric receptor of any one of claims 2 to 6, wherein the co-stimulatory signaling domain is selected from the group consisting of an intracellular domain of CD27, an intracellular domain of CD28, an intracellular domain of CD137, an intracellular domain of OX40, an intracellular domain of ICOS, an intracellular domain of DAP10, and an intracellular domain of DAP12, or a fragment thereof that retains co-stimulatory signaling activity.
8. The chimeric receptor according to any one of claims 2 to 7, wherein the co-stimulatory signaling domain is: the CD28 intracellular domain, or a fragment thereof, which retains the CD28 co-stimulatory activity.
9. The chimeric receptor of any one of claims 2 to 8, wherein the chimeric receptor comprises a stimulatory signaling domain comprising: The intracellular domain of CD3z, or a fragment thereof, which retains the CD3z stimulatory signaling activity, and wherein the chimeric receptor comprises a co-stimulatory signaling domain, the one co-stimulatory signaling domain comprising: the intracellular domain of CD137, or a fragment thereof, which retains the CD137 co-stimulatory signaling activity.
10. The chimeric receptor of any one of claims 2 to 9, wherein the stimulatory signaling domain comprises the amino acid sequence of SEQ ID NO: 13, and the co-stimulatory signaling domain comprises the amino acid sequence of SEQ ID NO:
12.
11. The chimeric receptor of any one of claims 1 to 10, wherein the chimeric receptor comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:87, SEQ ID NO:106, SEQ ID NO:125 and SEQ ID NO:
127.
12. A chimeric receptor comprising or consisting of an amino acid sequence selected from the group consisting of: SEQ ID NO:87, SEQ ID NO:106, SEQ ID NO:125 and SEQ ID NO:
127.
13. An isolated polynucleotide encoding the chimeric receptor according to any one of claims 1 to 12.
14. A polypeptide encoded by the isolated polynucleotide according to claim 13.
15. A vector, in particular an expression vector, comprising the polynucleotide according to claim 13.
16. A transduced T cell comprising the polynucleotide according to claim 13 or the vector according to claim 15.
17. A transduced T cell capable of expressing the chimeric receptor according to any one of claims 1 to 12.
18. A medicine kit comprising (A) a transduced T cell capable of expressing the chimeric receptor according to any one of claims 1 to 12, wherein the chimeric receptor comprises an extracellular domain comprising a mutated Fc domain or a fragment thereof; and (B) an antibody comprising at least one antigen binding portion capable of binding to said mutated Fc domain, but not capable of binding to a non-mutated parental Fc domain, wherein said antibody comprises at least one effector portion.
19. A medicine kit comprising (A) an isolated polynucleotide encoding a chimeric receptor according to any one of claims 1 to 12, wherein the chimeric receptor comprises an extracellular domain comprising a mutated Fc domain or a fragment thereof; and (B) an antibody comprising at least one antigen binding portion capable of binding to said mutated Fc domain, but not capable of binding to a non-mutated parental Fc domain, wherein said antibody comprises at least one effector portion.
20. The kit according to claim 18 or 19, wherein the effector moiety is: (i) an antigen binding moiety, which is capable of binding to a target cell antigen; or (ii) and an immune activating moiety, in particular a cytokine.
21. A kit according to any one of claims 18 to 20 for use as a medicament.
22. The chimeric receptor according to any one of claims 1 to 12 or the transduced T cell according to any one of claims 16 or 17 for use as a medicament, wherein the chimeric receptor comprises an extracellular domain comprising a mutated Fc domain or a fragment thereof, wherein the transduced T cell expressing the chimeric receptor is administered before, simultaneously with or after administration of an antibody comprising: at least one antigen binding portion capable of binding to a target cell antigen; and at least one antigen binding portion capable of binding to the mutated Fc domain but not to the non-mutated parental Fc domain.
23. The kit according to any one of claims 18 to 20, for use in the treatment of a disease, in particular in the treatment of cancer.
24. A method of treating a disease in a subject, the method comprising: Administering to the subject transduced T cells capable of expressing the chimeric receptor according to any one of claims 1 to 12, wherein the chimeric receptor comprises an extracellular domain comprising a mutated Fc domain or a fragment thereof; and administering before, simultaneously with, or after the administration of the transduced T cells a therapeutically effective amount of an antibody comprising at least one antigen binding portion capable of binding to the mutated Fc domain but not to a non-mutated parental Fc domain, wherein the antibody comprises at least one effector portion.
25. The method according to claim 24, wherein the effector moiety is: (i) an antigen binding moiety, which is capable of binding to a target cell antigen; or (ii) and an immune activating moiety, in particular a cytokine.
26. Use of the chimeric receptor according to any one of claims 1 to 12, the polynucleotide according to claim 13, or the transduced T cell according to claim 16 or 17 for the manufacture of a medicament.
27. The use according to claim 26, wherein the medicament is for the treatment of cancer.
28. The use according to claim 27, characterized in that The cancer is selected from cancers of epithelial, endothelial or mesothelial origin and hematological cancers.
Citation Information
Patent Citations
CS176501B1
Synthetic antibody phage libraries
US20050079574A1
Shotgun scanning
US20070117126A1
Binding polypeptides with restricted diversity sequences
US20070237764A1
Binding polypeptides with optimized scaffolds
US20070292936A1
